var title_f4_32_4608="Biopsy incision bone tumor";
var content_f4_32_4608=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biopsy incision for bone tumors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A properly performed incision is small and longitudinal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis Hornicek, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4608=[""].join("\n");
var outline_f4_32_4608=null;
var title_f4_32_4609="Calculator: International Prognostic Score in Hodgkin Lymphoma";
var content_f4_32_4609=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"IPS_form\" name=\"IPS_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: International Prognostic Score in Hodgkin Lymphoma",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"IPS_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Serum Albumin &lt;4 g/dL (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"IPS_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Hemoglobin &lt;10.5 g/dL (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"IPS_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Male Sex (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"IPS_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Stage IV Disease by Ann Arbor Classification (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"IPS_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Age &gt;=45 Years (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc6\" onclick=\"IPS_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           White Cell Count &gt;=15,000/mm",
"           <sup>",
"            3",
"           </sup>",
"           (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc7\" onclick=\"IPS_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Lymphocyte Count &lt;600/mm",
"           <sup>",
"            3",
"           </sup>",
"           or &lt;8 percent of White Cell Count (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          IPS Score: 5 year Freedom From Progression (FFP) and Overall Survival (OS)",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           84% Freedom from progression and 89% overall survival",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           1 Point:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           77% Freedom from progression and 90% overall survival",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           2 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           67% Freedom from progression and 81% overall survival",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           60% Freedom from progression and 78% overall survival",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_5\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           4 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           51% Freedom from progression and 61% overall survival",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_6\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           5-7 Points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           42% Freedom from progression and 56% overall survival",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic  Factors Project on Advanced Hodgkin's Disease.",
"        <i>",
"         N Engl J Med",
"        </i>",
"        . 1998 Nov 19;339(21):1506-14.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"IPS_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4609=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function IPS_fx() {",
"with(document.IPS_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1.checked){",
"Score = Score + 1;",
"}",
"if (cc2.checked){",
"Score = Score + 1;",
"}",
"if (cc3.checked){",
"Score = Score + 1;",
"}",
"if (cc4.checked){",
"Score = Score + 1;",
"}",
"if (cc5.checked){",
"Score = Score + 1;",
"}",
"if (cc6.checked){",
"Score = Score + 1;",
"}",
"if (cc7.checked){",
"Score = Score + 1;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if ((Score >= 0) && (Score <= 0)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if ((Score >= 1) && (Score <= 1)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if ((Score >= 2) && (Score <= 2)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if ((Score >= 3) && (Score <= 3)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"if ((Score >= 4) && (Score <= 4)){ document.getElementById('rr1_5').bgColor = '#cccccc';",
"}",
"if ((Score >= 5) && (Score <= 7)){ document.getElementById('rr1_6').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"document.getElementById('rr1_5').bgColor = \"\";",
"document.getElementById('rr1_6').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f4_32_4609=null;
var title_f4_32_4610="Intramedullary mets SCC";
var content_f4_32_4610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intramedullary metastatic cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 315px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE7AUADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5aLqY2G1slsg7sgDnjH49acZgJPNUKGxtCjPy8Yz9e9Nyh3HHy7xgE/Nt54B6f5FTzTx4tWjZ/MiiwQwAw244xj0yDzQBIrRx22Y3UjplgSD3+6RgH3Bpv2qKWTEisqKDsJO5gSc8nHNNaUTWkUcj4MSlUC5ycsTyDx3PNLdWZjtkkDow7880AWEWB0WM3DzSn5s4PHsK6W017SbaK38szRzLwT/U1xT4Qo0e5WIzj0q0sUZt/tkrox37WhAwfrQB7BqTHXPCkkKXEa+aFbJztYKc4bHOD7frXNaVoDS2k721zbSQRKyPF86kHBCv5gTLMM9NoHAFM0272adFeQfJAFwkJ6/Wtrw74kgn06dbK3Ec+cMx4ANAGemgNaXVin2yK7Sfb5wgUxyOgBG35kIQEM245OeOBXd+HPD+o28u/wC2Ws80rRK7LGUURxRiOMbcAbgo5IHOaraNBDb+L9MEl1HNdyR+ZMgG5Qv9K9JIsWVrpYnjkLbI1i4J/CgC/puhXP2tbmW9trYADBwSXrrYLSSJBLOYXP8Ach5H4iotMtbaa1SQCYDaAC/r610tiNPhtvJRpHk6O+MUAecfFqKHU9X8PW9wiR2yyqQFfHP0rudV0uFfD10wXMGwYU/xY9687+J3h23T4heGRavI8zyByrMcAD2r2S+hiGgzpcybY3j2k+hoA8E8WfCPSkhutU1vxfDp2jOY7oRTWYZYiSNqN82GG7uME5weOuro3w30/wADePNN13xL4j0+ewdkj022a3ELtckFVAVflwN27cAOSM4AGe++IGkNqHw2kitbZ7m8iSPyxbx+Y5ww6L1PFch4tv8AUvEQ0S8/4QfXba/0md/KmKFlaPaheIKOcSbVXcy4BXOeooA53W/hz4a8V+P9V0tPHMJ1OS8kvP7La0WQxyD5mRvmw23JJxzzzwOZLDwXoPwy8fwax4z8Vae9ssLSaZbPA0TLIAELMi5UKoY4IAyzkkcCrmgaR4hg+Kl3rcnhO+hXM9+C+zGXThN4JBOW6DJyDkVB8ULLxP4psPDWszeEbx7uWBlubSJNzQMsjYBB5G4EEZ45OcY5APFPjP4Oj8AanYabY61/asF5vndSp3Lv5VWAJAJV+q4z1wM15dqKSmUtIgSMHy1AzhNoxg5GeB616v8AFDwvqvh7xDHFrFur3sFqFuL1Jd734ePAk2AnaI87DjnAyK8xkimmt3gtmjkhjYFn5G5sY43c4GMDpQAy6ea6vZbpLYW88mZsZYA5OSy5PT86oMcRHMSAs4KuCcjGcgc4xz6dhz1zpI9qlw32mSSZ3DlXYMoVyPlZhzls9QMj3NVmMbpPMluFg85D5QBOF+bI39u3HfI9KAGSODFFIFYSqOoXC7RwCPfIOT6mkXzIo96RlU3YEzIR07en9as3N1C0FpHFHPG8SMCsj7lOX3Lj0HOfr9ailWRLQJdKwEZKxgqRgk569COtADJVkeaGCQIgJyu05HOOevfFdDpM3kCWC52MirgRuOSK5qD7OUlNwz78fIFHU96bK6PJ8oYLjA3NkigDY1K+K2Yjs2uoot+PLlPA9watXSzp4ft/Pvmkkmw8cGN2R15z1qWzsLJdEe5uLhrhNuNp4Cn2rO1U2RsrZ4N7SqMY3cKKANbw7p8F5On79YlKMhhNu7RjKkf3gSRuYgk8Z/Cm39hNpmsQWgkecEgSOQ0LsuehOTx15HNaHw3aV5njjha7DrgqG5jHrXW3dqE1aJg63DKPkDDLKf7poAueG9BubQTTNqAv4rjYrMSTJEqrhV6nOB3rstE0pYbx0a7a4BA8tJF60vhHGn2O++t0a9uD8wC7eK3NKsrOS/eeYvHJnG0N1FADZNCudSjkEOFaDnEfQ1Q8W6PNImlxLE3lNIPNEXUH3ruYo7eCIrYs8EB+8N3U1zfi+3lstT0s/aHVHcYRD1/xoAbe6ZPaaaIpXRGEismR2B4zWNqfwe0/VPEU0t9qmoQw3Sm4jiSJHVJOoHzH5lBJO3APP3uK6/xA4kFpFMWLs4+8Puj1NdaFhuDbt5qyXEC4DDoQRQB434a8CaP4e+K0KvrU+p6sLX7Xb2txalQmOrmTcVOOcDrXKSaF4L8UeJru3stf1U3U8kk8cBtl8sOpO7azfeABbAwp5zkkV6T4yt/ENh8QF1vQtDbVoxpxtgplVE3NkHJ3AgjP0rzrQ/DXinTfEU2sy6EsN7FazbN8yOjueFQYPPXPbp15oAy73R9C8DeJlu9T1i4u554ybeN7dt0WflLswJ9TjvzmvKfENtHput3dnaSmSKJyAxPLg+vPocZr1rx7pHiLWH0i6bTFa7a2MdwiyKvkvvODgnj5cHgnHSvKPEcT2GrS2kyoXgBiaVTlpP8Aab35oAyZTuclyFwQuFHb2qaSFNscm/cjbsgNkgDHJ9CfSo4lHkSsxbaMYUHqex/nU8NuEhaa537B8q7COvvQBHbxJLFiTzARKi7s/KqnOcj16d/WrEtoDc7ElX7MCwDgkg7epwcHPT86pCVgjRhmETEFlB+8RnBP50SStIQ0jM74x8x7UAaGko8rTpBIkYxkMyBmP0rduNOkks0tW2o7kPJIx5b0rM8NWszXIZP3ZUgln6EV0Wv3Lx3EM1uQwQcu38R9qAMe5l+x6V9lc+dMDtDK2Ni1qeDdND6fcXVxI4g6DfwhJ7/Wsk6Wl3me5mCTyv8ALGxwCa9Jt9Fkt/C9pp92I2WeddyA/dHtQBqeCPDdto3ihTo+rNel7bdPJcqFEZP8KnvXr/hhEFqbiZCblXIU44/CvMPBduYfEusefGBaxRiOJT6V6Ta6hu8i0UKiRrv8wEc+1AHYQaPcXyP5OsxRn7wVhtwa6bQ7KVbPDyW0lzG21inKn3rzSz02XUruSVGlUk89gBXZ6BCUVIY5jb7Xyrr97Pv6igA8UwWp8c+HQmw6lIHI3DpGoGSPzrpfEiRyaRLHMu5XIX8a4ye4m1P4s2sUioq6dAdjdC27rXTePLs2fhyeVFZnyqrt65JoAl0HSJtMLMt608EgH7pl4T6GtyqmkeadMtTPkSeWN2at0AFMkG4FQSpI6in1Xt5TNPKy7hEnyDIxuPc/0oA+TP2t7o2nxA0+eL5ZEswN3rk9K+fJ1lzcSXMi73QlVHfNe6ftTM938Up1YgRW1lGMMe57/rXg00LRXBjeQHBIbHICnv8AhQBfuLCGeWPMMdl/okLqqq7CRmwN53NkZznjj0FR6YkkN0bfziYvMVeUzF8yscsc8EYHHOcHnjnOvX3+UskhkdBt8wuWBUdAM9APSkYiG1Chv3jndweMYI5HryfzoAvTW0QmtS8GC9q0nLMRMwLjcOhwdvQVXv5nMK25lZ4YmIiQnO31P58fnVRmcojmRiV+Vcscrjpj0qMDJAzigDY+y26ZaWExMbRJIkIZhIxwCfXB5PoKy5o2R9jbflJXevIbnrnvTnfMmY5X4+Vcn+H61vaNPp1pGW1MefNCh8uBx8qn1+tAEktqbTS7We6f5k6W8Y4YeprPur1LycGGJILUAeYoAz/+uoLzUZ54ynmL5MjZA7rz0qO0g+03CxCPdt+8wPB+tAHZ+BWma7eTTkEVpECzEH59v19a9f8AC2haPp2p2+rWD3N/FPH5s6zDo3oK8o8CW00tlcvBiG1lfYW7jFel+CtQZbi7lkvBiMiFbbHb1AoA9KvJdGmnimvLOezdRlTGeDUFnYRz6hczRnyVK/KrdWFUrqF7+9hWS4iMCJnyw4zWvbpDd3cDIjmNBtYD+GgDKtNVkkv3sY7OVIoxl5T2NdH440+D/imUl3NPJINoX0HrVOOF3vpo4mw5++uP4fWmeK9YE3i7QrIRs32dSUK8/nQBe8YSfZtEa+khjChxFGD1alsNNNn9luoJ5ZAQDJC44XPpU+s2g1rwrdR3sRF3HIJLZs8ZHetjRroXmjW83G7btYgdWFAEF2Oorn9QGM4FdBdng/zrndRIAJzxQBx2syL5qBc5DH8K+ZPE7I+r3MxYtK8zFwfrX0vrYOAXGD82QPSvl/XWLatdcgjzGx9M0AUARtIxzThI4iaMMdjHJHvTKXt0oASlUEkADJ9BSxgM4BBI9q2dG0f7dJ5iSERI3JxQBrWEE0Gnb4JA4I/1Gfm/Co5Ld5vs4D7pEO4Bj932IrXu7d9LtN8ePMzkMfSqtksd2zxoFjnkG5nJxQBe0PShe6hFcahGGCycRjpx3rr7XWoE8QjzoWFnGMJ3wwrn9LLWGnSSP+8kVf3ZJ61sSWI07wvDqV47M86EhO6k+1AG54UuGvoNUuru1kEcsu3z0bkj0xXR+HtM06S6ka0kvWnbClXJAUVk/CcA+FbRzExZpWbJ6detelWEpa4mtVaISH5l2qOfrQBs6Np6iyzDPcq7cHB6VuWZihaKNbtW2Hcdy8n8az9K1Ewxq100axr8pIGSxro9CnNxc4aOFYJAQMLyaAOZ8MXceqfEvUbqFCNkQQODxXYeNgH0ZY2baGmTJ/GuP+GVsYfGnioOp2xTAIT2BrtPFcH2jTomZwojlVyh/jGegoAfZXDL4iubUMTEbdJFyfTjj862ahhWIhZkUZZQAcc49KmoAKaHBJA5wcHHY06syOVIYXmlLKpndju7gZ/TigD4m/aGvhefFnxDJKS+zbbIQcBNqjr+deUNhZMJgELh2PIx3rpPiHqbar4w1293b0uLySQn8ccflXJfJ5gB3A5GfcUAPktsbG86PDk7ecf/AKq0bJdMi0K6a6XzNQZsRpnG0etY8xBkbb9zJ2j2pF2gEsMnHA/rQBdlhtopkEc5ZGhDgkA/P6GoL3yxcEopAKgke+O1QxlQwLjIqVJndBC2HUn5c9VPsaAJY5C9vFFLGPJjbdlV+Zs9s1r6/BaDToZLGN9ufnZhyp9PpWppVjJi1EaxoB98H+Ie1amqaPPKo8tQfMOPKxkY96APN44nlzsUtjrip7SK4k/dwZ/eMIyo6muvl8OmyeN4IpA+cHvk/wCFb/h/QJLPU1v7q3V5ANx5+X8qANrwp4ffT7TTrGV1FwjtM8eflcda09Bt3u9Tvbu1sf3xbaGXheKzrBrrWfGWmiLbBFcbolnc4UH0rtNK0nVfD1jfWd8pE6SkmVBlWU9CMUAW9M0ayvHaYw3EF2pAPJHNdjFbWyI0KNIsgA8xlP61zmjyFYvKbUHlkkOSG4wPaun0vUokeWAkc/IdwyaALkljbwMDHdOJQB8xXOR6VykEh1D4gzs0MkUMEYRXA6k967u1IlhiiLYYPhWA/nXNaYlwnjrUWkG6NQN56EelAHVNiRrSPbiFW25z1qLSIWtLnU7Vi21Zdy8fKAfSsvxlcvFZW0MIdpXmBG04Irorff8AY4/OGJdvzZ6n3NAFG8xg1zmqgsRk/Kpya6K87nPbNc7qZAVyT2JoA4jXrlRFLMRlFidsV8tXj77qZuzOT+tfSHjUH+x7wK5GLY89O1fNVACUUU4Y/izjBxigCS2QvLhWKnHUV3Phqye3ssO2I2O4hfWuO01YxcDzX2Ej5T1B9q9F0gP9kwAA+Mhc9aAK2oRyyzpCFkaNxnPZakOmfZ54pXtzccYz04rXsIZzdrOjrNBjDJ0K1sXUIeBkX5C3PsB6UActbo89w0NzKv2RmwqqOU9q6Dxq6T6NE1nHM/lqLdZH/wBWpPGfrS6RpVrd6tawuxSAg+YBwSav/ESc6b4bh0P5PImnEisq8gDvQB0XheCfRdE0+zlmCCOLLY6Pmuv0RwluHkj/AH2dygdx6E1xFlq9l/ZdtNd3GdsYSJ15I/4DXR6HrNldyIv2hYgq/wAQwGoA7Lw/c+E5bqaHUJLi31MJvc5YxD/dI4zXoHhyz02NkNnfm6k2b9pcdD/Ft6ivM9K/s6Cf93dWyHOdm/8A1hP1rs4CtjZTyEk3CwtIrJ6Y6AigCv8ADILca14uuo93lf2m8CHOQQuM811HihHk0tUgeJJmlVUMnOSTjA965L4KS7vB4uJEMbXFzJIwPXOe9dN4qvWttMt2i2tK06bY2+8wz2+nrQBoaXYtpVuYhcSTxli2ZDymeuPatGkRg6Kw6MM0tAEdwzrA5jx5mMLn17VzXja6Oj+DdSu3Ale0spJCS2MsRj+ea3NYu47GyN3OWEUTKW2jPU4/rXDfHO/t4PhZ4nk3Lu+x4B9Sen86APgO6LvG0mV3AlmyeTk5qgx3fMT81Wp1+UNu2EAcHvVQAktnHTqaAAkuRk5oGNrZ69qbT4nMbhgAfqKAFUow+ckADAA5zV7TI3eUvGFOCASf6Cs2tbQmKzoYxtIYbj6igD0bSHgbyWMaO6AAAKcZrsLC2jI807lk2/Nnoa5vw+zLOpjUuFGS2OPpXU2Mjqzm5G0uc/N/SgCqtqkhk80lc/L7A1VufLs7MwSu3mSHYgz1z710MKQr5imM7XOVJ5zWdc6ZFd6/a2qjq4Lt1C+1ADb3Q7ODQWmlu2hVQEjjJ/jPce+a6TQNav8AR9NtraW8Nw0S8icbjJnoCa5f4r2ltpd/p8EjyTWvmK5jX72R3q5Jq1tJJvIDW+F/1aEuD6UAd/FrCTATXWmWcc45BQ42/WrcdxYTN5b2jQ3ZG/zEfIY1yFpqtrc24fkYPyiRCCR71saa8EkxkmkjDuvyBiVOfagDufCcKXHiC0S54hWIyIpOMuO5rD0O5bUvFHiK/uOMXXkoc8bR04q1p8otrebyziQQsc5yRx2NY/wvikOkXM06lpJZ2OM570Aa3iqwn1XXLG2tZzFOi+buHQgdq6O2neWJFdcFV2sc85FZNxeQ23jDT3yoV4zExJ6GtuSLy5ZdgCxk5247+tAGdecA85Nc3fyq7yRg5ZPvD0yK6G7YDJwAB1rjTHIss1wX3rcMWx/dx0oA4L4iyNHoWsyqm4CLYPbivm+vof4rXQh8LaicHc5CDFfPJ6nnNABjrSU4EtgZ9TzSEYOD1oA0dKQmTKpuXPXuPwr0LTAWtogVJ5xkjBBrz3SUU3K7i6gAHjoTXo+jJsjA53H360AdHYQCNMlMH2HGasTs9vbyyOFKyjCqoyc+ntVeDBO1lK+q56VT8TyOLaCKAbn3DGDyaAGJqcml+IrC6hiD/LiRH9Kg8TXN7rnim1Mtu1jG4JQyDII9qll0+bUNRkzIBDBCDIQMMp9BWhr+trqfizQ4bQOqWtoRhhkE460Aa+i20lmsf2e0iuzg/vo8bl+orqNJE7r5j2pdSfvNEP5VyWnubdljVzvPWReMk9q7GyuDZlWeZlcjozZ2mgDpbR7SdGF7bwqqjnemM1JeapHonh3UTby5spYSFkBJZSfT2qDRtXAiK3H7xGP35VyG+lM+Jzeb4D8wIEEkyoGAwME9KAOy+FcD2XgvSlnkWSR4zJyeuelavicxz3WlWpKG6lVwWzllGO341BowS20aKKNAqJAifTjtUWuTbvFVlGbZR5NsfmZRlycdDQBseAJZD4citrkOLi2donDnLH5jg5+hrpKzNJb7PCsT7RkZGOvPrWnQBneIY3l0W7SPbvZMDd0rxr9pW7kt/hLeRRMdk80MTAj+v4V7Xfwrdxi3L4BYFwOpA5xXm37ROkQ6j8JPEO2JPNtlWcNjBG0jn8iaAPg272jePvMpHPrVIn04qe4PznJyfSq9ABUigGJ89RgjmmD3ooAStfRFWVzHEAsx6s5yuKyRxzW1oalHIKt8zDAxyaAPSPDsMwiRYXXYD/AcKT3rsBBm35/eEdSDnBrmdDRDGPtCtHGo42jhjXSoBHtAYKDyp7E+lAGmpkjRUJbdj5QBmsuW+m0vUVuLd0cqwLhhnJqxq2oLp1uZ958xhzzz+Fclc3CzWwuJrz7DHJy8rKSxPZRQBN4tm1DxD4oWW6ZYZI0Dqw6Y9MVu6St2kH7uKO4eQZZoWCso+hrlUSZteWSW4ZpfIyqY/h7E1v6ZvgtIZL2J4ywJ8wAjH1IoA6mw8+4WMvFMvsQCa6CB7dIiL7ZtxxuXkCuYhmmsgtwsi+WwGwkkbvpW5ZazC91HE8imVh0ZQcf/AF6ALd1dwadZXlxbr51tNH5fU8Z9K2/BVutnp1vFE+EyCAR0J9a5nxnLH/wj0LIxljluURgoxt56Cuq0kiBFVD+7BANAEWv2/nm5kj2+fDMrozcgmuqdzJDG5yGKAsPfFc/p8aX+v6hANwSMBlVum72rXXcXbzJd7xrtIoAo6jkxSjOPlIz6Vyl5sW98tG+WGEArn1rqr7ODtxknvXGYIutV+YEiUqD7baAPH/jLfKmiQwK+XnlLEc9K8Zr0v43SMdWsYicqIi3415pQAVIyjYCARjg80w9eKcg3EAfeJ4oA2dAiyclC3zZGTgV3ujCWPPSRm/h6FK4vRIgkvybz/dGa7W1dYLfdIcFerDtQBsx3Jtw00jQpAq8fNlia5231CfVtcFxKhhij4jAP3j6ms/UdSe+d1uAyWkPOBxv+nrV7RGC2rXKK2G+6CaAOl0CaI60LO6eYvM26Qr9zA9ag1TU49V8WajqGnLGtpZoLRGjX7ze3rWVqVyx8J3upoTFJnyw69T7ZrO8MXsMNjZkoYwP3j8cs3r70Adzpt9dJp/2ZZIhETl2Zfmro7a/he1t5r8FyGxLGg5dB2ridO1G3mvw8sssW47lWVCK6uzk024kbzboRqQeVf759KAO90o+EdUvkktm1XTVVAsck3zQxMeOea0/jNZR2th4Q8PW80jJcXoad+MvGvJPHA5rk7fF3YvDDCkELKI3KH5Tz1PvV/WbxZvFGmxs8/k6VAF81juMrHgCgD1KFkKwwRAhS6jcTnIFYl3f3958Sbu00q2ElwsShZ5xmKNR1z71Y065SLbcDcyxIZCpXHNUfhpqy3MV7eXZ2XlzcsUdepQHpQB2OnRXz3TtcpbyFW2sI5OpHXg1046dMVWtY4GRZI4owT/EFANWaAMrV7o2F5YzYHkyyiCU+mfun865D4/z+T8H/ABUcEf6Ltz65YV2XiCNZdLdHXdl0xx0O4YNebftMXDJ8JdcjGRuaFNxPXJoA+Drhhxx8xUVXqSX/AFp4wB2qOgBacH2oQuQT1Oeo9KbSUAKuMjOce1dHocDi4hEIAJOSxPOPQdq5wYzyOK6nw/D5dxHGV4+8RuzgUAei6XD5SkpM8MWMtDjeCa6PTk8yJ2Cr8oyWYf07VhafKsHzFCkafMSOTVDVNbkctbWkkkS3Dbmmx2HagBnjG9e7uLeCEhIo3yrD+Jveug8KafbT6rbXOphLiG3+cQlsrv8AU15zbzi/15LeMzbFJ6jj61seJZJ4tHnu4J2ihX93gfKW9enrQBtXEwuPEWq6ipjd5pPLjCnjaOwroNO1G7tQILKYI78GOUB1Nee6FqiGyhP2OSKOMfdQZZ/cVv2Gp27Q7VMtvEDy8iksPrQB2J1y3uoZLfVrVp3Pyxso2eW3t2xSeH1hF2XuZvLfGBMOQCe5rEs9StnuCqyxTIo2hpDgk10NpAi2sz5SSSX5VAIKg/SgDrPiMsFjrHg/Q9NHnR7WvLiRTnfgdTWjpMu7a7ABWJlKngDHSvP3vHHjOBPMCPb2whZiM8HsK7PTZgsN4kjfLFEQGIxnigCPwZfXjeJdRkkjZraZj5c/YY7V2VmgEsrKck8uR61zng/7NFZQyyh41YnLKOB6E11iKiByk4lZuuB2oAz73vxjvXFyyAavq1s0exsiUHs6leorsrxshq5PVFCarFMBkyxmM+2ORQB4b8cLQ40+6baW5jyPTFeTV7V8ZiG8O2yknK3DDBH1rxWgBQQDyMiprYZmXILZ6c4qCnxsVJx1xxxmgDpNMdQvzqxOcD/CtG5maUEPMywRr/q17n3rnrbVClv5QXBHOR1q74diuZ7vzZHVopAc7jk/lQBrNYmSxgkkctITlN3AHtWgJGtNNYDIBB3vjIBqGRfIuEhaVpIwMj0FLcPJJaPHHmNmI6cjH0oAsaxZyWXw80rSyd1xe3Pmbs5AFWbW1u7Mxxy28c6RDCvHgeXWd4l1Cd5tJt1A3xAFd3Qe5rbtRJMxk81ndiMgjC/XNAGlZznERujIc/dDR5Jre0WKAxzedHBIsjcKqgYHqc1mQrewAR/a450PO6P+D2rYs54ZbdWkhhBDfOpBBf8AGgDWsUtRIUhkWykiO5UeT92/vWhY+FvEniCe21G2mtooXl3SMScHB7e1ZMP2a6ttQmisocRRhWXOQfbmvdvCZtofC1jARtbyVO3HQ0AZmv2N9pmg6jcNJHhbc7iOnTrXIeF55dK8G6bfhRM8B80r3KE17WbKC6tZLe7hR45o9roRkEV5zBFBa6u2mgRtaW+YQnbZ70Aek6bdw3FlbTQ4McyhwV5AJFXawNKvLDT7ArBGttZRDjJwv1BNcx4g+NXgLQUf7d4gtpJ1/wCWFpm4cn0+TIB+pFAHXeITM8mmQQ/ckul83/cAJP64ryv9qyVY/hJfZLfvL6FRg9DXrGj6lDr+i6Rq1iGFrfQR3kXmjD7HQMMjscMM147+1xIE+E5jXH73Uoj+WelAHxLOcyHGfxqOpJzmVvTNR0AFFFFAEtvGJZlQkjPTFdn4bMCySxmDDgfLjqa421k8uUHcFzxkiuh0y7mSzuJbcRC4f5VVuqj2oA9N064EtnJczISFXARB/nNUoWS7lup5YWVlTCwgYyPWqngd72TSbia8kMjqMLGSAE9zW5pG2PBv1Mk+NzEdPbFAHH6BaTDVJLme32Rx52ZfDe1WPEcE09vYwT3CrHPLly4+UegNWmumfV5ZpdxldiFXb8u36VjarLOk0ZSVrrZNnBHygUAatraXlncIxAmSM7VEJxW3azyS4EiSgBvmRkHP1rKWe5RFkTDbzkSf3PatNPPj+yzRO8UbNlsnOfc0AbYnjjjVJVt8sdqs6AN+FW4Esm23TzizeE5IByr/AIVHNJbz2eZbaG8c8KwXlfxra0RJL6KK0gt4o3Y4C+XnctAF+w8My6vJFqKKF81gfl67R3rbu4Egs9TExdwq7Q23nNdPoqpp9v8AZo8rtX72Miprn7PFp10zRq/yEnd1JoA4XwLLcxWv2S8ztHzKuMkg+tdWZEhkTahBP3dvT6GsHT7V4rMzySleCxIPUe5rNn+JPhTQbZlvtYt2lXpDAfOfPoducfjigDsbttwBHQjpiuZ1R1+2RR8ZCMwHpzisbwj8TtM8aeIrjTNLtLuOKG3a4aefauQrKuAoJ/vdc9ulGmal/azajergxCVooiP7q0AeYfGyRRotig43TM2Aa8Zr1b43yoRpSI3BVm2+leU0AFOTO4bTg+tNqxaRl3ADBWY4BIoAktbKaZQ6DaM4ya6fTW/sqELAoeRuN+eKo6dards1uHIFvli+7liOoxUEF7AuorJd8xQksqD1oA6B5N5d5AVdR93pmnLIqhIwwPmEZUHJH0NVm1Nb+ZSoPksMu+3p7VcWH7RrljZ2cTBUTzJyRg47EUAVdYAg1FUhjZpzgKT3rqLbULeKMW12u0suCVbv7Vi3EFxD4ncXTRSRhcx5+9j3raURRWqytFC69hjlTQBp2drassItrh4Y8Zdp1wAe2TXXWvguR7dJrnxJplzNMAECNtUD3rj9OF3d+ValDmT7q7eMe9dFbaIbG5hgT96iNu5XgHuKAPVbD4dW+k+Fru+1HVFvCIw0a2wxHntz/Ec100Nq0cEEayhZRErLzyTjpXnF/r134d+HOoQOuLKOZZFTfk7SwJUe1d1pviTSr61h1CK7thbGBZNzsAyHHSgDsrXUTbaddSXZ8hoULGSQ/LXiLya14mW7TwtrMekySMzSXFxZCRpT2xu6D3FbOt+IP+Eh8UaZptsHk07aZnXOBJjufUV2+mwG5Baa1SMRDaGC8Y9MCgD5Y8bfCn4pX6GW7vZPEdun3RFfFwo9o3Ix9FBryLW9C1bQbjyNb0y90+Y9FuoGiJ+m4DNfpFbaTANryMUR+y/Lk1rzWVvc2htruKO5gYYKTIHBHuD1oA8a+Fvhbx43hLwfeJ8SBHpTWNpMmm/2FbnbD5aHyfNzuPy/Lv696wf2uLgr8PdLhRi4kv2Ykj0B4r3z7BDA2nRWkSW9tarsjiiUKiIFwqgDgAAAAe1eAftdg/8ACFaIvVmvZCMD/ZNAHyFKvmyHYDuOAAByTULqyOVdSrDggjBFXtPmjstXgnmDtHE4ZwpwT7A9vrVa7k82RcIFUKAozk468nueaAIirKFJBAYZGR1HT/Gm1qapdQXFpbRRXFxILZVjiSRAFVSNz45P/LQsce+fasugByjnt+NaujwsL5GuCIy3ChuM+/0qTw3aQXN/EJlMuOWXHygD3rbtn/tLxbEyIr20bZZyOFUDoKAOoaYaVoDtuCiMZdFHEp7c1J4fvZJrKS9vCAAu7y8Yx6DNYutXovbH7DAFkSWbczA4KpV3UJ7CGxhtkuWNui4YgdT/AIUAOhu5byTCrGkkjZJByQKxJ5mOoyQKCUD8EjA+hqzaTBJjJEi4AwZgc7R6irkE+kpEi6dCZJt/76ZzuMxPt2oA0bONZFa4uA0a42mMD5QPWrguYftUMTlpLJeZdnQiqWozzW0QghiCgjPqxFdD4atvKijhnRZGaPd5ajLD60AR6mWg1m3jsbmKSxkTdGUGAvsfWvV/DWheXoLeIHu41ITy4QrYG7pXk9zYRreRS7ZfsySA4xgr7AV6LomrW2meGrqxW3V57iYSxb34QfSgDrNIW+jg8u+dWuGPUdAKp+Mdat9B0Ke4up0KyN5e4npmoZ/FWnS3HlW07tcqoBTGPmrC1NIdS1A2OpQh7RU8xw/RmPTIoA4vxl8OTr9lFdQeKNTcSqHSC7fzoh7LjG0fga861P4OeLbWEz2drBqMI720o3f98tg/lmvo3So4dGaMXdoZbIABFB+4PXHpXVQvaSxvJZbSjdcDGKAPj/wH4e1OLXr+0uzrOj3f2Ninklrd5D5kY2nI5XnJHsK9e+H2m/2V4cuIRdXNxmdyfPfdtIGCB6ev1r0rU7f7Rf2hMgCxMW8s/wARPANef+F/MGhXqzgrJ9qnzn6n9KAPJPjSR/aGnLn/AJZHj8a82AJ6DNeifGUf8Tay4xiHFeexsFJJGcgjH1FADK09IEWZJZif3afKMcZNZlbOiBmeFE7ybmB6ECgDU0XSXtra5up2HmGM4Ue9Y9paRGSKZwWgWUeac5G2uxuhHaafeykktKMcHhc1k2GmytYrbw7ZETM0xBwCKAKmlAy219DDua1EwIYcDGeK7nwzG0U9xNcYyxVQwbovoDTLVYp9CgktVEQU/MiDhquX8cVn4amEShFceZlzkg+woAxr62+3+JNUvdw24EUW1vu+5NR29ojaij+a58sbWJfv6gVb0hbG50q0luJJHaYksFO0Ejsa19KsLXzRKzyqM9MbsCgC1Y2sljDavcTXM0LttT58MM10Gm2OoadqKDSdRuYkl5IufnViR0z2qUaUt3fQtHJGI4E3ICcMTWjPa36wKge2CA72ZG3Nn0oAzfFjyTaBDa6hEImkulibc2QTnt7Vg2elLceIhYkNHEbhIdqk4x64re1t5LvXfDtnqYgbdLvRV/ix3NSaDYXkPxPMc/MRn3bFGCBQB1kwiT4ktZorLDZWYCFeMmvRvDmqSLq40mZW+0SwF4+c5HrXnkdssnjfXLwH5RiFec/WvSNBsbPU3tL2S5NrqVsDDFLG2GdO4IoA7LS450s1S8w0iseSPyq7UFlC0EIRp3nHUO/LY+vep6AKs0uL6CHPDBmx9K+f/wBr5t3hbQvLbg3MoK4/2a+h2UGRW7rmvnL9r87fDHhtB1NzLg++2gD5Jmki+zsRv848D0ApNWgFvqM0aQSWyrgiKXO5QQD3+tQ3BAkOCSO+afqEbR3ciyTJMy4+dSxDccY3c9PWgB+oWyQsDC26IKnzNwSzIGP1AORn6eoqng8DufSrM9q8UIdmBwEyPTepZcfgDVYEggjrQB0ulNLb2JWNjEHQh2P8PvXR6JFFB4VlaLeFkykUmPvMa5NLuX7FFlDIv3WHQ5rurWeO40zTrcAbEO50j4oA5HWraXR9NRV8wTXDYdz1x7U2KG/tdT0+K8mjmimwVG4FSPeuh8Yapi6t4beBWEI/eRNyeav3Xh2C18MJqgjDXSjcoz0z2AoAzrwjT7lgkPkwyg4VRlKq+GbRBFcNcRykMx8squAD7mpJb5R4dgRmUXEkmXRs/u1rqpZ9O/su2T7HI4ZQRsfAPuaAK1pY28VszukrXD8E7j09jW1pFhHb6mbz944ZQiuJDlKr2zGSFYAJBF1XJ+YV02j28Ij8uKdfLI6SLyDQBTvNI+zTtLa3NytyxyUkbcjD+lWtQREsNJkAEGpG4VTGWyGGeeamlW537Wu4jj7uwE/gaw9Vs7u78R6apm3OJAQg4IPuKAO8sdPgk8bTNEoRtqdRkMe+KztZnkXXtTms4vOWGRFkTvW7pBe012VZG3SIgyT2qPwzp6X0t9LtBdpiWYnrQB0WiiDVIUmlUR7l2kE/d9q1IrGKwSRIGYqxzgnpWdplvPHfyCykQQEfN8u4A+orV8kW8LIJHkPUs1AGfLg3CH5c5xuNeaeGX2+H7oly5F1Pkt/vGvSbg4f3615z4eQHQbgNgB55ice7UAePfGeTdrkS4P8AqxjNedDr0zXonxpGNdte+IQAc9frXndACVu6KxRcgBgq7m3DG0e1Y0C7pVGM5PStiZmggcpLkkBcn+VAHS6qV/stpVUHABO7ofbFN8NXsMdle5PzsuFQ8VXnkU2VtBkfdDZPTNIiTWksKNt/eHewAyQKAOs0ZI0s4kjUqjncc9jSahpz6pcXyhpGghiL7/4QQOlTaXMpghEmX9umaZ4j8QNpmlahYxQqHnTYjqfu59R3oAx/CUKSeHkdgxZnOUJ9D2rq44PslnAZGB385VvmUelc34XU2+lIkSsDGPmZhwT7VevZ0hxGAZT1LEcAmgDprXVXlml2LJHCq4VtpIb2JrX0vU58SlYxNysYjjXLZPQe5rm9J1zUdJvRb24RoHVWaMgMre+OtdnZyzNfWAUQ2M51CGZJUTnOR19qAKnjeKbSPiB4eLxvHIkYd4pFw0ee9dPosRX4mzTDMjGHezH3FJ8Xfscvxa07yJZ5r/yY459w/dKmeNvuT1x0rpdG0xbrx1eiNSo8kKMnrxQBlaFZC81Ce3WfyWubokueSK9Ms9GtbHfHD+8EQ++fvE+1cRpPgmGTUpb+TUruOSKRlSOJgAP8a62K2vLRLcPezSoTjdKBlh2GRQB1mmSq0XUg9ACetXjVSyt/K+bc2SOVODj6VboArQwNGZHkcu7nk9gOwFfOf7Yy/wDEp8OZI2+ZLwOhO2voyO6jlnlhBxLGfmU9cetfOf7X2/8Asjw8rbcxSyuc9+KAPk0p5ksnO0KuWbqMUy9uHkvTMYUgf5fkRSAMAdjnrjP41Pbu63TmNd3KuUXgnBBxUN8MCFNsg2Jty67S3JPT8cUARyXMkkexyMfLnjrtGF/IHFQg4OR1pKcuc4AyTxQBryQ7I7VNzmKVgxJ4Yn2r0BFaC7sFf5UZcZIrhbuMQPbfLJKYoVYc8fhXe3Jf7BpVxJGftGzJVj0B6UAcl4sinTW7qWORASvJY/eHtXU+HNbu08J5kiSdBIEhL9M+lcp4r02RtThiy8l1MAw54AParNyt/p9vaWKZAicSBCOM+9ACa9p11Amo3mobUR3DJFu657VveG0mbRYpPMV4W5Ud/pXO+KlbUJ/MR3kmkCqQeF3e1dBbq9laWlrDmOaJQJgD8ufagDpEmtUmRbMuHAAmSTt9K2Ha7tgsxjZ7VjtRhyc1zcEb3PlAoUTdmRmOM1u2X9oy6KftkhSxEhEUfcr65oAuwS3MUbmMHzJHVApXOSTxitnxVpwtviDo9hEALyC1+1TkD+LjFWfh/dS2nijSIvLBsZmMY3EMAfU+9XGeO4+NXi2S48yW2toEhyRjbnsPagBIIG/tK/N2/m3LRBiynpXQeHLjTjpEa2cqtJz5vqKqeCtOgvG1e6uX2quQnP8AD2rE8D+Fp9Iur64i1B7u1vpC5R1+4PY0AeieHlRreaRD8pbAHpU90OTg+tJpAEcU0SMflIwMY4ous4P9aAOfvLlY9TgtSMmVGdTjjjtXEaImNDfnkzSlv++jXWX0EjeJoZyxMK27YHoa5rT4RHoxUHhmc5x05oA8Q+NPOu25BBHlDGO1edV3/wAY5DJ4lUdliT8eK4EUAWbHaJNzc49DzVqVDMieWQRu6en1qjCqNKFbkH36VePyTLEF2xHg46n3oA24UNzcxIrlljYfJXRtJHLr2FGViQKQB0rnNGRTqiEE/JzWrC+y6uZI8oHbk+tAG/YwMWkVXwScqw5ArnvGvmNq9hCPLmnBDuV4yPSun0wukJO0Bm9e9clezm78XKIwpjh5OOCD70AdHZXLSlons5mV+0fQCrpdYQWGnzSF+Nu4crUVvcTrGXQARHpitKaGJRA0koUlckZ6GgB0d7aRahbyT6fd2IICiTbv/lXWWF5Bq95Gkd2kz+ZgOB86+9Y+liM/dkLbmAwDkAetbWnWVqpnvUREmOQJMbQcetAGLYXE1r8RYTqE012Ip8NNK24gdufSvV3117XVdQuLOIBRFhHB+ZjXiHh+cS+K4p7hyIFdgSTkE16NrF4JJbyMbt4VQgHAwaAOv0i7v7S58qaeIWjw+a2eoY+9emaE/mWkcOFkjIy5bnr3FeWaUsciQpcNjzUETkDOD2r0PwXZXmjwGzvpEudzfJMjcbe3FAHWAAAADAHFFFFAFbEf2iaRUAkCBWfue+K+aP2vpXj03w5GqjBDuXJ5JP8An9a+m0UZkbOQxr5a/a+nL6rodvIozHCzD0PJoA+ZMvbSpKiMoPTHU0momaQJLKFCt0wa6E+TLFbjaC2zkscbT9KwdZKCYJEGVB2PT8KAM6rNi5WYYx17jNVquaeSk64OGzyCO1AG46Pc6zZxxMH3uiAoOnPpXqPiwNHLDFGqh41AMe3vXBeFbQTeMNOhjLqd/mEEcj3+legeMZfP1TaGGBy0w9KAOP2y6p41sIJY8S26b9nYj61JqRY6vcNcylUDDeMZwPQGprfFr4hupZ2kRHiASTPJ/GsjVLS4nikubWdorNH/AH9xK3GewoA0/EniCK/1fTNHs7S2e3tgGWXAUk4zzSzXVxPLJbiynkO/duTGCfQGuS8OIZL+5neF54Izh5R2HtXfiGGGMSqWW2AHyqcsD70AOSW6ig8trK5eYkDJYYArbe/vI9LihksrqN1cKHB3Kq9yaqNLGIAZJHTyxuDEEBhXQWDxLYWzxSuDIdw7k/WgCaCURzWE1hcIZUlBRV457kirWkavLcXfiuaQs93Mw86UDsBwBSJHZRO11IqLcKhKEdfyrB8J3L+Rrtz3myvHUfUUAd7aM8fgCHaXBlf5pRwSPetPwTqkhD+VsWNf3SlOc+5rPkMlv4P0tWJWQEExkcEU20tvIsZRbMIY3kDkIMFjQB382otbCNJk3di+cHFJOwZdy5IPSobJHv4ojNbItqFAZXbLZFTyosce1BhQOB6UAYt0AHJ/iwefwrj7PB0uIjjJbH512GoNsimfP3UZj+VcVpTltBtJHGGdc4HuaAPn74uS+Z4xuFA4VVAriq6/4qHPjO8GeABXIUAPiGZFHQkgZ9K3NMtpLjVxCQNkfJOOorIsiVuUKgEjnmug8KvxqNwQC5TC0AX9MUrqlxKo3IvAAPQVeSCbcELKTMdwz2+lZtjII1O1wrg9/wCPPatOwSRrvzmLN2AA+4KAOrsOFhQq74IUnPTNc8unf2T4s1ezdgYZUEwGOSvfntXU6S5w0pXaBwSe/vXHasu/xFqEz3nnExhdwPQelAG08Fn9jhNskkaSNjYHPA9a17XTFuLu3thczxLnKpIgbI+tYPnTxwWTGOM4TEYVuD9a3dH+33OqiWztbieZIsmNOSo/woA6CXRLeD/X6jL5SHf5cKAE1oafaaXJaeZbPdYQEsWflvbFYd5qN1txHbS28Q4mklXuewro/B+l/wBoWmv6hdXP2Sx0a38wOOTMxUnkelAHBWbRx6tM+0rAz4DA8Kc9MV2NszXd/OrM/wAqKW9GHavOdDu/O3SSxYF6/nEA8Jk8Zr0PRA8mqXnlkONqrjOAPxoA61PtMpjSzBZ0IO9T9wfSvS/Dl7NHbCBrWeRkGQ56n3Fch4X1rT9LsTZNpkqO5zJOVJLH/Cuu0vX4SgkdZ4FiHTYSSOwxQB2NrcOYw8ymOPb1fgg+9W2JCkgFj6DvWUupRxWP265fZYCPczFCce5xV3T7+11G1S5sZ0ngYZDocigB1tG6QfvSDISWbHvXyt+2Pt/4SXQCpw5tWyfT5jivq9/umvkf9sZ8+MdAySwSxLFSeD85oA8IkkcWm0KFYgAbxktWPqU7TTDLAqowABjFbdxBNOvnq3lRgBlU9DXPXUjS3DswAJPQdKAIjV2MqtwAsjOgQFiFwapdqvRbY5Fi+9IcEsD1HpQB6B4HU/8ACQW8zY/49mKs9bGr3Eg1Wxt4gcAZkUjg5rkvDNxEmrByWAjQLjdnj2rtLWWG+18upP2fZgue5/pQBl6rqRXX0ihjRyMAo4yD9K6yws9M1bR5dP1NEiw3nuhG3cR2FctZaZE3idZQheVZP4j/ACp/j/V5tL1eN/8AVeYpVxjtQBmeGDbRWWqW0W+WL7QxNm4wEUHjmt62nt0gV/7NeOQtjcrfLj8a4vwbKhur6PepimOWwecV0ay7tsFvcs0ZcHZIP4fQGgDrdP0mO9LLDdXEZf5nD4dB9K3odJt7CFRcX086AEHYNoFc1I2p6ba/2lFCBYqQqlZAT+IrRm1K4uZkQx4hZByBwCetAF6eKztrZkW3EjiMshzmQD1rE0DFx4au5o4vkuZQvnLweDWzLeR2vhnxHrDMHuIIPs0TAfISf61V8PLGnw70eC2+87r579lYnJoA9E1pDNHpFmVO5Ilwf7wxUoYQNBGCFYN19s1kaprRtfFdpZXEkQRbcAeYcNjHUVqW0j3c67ceWp4crgmgDsYbR7bcyB2eRQy5NJddDkfhSafcNMPl3DHBDU67A52HI9TxQByviC6SCyvhK3l/uWKk9W47CuY01Gi0GxRuG8sVseOUVdPuZXXc6x7UB6ZJ7VQlVbfTYN5wscQJJ+lAHzR8T2DeNdQwMYYD9K5StfxZefb/ABDf3GSd0rYJ9O1ZFAEkfRj3xjFbGi3ItrR1xzI3B96yrc7QWwfSpzK9vGAnKE5J/pQBvaK4e9UPGpJJPPSus0e33xsPNw5k4UdAPrXC2Fx5clvgkry27+ldn4Ov0kQlSAA/KnqaAOivI2GmzqjFpAMbRwzfSvOdPlhS+u7qUszp+7EUgwc+9elX00AWRpZAm1Cw5weleUaVeJ5M7zK0gaUvIMZ3KaAOwCGSKAGQncMbRwF+hreS4uFvreLTrh4JBFiR43wXHoTXFiaSRoFt7dhbYyvmNyPet7Sru7tZowkUJXp5sp+97CgDegVCJPOMkgT7wLng+vNbUtzdQeHdZit5X2XEO2YKcZXFYpvrg7z/AGfuUjDmNuKtQNHq2nXUSeZBmM788YxQBzWlyi0tjAqEqyLh25KgV6N4Sk82633EazW7su89OB3NeUWsioRF5heMnAI/i+vpXe+HbkpAdpeJwdrAHpQB9A6JfWGqM6NBthjG1WXjFdnowtBawrGFaQ5wzDk14LpHiZtFlsLmR5JbGZxbzZ/5Zk9DXuXh6RQQ0wUZH7oAcY9aAN1I1RmxgBv4e1NNtGGDRjy2HGU4yPQ1Kqge59TQ4JRgpwxGAfSgClYh0t5o5JPMZJGAb1FfJP7X86L4/wBMbPzJZBSrDpliea+t7LP2HbKymQEh2ToTnrXyB+16SvxEhycg2a8Y5I6UAeVtcie0G4Reb5fyKenHpXHzv5krvtC5OcDtVmWdgAFUoNuBVMnJyaAFRSzADqanLyRTb5VIk2/LURjIcBu/pzWxCAtxblRlFXBL/eFAE+gNImqbo1C5UHPXP4V22nXot9UchHSKTjbjqfXFcfbCF9QAjVWAIbeGwQa1JL6ZNV3YEiyHaxB+ZBQB2vg6E33iaaQp+7jG3cTjb71u+LdDF3qUE0gWeFIyqqwByfWq3wpjSTTr+UxkmSQgSE5JrofHM8Wm6Fe6okZZoIdijPegDw/QNMkS9vZyAVaRoxtPTnv6VrxiJZBCki7k5Vv7p9Kx/DF5OlorxkyvJKzOnvmtK2F1eXz/AOiNC8eSc8bvpQBs3EJlKzJIX82LmNc4yO+K3NJeTZC0odfKwHP96sbTjqsh3bLVIcYTceUxWtpl9exi4d7VLiGNctsbG76A0AX9YuhB8N/EGjSBHZ5xNH+J71NoWoR/8Idpdi5Hmi4TGB8rc965/X4nudLDgspufm2fxKB2qz4ac/YtHMS+est2E6YKgUAdr4p0qy8QeKbme5hVmsokKMJNhUj0rrPDk0U0cCksScKGbpn0rznxGFk8U6jJbzS7I2QOjdMiu102dpYFjnCxt99dvAxQB6ZDbLBGuwYHU561Vuhwfyqh4enW5s1EWoJJdr/C57emO9XrjfvdZIyuAOc9TQByPjeJZdCuixICFWz+NY+swrc6a8ZJCtCcEduK3/FX/IGuwecgDnvzWLelVswc/IIv6UAfIGoxeVeTpnIWRlz+NVq0tfH/ABNr3b93z34/Gs2gCaBsdSdvf0pZSGcfKV9DUanBz/k0qkmQHAz2zQBoXULB4Aowdv3ietbXhqR474CNyVUZbP8ASsC/mLiFQTkDqeBXReFYvMvYAVwzAhmPSgC/42lna3R4sqxXkg8kf0rB0Ly4rEPLnDOcY9feu61iwSdXhXJJhbBHc47VymgPFbaXGkqIx84+cP4koAt2MoaKRZWU4PysBzWqnmAIFTcc8egpiS2qE5gQq7ZWT0/CtJXiaZhb26FlGSZOB+VAFzSyTFv3PuB4RTwT71qTG8it5pUMSIkRMmG56dKxoLwys0FssURK5ckY2j2pbgi4sLiKNWaTyid/8JoA5myclSFRI4nbJfPPNd74URzpt9nDCJgSD2968+sm3pEjnDjhgRgHFd54bnc2WoiRCrnBI7EUAdf4fWG81CGzuQGhmGWAOAhHQ17f4a1GKzt1tHmzN91VlH319VNeReFdFENgl5fMrTzDEUaHAVfeu50kT2626TSQSwBsxlnGYjQB6tp9wk9urIwK9B60mqu0enzlGCttwDXO6LezxRyG5iLOWwjr0x61qw2AeVy97cXQPIRyNq0AWNLAGlwqM/KuCx7n1r5W/bIijj8UaDMoHmPaEOfXDHFfVsEBgYoP9WV9e9fK/wC2OkrazoUjjEf2ZlX/AL6JoA+ZZOQ2dwAPC+lQ1I4IPzUygB8YQDcxJx/COP1q5B5s8xmGdiL1Y8D2qpAwDgEDB4ORnNPO5XaEM5GeB/8AWoA2rP8AdSwGOBnEr/l71bmZE1xI3dn3E5wMfhUWnJ/p9tbiQkj5kINOjlzr84uMA7GwxHWgD1b4aqlvYPArhdz7lAbIIrT+KbLcfDzVch8QumCvc571h+DLl7exgnmiWONQN23jPvW74lt5tW8PazY2zqY7iMSRk9yOaAPHdOgk0u3tDcRMksqhsr6Hpn8K0Fvo4dbkSUSltmVbdwKtyJEvh+0MkgaONVjdQcncPWq9neGbWFZUiMSLtZSvGKANizv4AuI0Ut14bBP1rftN03mXUWFk8vDxg9feqNo0K3MxS1hktvL5kC859KZp8s100sqy+X5eFCKPur70AWrt2mMKbcC3Ukk9W9qd4UhL2umbC2w3ReNR2qXXNMt7qxur4TSra2qL5rp945rp7XTbOx0jRjol0k0sqh1PU4PNAENvaSTajfoXDu8nzMOcVPYvcf2xF9nlO1fkG/oKuaRNBJ9oMIEV4shEiMMBvfNLozedrALQAMTtxjhT60AdZp+nx3IklYyx3YHzOq4U/Stqxb7Lp8FvcXDzSgH5mbcT9TVJNSSAGJ2JC8Pt7Cs9HmtNPmeIbt0m5JGHQUAWPFThNIuSw6jFYWQbGIlQPkww/CtDxDMX0iQbvMTywzt6H0rNJ2aZEcKcRg49RQB8r+MEWLxDqKrj/j4c/SsSuv8AihbrbeK7tVTZvw+D71yFAD4wxJC96teV5JwMNLjiizAKZB56EVHLk3BPOE4JHpQBNcK0kaGUHIHG2uj8FyF9URW+WOKPv0Fc95pihCx/O8n3faul8ExeXqRR8JOw+4elAHYayJG0Wae1bZNGpIcDFeaaFKDdT+cnmO4JIzwPevb7OyUIElRWSQYaPHUV5FPYxweJ9VjtUESwv8iE8AHqKANG0jmkBijcEHDBs1t6U1rdanMdTv3siFCruXcHNZVrI1vfRLGEBAwwxwtWzaGVGcSBn3ZDJ39qAOy0Dw1Z3OqOtzr1jYW7J810V3Pn6dqLqHTBLqlhZX5vTFCcXDJsV+O1YthJZWUsz3EMnnhR5jMuRVv7RaX6LFZ3Vu15Mu1P7x9sUAcGl0nkx/vVCJkOcEn8K9D8Dq99Bfraf6QfKEvkt1YD0ry/Wf8AiX37246qxWRcck13PwovC+uWoilMZmPlJtOGPsaAPZvCN1pN3awCHzArAK0cgI2P6c16PpWhRBlPkRMCc5evJ5zHpeqXCXUL/Zo3AdAcbWPeva/Bc6XtlHbSRBo0G5Wb7w/xoAfYaGi3pmtNQuraA8SwIwZXP49K2ra1msZ1BkkuYjnDueU9j61aWOJ5z5OB5Z+cAYo1aSWLTbmSAr5qoSu7pQA63nE4LL90MQc/0r59/a30ISeE7DU8qJbacx9eSpya950BvP0m2lcDey7jjpmvOf2lNMe/+E+syoA72m24C46AHBx+dAHwVcptKnP3uevSogCx45Jq5dqC8ZZVAJxgd6q4ywUEAk9OmKAJIHMH7z5TnK7e/wBa1bbTGg083U8jRsx+XYNxYHtismYDeSqk/MeexrpdIlMlsEurgBghKbRkrQBY0C0V7sXIiLRhSExwVNV7acTXd9KyCUL8uTjIpllqpt7gKzO0Zz8y8VmwTn7fM9qFCuxDI5+8M0AepeFpJJ4DbSqJ4UA8or0I75+ldJMpEkEbSLtkG1NvO361lfDmxik0xlicKQ+Quc8eld3BZxrJ5U0ClicE7eg9qAPFLGyCXPiGCKMtEj45PDHPUVqaL4ft5oEczRK2zAQnA3ehNPvDZad4v1SG1ieSzz8qZJYN6GoysvmSxxSGON4yNpHyj2oAtapG2gyQ28V1BdyXCZdIPup/wKqvg+bnUJrmNnQuFQHgYq1Y3FuNGhiNuN8eVLYySfWsU+IbO0naCW1uWRWAd0X5RQB6M2xfhr4h+wB/MiYFxJzvHtWf4I1Owg8N6L5vMwkwdvYelEesW99Zg6W+1LyIxMOgJHqK5TwxG1taXFvcxyrPazk7v4QOeaAOv+0XUbXd5Y3iPbrdHdG65JHpntW7ZzSiWC5tZHUNICUkGNv4965jwJBDfT6gwlnMTTeYwH3S30rvYYoRqcVvqDjLEeSRwG9qAOonsyQt6hBRl/eKgz+NWIYZXtDFDM01vx+7K1PYgiJo7glVXoV6kVpwR7olfacdMng4oA4vxPG1toF5GpEZJAGewqoVX7FEApYmJc+9b/jG2Fxot0OcqN2fpWBaZfTLdyuD5YA96APnz4023k+KlmAYCaEdfavP69b+O1ufN0+4zwcoTXklAFm1cLu5O7qKkQl4nfHLHBHrUNsNxZQQGI4NIjeRKPm3AdRQBZd38rKBUI4OO1WvD16YNSth8xXzAWye1VUmgaUMwIBPKgcVdsjBE8hXbvkOMgfcFAHvWhXCTrEy5JY8bvSvLNaCHxrrMeyUF5B8qdD713PgF5pbFWneNjGQiMDwRXL+ID9h8a6lbsuyScCTeRwR9aAMm7S8g1EtE8UK8AFxu3e1bkSuXiE6sEJ4QDAJ9TVW4IVssC2ANmBkitm0kEUHlsqNkgu8jdfpQBNaWFuXmBjVT/EGJIp0mm2sGySKBPOjIaM9CCTyc+grX037GWZEVXZhgIvOM962EsLBlP8AaA32uzAj6En0oA5b4y+Dbbw8dDv7fUxfR6im+SVgN0b4zj6Vy/hxJdO1uxuoG/fxyrKjAcD/AOtXa/ExLG4XR4zbyw2QXainJAasmO2k8lRCY0nRCA5Xgj0oA9ku4rTW7mS6vXVorxFWbacYb1FeleDYYNPs4NNu5laZfmhm6Er6H3ryr4TXqXOmWranbEpE2xc/dz6k16pZLaXNzJDeyiOJSCrA4A9ADQB24XBBz2596q6uT/Z06ry7qUUepPanWEkbRFY7pbnacbgwJHscVYKgsGPJHSgCpo1obLTIIGGGVfmHoayviDY/2l4J1605/fWUoG3rkKTj9K6KmSoJEKsMqQQfxoA/MjUE3SMjgCRFCsAMc+lVtTs1txEyHKEfN7Gui+JWnvpHjbxBZfdeC9kUD0Gcj9K5c3UoiaGXDKe560ATRj7TtTYdpyUw3A+tXLI3NuCFCCRj0A5xWdE7wR+bGRk8cdq17eaH+ylHljzgchweSPegCrp0+24mj2gkMSN3XNTwwbZbiCONWu2+be3G0emKLOK3aV5ArRcfxc5PtV28mkh8i9t44yxONpOS1AHofwp1VXT7FHbiN4GBkwOtevWTGS8Ysx2su4AjHNfP3grUbbT3m8uYpqN3IDk9E9q+idKE13bWSXKxCZgMyJ0oA8CTUJP7e8RxpCEn84hZZOg5p7/bJLdVkmgkx95Ixyan11bax+IGvWMsY3OdyFu3vUel3MSGdZrfJT5RJn9aALOgW0MU2Y3zIOS8g4T2rQS2xdsTbx+XMf4R19TWdbPMrCIXKNBuySe4rpTqNqLSOI7XkB2qiqeTQBPa6NZXj2+n2MUcE5cBZX4Cn1Jqv4z8O3fg7xfBp9zJDM2pQ4imQ5jc9wfepNJsbh7wTawhW02nbChxuPuasfFJM6T4XmhjeNYJNytuLlD2BNAFT4YwHRfFV6JYiyONjIx+UH1Feh6noVlqUcJnRh5Mm+MqcFT7V5n4d1jZ4mLXCI8snKnOAT717PYXsF823yGEyDLAcqfoaAL3h6BJ4Ssyslxbn5ZWb5XHpWvLGwJdsbiOinilt9MJkScpF5TD5kPJFTzRBIyijCjoKAOb1Ih7WV0UOpU8HvXNM3mWcT7VXK9F6CuuuI1jTaikRjpXMzwGCBY+uM80AePfGq2EuhROw5SbA46ZFeF4654NfR3xSsmvPCt8sYJaMCQfhXzk4wxGQcdx3oAntFDOQ2MDnPpS3UJX95jCt2pgYRyqVwwHPqKtSSmVBPKCIxIF2I4HBGcY6/jQBXED7VfORweavRkJKXYjDDAwOhqku9wqysxRuVGeAM4zV22uIUs4llHyZO4jqeTQB6X8LpzC13Yzt8jgPHk1q/EXTDFqmk6yF3WjgwTIOx7GvPdGvzDFJOxKgfLG/fHrXV6d4nN/aTaBqUZkmwJbWVf4x1/OgCqLVYWL3srg5IZUPBXtW3psULxoFi3JjK7jnHpWfbxrfmQuAr4CMT1BFaek6bNBdJFcSYhfunOB70Ab2nXM9hCk8iRfaJWwMr0WtfelzI91GAyggMvUr6kVkyw6XNDNtnvjewHCQ4+Qj1rrPBcllLAztbiOdBt4/iNAEup+F5tf8D6vLb28hSxHm20sq/MSOcAdcV5JoouplEib0nIDsrd8dRivoOy1q6sNVjmnYyQMhjWHGVx7iuK1jQorXVmu0iRYJZTIjrxsY9j7UAJ8MdTlsftmiTwK0dy4nhJ/hPcV75oMVvcRMJ4Ud8AEbeBXgujskV9HNJuju4JP3ijoUJ6iveNGscyxOsjhAolV1P3x6GgDehtYIHZ4IYo2b7xRQCfrU1FFABSN0qOUN5kTKTgEhhnsRUj/AHTgZPp60AfCf7T+niy+LussuFW6WKbH1Tk14yevrXovxc1S51jx54lvdRkYzretCqE52KvAUewrzx+GOSD9KAJbQp5qqVJzxWrY2/nSkLs2/dZF4wPWq0P2Uy2sc6RLGhcSSDcS/oWGf0HWiwvWspJRbL5qcMSUzu5A69VBz+eKAEn3RASQt8kL42Hn866GBmuLWO5khjEEgwSv8Jrn5jG0ZurgQNK0zq0asQ2NoI+Xj5Qfz5qkjFUKGRgOuA3HTP50AdRBot1d6bLJbSE3drlztPVf8a9A8HeMLl9Jint2Zvso3SoWyTjrXK+Hb5LRmMu/cIQJF/vAjqax9BvBp2qXUm4rDKSCijjBoA9J8eXdprOqW2vaUsLpqdr5PmdSkg7fWsOGS2ENrDIGN/ChWVV6Oap2NwPDWlJJgTWtxcboz97y8+g7V1emeFptWu49Usp7W2VDuaR25/EUAUNKlhkypVY3J5UjpXT2F0Fj8udY97EeW6r1FUX02wivWnn1SKWTOGEacEexrRW1jupbaENiINmI44/GgDUeUPAkC/vVZ8FCcHJ9KfqcEg8G3llJC/mWsgkVmGSq/Wrr2SWLecZ7UXCjjc3X8K0NPvlhhmnlH2yO6Ty5Iz0I9qAPNobWOUR3cce6aI8le4Nd14LuHgA+1bzFA+4ouSSD3zXMX+hXGg3ktzbFhplwf3WTypP8JFdZ8NLvbq6xSMSJjsCkc7vT6UAenWV1IsfnwAPbSn5cHJ/KtGf5lDDoR37U/wDsxbW5+0wv5fGHjH3fyqSdQc4OR60Ac/eA85rntRXr3OK6i8TqfWue1BOTx0oA4jWoRLDNGRkOjL9civlTUE8u+nTGNrlcfQ19V+LWkttHvpoX2SxxMyMR0PrXyjdSPLcSyStukZiWb1NACDIc7eR3256VdgeCVlFzEORguGOQMZGaogguT83PvVlI2dese1CM5bgen/16AEZV2yyiNFRSBgsSTkHjjvwaQrGk0RAYq4Bwwxj/ABrVmsyIxEsq7DEHMeTvcjcd30ySfwqlbbPOia4kRnAGASThQOKAO60nTUutPCF13MvyBR3qv4bjeO+vWu41W4s1Kxljhhn0q14U1FJ32RbUDfcPrUniUaddanH9jvYmuMFLhIzyMdfrigCXwvFN5Tu4ZrjfuYt0IJrqdOuV894djqJDzIf5Cub8OuiwrFBObqINsyOorqo7dYYg0KrJhgAA2cUAa1jHHHqSyx52rx5p5ArpFhS4uEMcphixh2jH3q5K+1W3tpIdLSdJdTl5+yQjO0erHtXS6HdukBhXTprq7B+7Ccp+JoA27PTobNH238hz8zM54Wtax8Ov4l0eeWLUSkzqVSBl/dv7g1XttCuLqeKbWDGqMQDaxH5cf7RrvdJsDLDJp9mnlRwrmKVP9WnoM0AeJ2Md4k89lK2y+twYpA45GOn4V9BeB9TTVvDlnMu1ZY18qVB/Cw4/+vXNeIPBdt4gt1v7IfZdftfldgflnIH3W9j2NY/w61MafqqwsGtlmmNtd20gw0U2PlyPfsfegD10jNFFFAFe8fZ5J9ZVH58VO43Iy+oxVXVnMenyyKMmPD9PQgn9KtA5XI5yMigD87fjFYNpHxE8QWbJsVLlpF9w/INefnqa96/aytLKP4liexnjlmuLdTcopz5Ug4Cn3I5rwU9aANH7I1xJbLCYzJPuBjVWLKR6j1+lWdCltlZhPByhDJIq5KnIGTzxyR+JqkJ2hnSVcOAzFRyN2evI/mKksY4knT7XKsMeQwyGYqMg5GO/GOfWgB97dpeSNNcwIHYZ8wMck4yB157AntVeNmSGK5a3iaNJNuChwx64Jq/cadACSuq2rRpIscjbCCOCFIAHPAPT8TU19p8EN7PbRzptSPKxP1XIHzZ6E9/xoAvWt5DqOtXUciSo88WFBXac4zjFUoxGsXllCk6thhnORV3wnqFjpOrM2oGOV0RmMrLznH3QTznFaN7Db22q2WpxKrWOpZZSw6ev0xQBa8FyTWsd28EUU0mMLHcDI+oFdF4dge2inaf5TOcvFnv7VhaJJpl29+trd+bMqGQjBT5R3BPWtvwbLYzbUt7nzVlOfMuGAMbemKANiGGFoHt/LHnE5Q4wFrb0dmtp2ZlEtuq4b1J9qZexzRQpFAbW4Ej4kdW5QetULbUdJm1prXzLuSG3x506L8in0BoA6600yO+tvNjgj8wHO9znaPSrt9qGk6NBDHcl4pyQInCZDP6CpdHuJbiPPh/S55WH/La4+WPGOtbFjpOZVN0UvbjfvOV+WE/7IoAl8Q+E47/wnKbSSZ7+RRN5L8EHGeBXmmjXEiTwSW6sl3byBhkcq69Q1e6LZXNxKlxbysksIzufgN/s1jeMvC9tq+nTa94dtvs+rxDN3bAY89R1BHr6GgDr9Kv49W06C/hAPmrtlRT91u9OeBVB5JOeSa88+Gesx297aJE+3TtQLRbG+9HOOx9DXpskLKCrMTg9T/KgDBvIgVOK56/hPmOcYUgfnXWXUeM5ArntUAjkTe2BIdi/WgDz3xdp4v8ATLqAjO5Dx68V8lahA1teSwyAh0Ygg+tfZ+rQth9oAbsT0r5L+INutt4qvo0kWVfMLbx3zQBgKAjuCQe2QMjrVxMhYB9lZljLFsR8vnpk96qqoBZCMscBSwIq7p0syGIJcSxhiqsQ/ZmIOM8dBnNACS2zxWkqvDdecu35iuFXG4Hn0wVpsFuGspZnEhAwE29Wb1+gFWGup57BLdmkkMuH+ZicHLLt5PQ4U/nVi0eK20+dWceeApjVz94d9o7+1AEsU01pdCZUaT96zCXYyiU5B+Udup68VUufMZ5Gjt5CfMySEPHXPI9c9qvLdzS2wDK7RwRyOETKNlTwzDnjtjPWmzSm6IuLi4SCOaV12wS5AUIGC7Bg4zxnqaAK8FusFvkLOrtO6nYrK5UKpXHpye//ANavVNJtZpbaP7H5iMVUysBn58cmuR+H8Vv9puRPHHc3Mp8sxsSf3JAICkng+x54r0Pw/b2Vhc3FraX7iGXhY7n5fLPoD6UAbGg6LYWPnTS2nl6hMf3tzu3M4/pXZaQ80U8EVqyxxjqE/rXIabciwnltL2VZGDblVG3Lz3rsNEj3l3gcxoQNzAdqANrTrm5OpW8N6xa2kn2kbccfWvTYhcW928EDxLaIvyIi8n8a8+tIi8eyLcyg5UseprsbKSaziW4dhJGgy46k0AbUVlsijeJ/LmU5z2P+yfUVT1Dw7YajeC/MPkXxAVpVHLAdNw747GtHTboahZRXPkSwq/zKkq4b64q3QADgAZz70UVEkjmeSNo2VVAKv2bP+FAEjKGUqRkEYINRWbs9rGzqVbGCD2I4NTUgAHT1zQB8m/tdeF4rHxBY+ILaNUjvIjFOAMb5R91j74r5kuEIlYkd6+9/2mNKj1D4X3dxLEHFhItznuuOP618H3/+swR1JP4mgBZA1vGyzJIr71PIIxjsfUelSWrHzMRRSThZFYFE+8q54xzjORUl1FHBDBMgDCcbok5PlgH5uvXkEc/WogiFri32Mkvmbd8sQG0dMNz8nv1oA0BZamzWMZ0+RxDE0EZEQIbczNnPQ8uevT8Kp31jNZ2TJPYXEUiSAmWTIUDGCAO+T39qZG+Fj3TOokKK58zG5Tndn24H0/GmzXU01jHZAs0SEy4J+62OcegA7UALGNkTSzqweR1KyEfMnOS4HeuosrvUdUs7PQxaCa2LSCKeWPB+bPz5z8n05rBEscNjHCd/2tZcxLs3fKcYOOh9quz3M8L214GS4a2iScAZUQNvx8wHHPGR+FAGbJYXpkaMWcyyRStuG3pnA4x1xj6U9dPniRP9Gm8y3cm42qcxZI2liPu9+v8AWrGpzi9cX+oXkcl3c+Y8nkgs5dXwu9GwAMdAOw6dq9A+D94+nWFwsAsrr7WxjubacAGeMAYCtjtnp60AdVpekXNzawTWuGEg+Yg/Kw9a6jQGsI4JLSIQyxwn5kjTA3+pPeq/hzStDSKXTtN1e60SCRjI0F+nmKh7hG9K37TwtFbTie0vUuYW4k+zEfN74oAvW9/qCW6x277mYfwrhVFavh2URyxzSOPOLYlj7fWmQSR28f2L7Hcwsx+S4PGcdq6DRtPtGlPmu/mY5UigDobe1EzCS1Z2iI3AN0q5bRhZllXC3+04UdGX0NT6dE1pEI1/eFj8oPatCG2jiYuEXzD1agDhPEHg20hmudZ0e3MNzMyzXEC9C4P31HZh3x1rodYa4i0v7TbIJpolEhjPHmDHzCugqJ493HbvQBy1tdW2qWEV5YyCSCQZBByVPcH0INYPiWzkuLGZYMrMmJYj6svOPx6Vr+F9GXT/AO0ka1a3mW4b5gfklQ8hgKtXtuQTxgigDzu6KXdpHcIMpKgcD09RXzB8Z/Df9keIWubVNtpcjzAvoe9fVaWq28l/YgDZBJvjGOiPzj881438e9MWTQoLlhxFLtGPcdKAPnXcxYnJJPBJNaNjDGSqSoW7nqRVBOHYit7QFDS/MM4GaAH3llFbBZoAwkfjqTtGOtNt7S3G2OSCSYqDjLHA+npXQKizRSCRQQq8dsVn7FSW02gDeTu96AM2K7tHR42tisoyikFuQTkgnPPPrWxp2m21yyLqcfkySgLHOwOAB0A9MVSvyTpsk+SJYp9qkcYH06Guw1SeS6sIbaZt0AhVwoAXn1yOaAM7ToBBcmwtXS1uoHLpLjmY+5PrWjHr2pTwXd5f6VFefZowJCqECCXcRhwCSyALkke1bmmaZZnSFkMCmQW7uHOSQQpwc1xyXdzp7aHaWdzPFb6va25v0Eh/0gtMQ27nuOD6jigDq/EPisWGnxRtoGk+dJbrJ5qu24HaGJ67gpzxx06nrje+Hmp+Kta1q70fTTZX0VpEZniDBS6ggAxkEhlyw75xg4rzfVZ5kvfFSCaUrayi1hDOTtiyYwnPUBHZQD93PGOK9s/ZeJbxhEpJ2f2D5wUcKrGZc7R0A+ZvlHHJ4oA9E0HzLe8FtqttNbTFRtgmXAP0avQbayQJbCMmOFTkpnduq7rEEU1hL5sasVUlSRyD7Vzej3k6anFaLIfs7HJUgH9etAHY0VTuZpE1OziVsRyLIWGOuAMfzq5QAUUUUAFFFFAHP/ECwTU/BGu2kmAslnJyegIUkfqBX5v6qm0kuVaQnnH6mv0s8UosvhnVY3zta1lBwSONp9K+JrzbZ/F+Q28MCCKAIi+SpUDy/wC6Rj8aAPLjbGSVmTazOMsgpsVmSxLRERjgsM49cGrkCg2aufvDoadFPJGkLo2Gkfa3Gcj6UAbnhzTYWlYvaQujqcvjeCPTHaoNQsIIroyJaCzyceZzsf8AAmu38J2cH9lXkwj/AHijKnJ4OPSrms6ZZ3eh201xCHkIznJH9aAPLodNSYXkcMMYJHDuOB/u/wD1qu3NgZ7GzVraPfAoVmZcEqO3vWjqFtFb8wrt2rkckgfhTdQvLi58L6b50hJkuljYgBSVz0yOaANm3tfsaW1ydPtL3Sb8qJ3eLc8TjoxPXjNXbzQ7WeX7JpssEOowIWtMfLHJ3C8dO9W47ePR/iVBoWn749JltBK9s0jSKWIznLEn9asarptovhvxEywhWht5HjIJBVh0I5oAwtI1/wATQ+G72YQtc2MdxFbNdyW4ZbVzgSFgOCoYhQSe/wBBT1+JGtaZIq6culQxuU3GSHcIcqhJbv1Zjnpx9a4qx1a8itGEUqpF9os2aARqIXKxMQXjxsY5UE7gckZOaoad86vGcbZJTGxAwSmD8uRzj5RxQB9VfAvX9c8c3+uWmrXNlJbWCRNFAYcGQPu+cMONh28Y7165Y6JFp10zQQ3EWTyJDvj/AAPavIP2P1E8PiW7ly06/ZYVOcAJsZsY6dSTnGa+jaAMi3t5zqRuLkmPaNsaIcq3vWsBlec8+9YOq3U9rq1pFBKyxyygOvUEH69PwrUjdjqcyk/Ksa4H1JoAt0UUUAMKZYkng9qqXVtnoMir1FAHAapo/l6096C376DyHHbIOQa8p+OGmlvA+oPt5iw+7snvX0PfxIVyVGa8x+LVtC3gjWS0YJ+zv1/3aAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lumbar MRI scan in a 57-year-old man with known squamous cell carcinoma of the ethmoid sinus with metastasis to the skull base. The sagittal enhanced images demonstrate a large, intradural metastasis at the L1 level (arrow). Surgical pathology was consistent with metastatic squamous cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Welch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4610=[""].join("\n");
var outline_f4_32_4610=null;
var title_f4_32_4611="Anatomy choanal atresia";
var content_f4_32_4611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomic section of choanal atresia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomic section of bilateral choanal atresia, the obliteration or blockage of the posterior nasal aperture.",
"    <div class=\"footnotes\">",
"     *: choanae, u: uvula.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4611=[""].join("\n");
var outline_f4_32_4611=null;
var title_f4_32_4612="Multilumen catheter";
var content_f4_32_4612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Multilumen catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 463px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHPAgUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzLXvD+ja78U9W/tzSNO1LydG0/yvtlsk3l7p73O3cDjOBnHoK9NrhJTj4qa5/2BdO/9H31NbgVf+Ff+Df+hS8O/wDgth/+Jo/4V/4N/wChR8O/+CyD/wCJrpe4pasRzP8AwgHgz/oUfDv/AILIf/iaUfD/AMGf9Cj4e/8ABZB/8TXS4pRQBzP/AAr/AMGf9Cj4d/8ABZB/8TR/wr/wb/0KPh7/AMFkH/xNdNS0Acx/wr/wb/0KPh3/AMFkH/xNL/wr/wAG/wDQo+Hf/BZD/wDE10wpaAOZHw/8Gf8AQo+Hf/BZD/8AE0f8K+8GHp4R8O/+CyD/AOJrp8U7FAHL/wDCvvBn/Qo+Hf8AwWQf/E0D4feDP+hR8O/+CyH/AOJrp/xpcH8KAOXPw+8Gf9Cj4d/8FkH/AMTR/wAK/wDBf/Qo+Hf/AAWQf/E10NzdW1qpe5nRF/2jisW58ZaNC22OR7h+mI1LU1FvZAV/+Ff+DP8AoUfDv/gsg/8AiaP+Ff8Agz/oUfDv/gsh/wDiacviyab/AI89FvZB6+Xipv7c1sjI8PXOPp/9anyMCD/hX3gz/oUfDv8A4LIP/iaafh/4M/6FHw7/AOCyD/4mpz4k1CPP2jQrpQOvy0kXjHTmYJcwz27dw6Y/lRyPsBEPh/4M/wChR8O/+CyH/wCJpR8PvBnfwj4d/wDBZB/8TW5Z6nYXgzbXKN7AjNXdvcEN7g1NgOW/4V94M/6FHw7/AOCyH/4mkPw+8G5/5FHw7/4LIP8A4mup2mgigDlv+FfeDf8AoUfDv/gsg/8AiaP+Ff8Agz/oUfDv/gsg/wDia6jFJg0Acx/wr/wZ/wBCj4d/8FkP/wATSf8ACv8AwZ/0KPh3/wAFkH/xNdPRQBzH/Cv/AAZ/0KPh3/wWQ/8AxNH/AAr/AMGf9Cj4d/8ABZD/APE109HagDl/+Ff+DP8AoUfDv/gsh/8AiaP+Ff8Agz/oUfD3/gsh/wDia6eigZzP/Cv/AAZ/0KPh3/wWQf8AxNJ/wr/wb/0KPh3/AMFkH/xNdNRSA5r/AIV/4M/6FHw7/wCCyH/4mk/4V/4M/wChR8O/+C2H/wCJrpvrRQB5/wCKvB/hnS7XTLzS/DujWd5FrOl7J7exijkTN/ADhlUEZBI+hr16vPvHg/4k9h/2GdK/9OFvXoNSwCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcHN/wAlU1z/ALA2nf8Ao++rvK4SX/kqmuf9gXTv/R99TW4G0OKXp0pKWrAKUUUAUALn0pe1GKBTAMU5R7UAc08AYpAJjig8dfxpksyxg5IA9c1xviTxV5DNbWGHn6Fuyf4mqjFy2EdHq2tWWlx7rmUBuy9SfoKxYrjxD4hI/s6D7FZN/wAt5eCR7f8A1ga5vwzNbrqv2zV4TeuTxvOcH1x3+lexWVzDdW6S27BoyOMdvanP3OgbnJ2ngCxMgl1a5ub+XqQ7kL/j+tdLYaTp9goFnZwQ47qgz+fWr3SmSSKgyxAHqTisnKUt2MUtjNJv9qpTatYQ8yXUQx1wc/yqJfEGmN0uV/75P+FHK+wGmGqK5tLa6Xbc28Uo9HQN/Oq66tp7/duovxOKtxTxSDMbqw9VOaVmgOc1DwTpNzloEe0k7NE3Gfof6YrJn0nxBo3z2U41C3X+Bvvj+v8AOu9yKRmVQWYgAdyapVJLcLHE6X4nt7l/Iu1NvcdCknHPsa3lZXGVORXD+NtVtNQmeOOzVJUODMT8zY+nWsrRfEdzpzrHclpbfpk8sv8AiK29ndXQrnqGOKaRVLTtThvIleN1ZWGRg1f4NZaoZHx6U2pCOaaRxQIbRS0lABSdqKWgYgoo60GgBKO1FKaAOb8e/wDIHsP+wzpX/pwt69Brz7x5/wAgaw/7DOlf+nC3r0GokAUUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhJf+Sqa5/2BdO/9H31d3XBz/8AJU9c/wCwLp3/AKPvqa3A3O1KKb9eaUe1WAvenU2loAXvTwKaKcO1ADgKp317Hbocn/69N1S/S0gOThq4nV9ScRmU8yNwi+lXGNxXF8Ra7K7G3t2w5HzEH7g/xrm44Mc4yepqWGEk7pCdxOTnvVyOIDHrW6VhDIBtI+XNdV4Z1pdOLJLuETckdeawETI6VKi8elKST3A6XU/FlxMSlkqwr03t8zf4Cueubq4umzcTSyE8/M2aTy84pRHUqKWwEI9hjFLg46mrAi69aXy6oCspK9DUsV1PC4aORlPsaeYxSMgB6H8KANiw8T3cGBL+9TuD1/OpNd8Qm7s/JtmdN33+O3pWCY/SmGOp5Ve4FKVc9eaqywjPStNkx1pjQhgOKu4FHTr+TTLrCbvJbllHb3HvXoGk63HIsYkcFX+63Y//AF64We3Xb6iksZPszmKQ5gfj/dPrSlFSC9j1r7y7lOQaawrlvDmtNFOLK9bqcRue/sa6xhn3rnlFxZREaT9acRSHikA2ilzxSdqAEopaSgAooooA5zx7/wAgew/7DOlf+nC3r0CvP/Hv/IHsP+wzpX/pwt69AqJAFFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4Of/AJKprf8A2BdO/wDR99XeVwU//JVNb/7Aunf+j76mtwNvNOHSminDpViFpw6YpopwFMY4Cm3UyWtu8rnAUVKorjfGuqZnSyhbkctiiK5nYChf3zXt0WYkoDx/jWFPKbq6LfwL8q/SrMxMdmcH5m4qtbxkAHGMV0JWJLESe1W41BYjHSmQFcYPP0q2iEnOAKAESOpVjUdcCpY4SeWyamSBRwFGPpSArgJ9acoHYH8qtLFnjHAqZY8DjpSApBP9k0pUjsfyq95YxSbcevNAFAr/ALJ/Kmsoz0P5VobO4oKdaAM7ap6GkaMYq20QJ6A0wwAdARTApMnam7KtvEw6N+YqMhl+8v5UAUZI+9VJoxjBFahCkEKaqzR4BzVJgVyRJBgk704z3x2Ndr4Q1g31u1rct/pUI6n+JfWuHzscHPHQj2pIbqXTr2K6g5kibkf3h3FKUboEetMKjYGksrmK+s4bmBsxSruH+FSsB19a5iiHHHNBpWHPpTaACkpaDTASiiikBzfjz/kDWH/YZ0r/ANOFvXoNef8Aj3/kD2H/AGGtK/8AThb16BUSAKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVDcXUFsM3E8UQ9ZHC/zoAmorKfxDpSdb6I/wC7lv5UweJtFJwdSt0/322/zouBsUVDa3UF3F5lrPFNGf443DD8xU1ABRRRQAUUUUAFFFFABXBz/wDJVNb/AOwLp3/o++rvK4KcZ+Kmt/8AYG07/wBH31NbgbXanA0nGOOTTgPWtBCjmpVFMValQDGRSAg1C5WzsZZ2P3V4+teTee95qcsznOWxXYfEXUfJto7RWwz/ADMK4bRMvIzHjngVtTVlcTNW4IaSNMZwMgVIkefvH8KQqftB49KsxLntk/yqxD4IRuGBWjFCc5xxUdvEM81pQxfLnBxUyko6tjSb2GJHinmM546U55reA/vp4Y/95wKrTa3pMP8ArNRtQfQPmuOeYYWHxVF96No4WtLaD+4s7NoyeakVPasOXxjoMfW/Rj6KpNUpPiD4fjODPKfolYvN8J0lf0Tf6Gyy/EP7J1RQelLsrjH+JOjbsQpcyehCU1viXpSYMsF0g9SlS83wy6v/AMBl/kV/ZuI7fijtNg9KYycVysXxH0Fx8zzr/wAAqZPiB4cb7126/VDULPMJ1b/8Bl/kDy3EfynQtHTSlYy+N/DrgbdQGfTaant/FOiXBAS+QE9NwxWsc4wcvt29U1+aIeX4hfZZfaOozHntzQuqadIMpe25+jCp0eGUZjljceqsDXVTxlCr/Dmn80Yyw9WHxRa+RQlgVhyPyqnPEwXgbh71sug9RVaVARxXSmnsZNNbnOXCKwIHDehqrcNkjPVlFbF/bhxgjB7MOorFmJidI5wOpw/Y1ohHWfDPUxi502VuRmaIH0/iA/Hn8a7pq8Qgvn0fWbe9j/5YuGIH8S/xD8s17dEyTwxzRMGjkUMrDuCMiuepGzuURuKYR61K64qMiswG0hpeetBoC4lJQR70hoGc748/5A9h/wBhnSv/AE4W9eg15748P/En08f9RnSv/Thb16FUyAKKKKkAooooAKKKKACiiigAooooAKKKKACiiigAqjqep2+ngCQl5mGUhQZZv8B7niqutaqbeQWdkA964zyMrEv95v6Co9J0gRlp7lmkmk5d3OWegCsX1bUznf8AZYT/AAQn5vxc/wBMVJF4et4yZZym7qWfk/iTWrc3SW6bYgCw/IVzeo3zyE+ZLn29KVgNCZbCFSVk344wAB+tfOfjX443EOtXdnoGlaXNYwuY1nuN7NJjgnAIAGc4r0Hx7rzaf4X1a5idlkjtnCEcEMRtBH4mvkM7ieT+NXGCZE5NaI9Gl+L3iFLoXNrZ6daTDq9qjxsfqQ3P0Neg+Bv2lbiKaO18Z6cJYScfbLMYdfdozw31BH0NfPB5OOxpjxk5we1PlsJS7n6MeH9c0zxDpcOpaJew3tlKPlliOfwI6gjuDgjvWlXwN8K/E/inwnrTXvhiOWaDj7XbMCYJFH9/spHOG4I+hIP2h4E8aad418Lx6xpTCMEmKaKY8wSjGUb16ggjqCOlZ3V7J6mlna7OporkvFuqa1o9nNqVnBFf2sMJAhiBVmkJADE8/KDnIAPFcp8F/ik3jC4vtC15baDxHYli32c5huEDYLIcnkcAj6EdwGK56xRRRQMK4Kf/AJKprf8A2BdO/wDR99Xe1wU//JVdb/7Aunf+j76nHcDbAqRRWfqmq2mlRRvdyYaRtkaD7zn0Fc5H8QNMj1n7HfMsKRli4Ulmb0Ax3z/KtL2Got7HcBec1KB3PauHHj7RbnWBDb29+jchXkJWNsdeM/0rP8Y/ESG00ECy5nlnSMeuN3zH8gaUWpbA4SW5zvjPVlutamkZvlU7VH0rA07XorEHcrSNntXP31//AGjfzyW4O0n5FJ6CnW2nTzf6lsMf4sDj6VpKbS0NYU4/aOwj8ZWMbs13HKO4HCj9ck/lUVx8S7OEFbDTFY9nlcn9K5j/AIQ4SXG+6ueW9ZM/y/xrdsfCGhxqPPdZD34/xzXk1qE6krub+/T7lY9CFShFaQKF98TNUL+VFHFC2M4ROcVkz+Ktfv2CIl1MWIAHzY/KvSLDTNDtGDLbRu5wN0h3H6VtW9/ZRLtgEEY6YRQKxeCpSXv6myx0o/BA8kg0Xxlqcq4sXhRv45jtA9z3rbh+H2uvzcanbx8c7Vr0QahHLJt80jPfBwK01tYygZrlatYehHZIzljq7f8AwDy1/hncsPn1o568AgfpWhZfDuyht1juLtrh85Lse9dzI1mhw1yAf901Uubq2iTckruPZCa1UYR2M3iK0+v4HMN4A0RkKyvL6homKsPbOauJ4J0mC3gktnnjYOFErtvIHP55rat7uJ4UcWc83mZVCARlgOfyqxe3BtLS1F1azxZkVsbM5+lVGUb2M6kqtt2c3ceE4DK3+mvnoQU/+vUEngxJI2UXUXscEH+ddeZbR28z52DdMg8n09qqrPayEAyiJyOY+WwfTI60e51sEZVOjZwj/DaZsE6zKzdyQpH4Ais67+GeroQ1nqUUhzyH+X8eBXrFvbRXDIsM+9nO1QFJya0BoN4mDh8H0U5o9nCWti/rdWH2vwPB7rwJ4ytoxJatBONuSqyDIx+VVPs3i+yR5ZtKuQsTYZ1B/Doa94vlawbbIxDgZKspBx61VXWrdeJH4HHIzUvC4eW8S45hX7JnjNp441/TiUMd4jJyVkUsBx3zWxp3xdmkUre29pIP7yja35HrXpzX+nPvY+US4w2V5I9K5e60LwvLEypbQxjqNo6VlUy6jNaMv6/zfHTOf1Hx555X7DJEGYbtjjaefbOD+FZH/CZXBfyruOGRM89VYD6GtHUvBuiSkmN1BHTisC78Nx26EC4WRAeAScj6V2UITopRjJv1dzCpOhVfw2+VjdbWIL6H73zgZGa9e+EWqnUPCyWsrFprV2QZ7x5+X+o/CvnR0axkQj51X7xPdfeux8E+MJdJnuXU/usR7Bn0JP8AWu7m51ZnFOlbWJ9FTyJEwWQlS3Tg1AZUJGCx3HA+U/4V5gPHuoarNarBJDAxk2mUqWCLg8kDnrgfjWtH4gubZxNqeu28tsisxhgiaN2I6AMRjmsJS5XZoFSvG9zuypppBrltB8YtfXMAvtKurS2mfZHKZ1cdCQSMDg47V1ZvdPH/AC1/Jx/jVXMmraMZim965/UfEum2/iKG1e/ukR1GIkjBQn3fHH51rvrOlK2DK/4MMU2rAYnjwf8AEosP+wzpX/pwt69Crzrxzf2M+kaelu+ZG1nSiPnz/wAxC3r0Ws5AFFFFIAooooAKKKKACiiigAooooAKKKKACqGtagNOs96gPPIfLhj/ALzn+g5J9gav1yrv/aniG4l5MFmTbxem7+Nvzwv/AAH3oAt6Bp2zdNOxkmc7pJD1dv8AP6VZv9SUExwtwOCw7/SqesaitpapbQMN7LliD0HpXNXV95Cn6UJAat/qsNtaSzXUqRRRqWd3OAoHUk18/ePfjG0k72vheICPvdzLnd/uqe3ufyrB+K/jyfXLuXTLGUrpsL4cg/65h3PsD0H415oSd1axh1ZlOfRFzWta1PVHeXUL64uC3UM5x+XQVjM5bJOOe2KsspJ2nNdP4R8C3msLFe3rtZaY5OyXZukuMdRCn8Xuxwo7ntTq1qdCHPUdkFKEqj5Yq7Od0vTrrVLuK1s4JZ7hzhY41LMfwFekeHvh9a2zpLr8v2qUH5bK2bK59GcdT/sr+LCukxpXhWB7VQbEMo3WcLCS5mHrO5wFHfbwv+y3Wtnwh4a13x1Irsj6H4dXPnSocSTr/dDHBxj6D2ryqlXE41fu/wB3Dv1fod8KdHD61Pel26GPJpc+vXSaVYQFoIMKun2QAih/66EZAPt8zfSp7y01X4XyMq3sfk3xHn2dsNwgYfddj69sDJwfpXqd3quleE9MGkeE7ZU42Bol+Z29u5Pv1/nXOr4WmviZ9WQS3BJKwE5SP1Lnue+PzNcFOrGM1Swi5rby6f8ABZ1VIOUeeu7dl/XQ57SPGvibxDbjw/bzRxxXDmMu4+bYRyAateHfhdqGjfEHQLrwxPbwJprr9twSMxkZfJ53buRt9+OOlHTZrTSviZpWi6q0ebueMQyKeu5gAhx0z2PvXqP7O2o3Wt/CbRNY1SUT6jdifz5tioX2XEqrkKAOFAHTtXsUnJ6tnmSjY9KooorYQVwc3/JVdb/7Aunf+j76u8rhJf8Akqut/wDYF07/ANH31VHcDzn4jalcjx2iW6h0tokU5GQCfm4/MVS0EWh8U6drmtGJonuHiZM5wUj6sO3JBq74jgM/jzVS+7CygDb1I8ta8y8fwXsei2skUqiFriWIjI3s42kcdcY71klz1HG51LSCO7+I/iSye8mbQZYJLKSfchXAeNwo3YXqFz3PfpXmGranNK0SMzHksD9B/wDXrE8GWc4vL0ThtwQcE5zzUniu3lEdv5QbcJMcemK64UVBclyFPrY6LR7kGJXQoW3FcE9sda37PUZ1wQbYf7z15zottdCWJQr8DkCtp7G8JOIpCO5ArOSSubqCk73PRbW9ka4iKS6fKo5YMx/Liu30SW2bElwtgvPGI3YD9a8KtYb+Fv3MU6c/wgiryXGrrkCK7b65/wAa8fFSrX9xHdSw9Fr3pfkfR9uNGY5MkRzxxbMMH/vqrTLoxi2oYwp9ID/jXzlFc672tpiOvI/+vVgf224z9nI4/u//AF68yTxfb8X/AJm6wlB/b/I9/mh0xraaOGVY5ipCOYD8p7HrWza6osVvDHJfQlxENzHpnGMdOtfMF0Nc8tj5ckYAOSsan+dVtOi124gEkJvZlxgEBDTj9djFtW/8m/zFLB4dvWf5H0ZqWp2c9wwuIraV1wBLgEEfiRU1peaAI8XEdlu/4DxXzu2k6wxzcW97gc5woqVNL1TyjiO7CdvljNZOOLvf9H/maLC4dq3P+R9BjVdCiaMB7NEiffGBKAFPc4yKXVvEGiXVog+22McyNuUtInHsOa+b5dI1ZJTvivuecjZio5NK1l4kzb3zKx+U/Ljp6VUVi+jX3P8AzFLB4ffn/E+kl13w4iyK1/phiYbiPMXBb161Hbaz4aSNfMu9LP8AwJc/oa+c00fxA6FY4Lrb6FU/nU0Gl+IUAVYLnHoVSk6eL6S/B/5gsJh7az/I+jV8SeF4GBjvLJSG3AxuoOfany+M9MaN8ajEMj5CJU6/nXzz/YviUJlLa/AYYzuQE1mXem66gdbiO9TPUGRRWsHjdrr7n/mS8Hhf5vxR79F4ksjql/PPqdrLDKIxFG7oxXC4OeeOc/nV6PxDo2QWaxcHrgp/8VXzPbafrEks/lfbCwZd2HXg44/Srj2euwAFxeKD03OtXKONbvdfc/8AMPq+Gta/5H0bN4i0ZUYwx227rwq//FVyOs6zA+/YLeMD+6o/oa8gltdalwcTYP8ACJVFQPpWrMnzRyk57zCtqaxf2rfj/mS6GFXV/ejr9T1iBWZTeRhvTb0/SuduNTAYlb2PHpisWfQ9UxjyZMe8magl0LUioVoXx65r06Uqi+JHLOlR+yy7e34eJm+0IzH0rOt75WXbEx4OSKr3OjXcKHKH8TTdKsZFllz12j+dehT13OeSiloz0n4W+JtM0fX/ADdchEto8TICV3bG4IOPwI/GvTNd8eeC5tPf7TbGKy6POlvhkB43DjqM56GvBItFub6SG3tmVJXbgscDgEmpta8G38Gnuk13CVfAwpJ6kD+tc9WM/aKz0HGFKUG38R6D4Wuvh7pmoCe18fOLVXaSISRusoJ9crjPXnHPpXZN48+H/APjy4z7Kf8A43XjVl8FZmjUS3cksg+95KjH071JH8DbqQnbNdgZ4BiA/Wunkp9zgk5N3Z1uu+NPBJ8YaXJbeKby4siT9quDG+YvTb8g/Hg10x8d/DZZNx8c6kVxjAST+kVeP3HwbuYb1LdnnDP90HAJ/SrJ+Cl2pAxdkntkf4VXLB7sWp6Zq/jDwPqkmj2Wh+KL6/1KTWdM8q3lWQK+L2AnOYwOFBPXtXvlfIOl/C258OeIfDuqyJchLfWdPyXYY+a7iX0/2q+vqxqqKfusNeoUUUVmAUUUUAFFFFABRRRQAUUUUAFFFFAEV1MtvbSzP92NC5+gGa4R9Zt/CvgO513UeVggNw65wZJXOQv1LMB+Ndh4iBPh/UwvU2suP++DXzx+1DrZtvC3h3QYWx9qc3cwH91AFUH8WJ/CkwbsjyHWPib4r1Vlin1aSCMsdxtx5bNlieSOe+OOwrFOt6pNPK51K9O5iRmduR+dYBOCMd+alimKrjrW0DKUXYuDOeT1p65kdI4kaSRyFCKMknsAB3qbSNOvda1GDT9Mgae6mOERf1JPQAdSTwBXsfh7StB+HWmjVdWnFxe7SFlj+/O/eK3HVU/vTHk9sZ5xxGKVKSpwXNN7L9X2RdHDuonJ6RXUg8HfC+DTrIa545mtrWGMZFvcPhI/+uuDlm9Ix+PpUus+N59Tvm03wJZ3G6QCJ9QZM3Eg6AIBxEuOmMY7Yra8Cadq/wAT9bTUtdITSY3IjtVGIljOcqg79ssea9j0rQfDngPTVWKKLzEBZWZRvP8A9b61xuMKF8RjJc0l/wCAryS/4e7OlSlJKnQVk/vZxXw4+E9pocI1fxe0FzOQZPIfLKrHoWP8be3r6mtvVtavdauDpXh6AJZx4Un7qAern+g5qbGo+KbhZruV7Wx6pEvDOvsOw/2jR4l1rQfAVlBLeyiJ+kVnBhpWGDyATx7sf/rVwOeIzV2s40/xl/kjqUaeD1lZz/Bf5slttM0vwtp0+p6xdxx7R++vJuP+Aovb2A5NcfrHi57qFp4Ifsdiyg29tIvzyKeRLNjsf4Yh16tniue1G4vfEckHijxavk6cp3aVpTZKsD0cr1bn1++fRRXnPi3xNPqFxNHFIcsSZJA27GeoBHUnufwHHXplTcGsJhFZrd9F/wAEiMlJfWMQ7rou/wDwCaw1SK9+K3hkRsZ5X1m0Ms7nczHz04B/nX0B+y4R/wAKL8MjIyBcnH/b1NXzP8O7GeT4h+FpBE2xdVtWyRjAEqmvXP2Wtbe3GgaK7Dybzw9JcqCf449SuxgfVZDn/dFejToKhFQTucU6rqycmrH0lRRRVCCuDmOPirrX/YG07/0ffV3lcDcf8lV1r/sDad/6PvqqO4HK+Iw1v4yuW2hVlRX3McA4Uf4Vwvi+18/VIbOFo3h+2vcCIDJbfEDn8MYr2TxNoI1aHzICi3SjAZ+QR1/CuU13wZcSC0vY3+z3iyqJHUAovOAR35ziuecZRm5JaHVTnFxSbPN7zTBaTyM1k9vIW2lim0MuOP61y/ieD93Ac4HmjPHsa+h/iP4dvho6T3GordQxSrtj8gIVJBBOQea8K8a2Mq2J2AllkVuPTNdGHbatLcUmn7yM/QxIJlKMMDuTXW2kkpYAspP1FcVC01rYouzL5Lc/h/hVm11kW9sC8LGYP1JyuPpTlGy1L5XJ6Ho1k5DDzbVpPZXArUWUDDLpdzj08wY/PbXFaH4+jsCG+xxFs9RXoGh/Fi2uZY4HGyZgQAqg5/OuOpCTei/EqziNS5cr8ui3DHticf8AxNKbm46jRZQP9qfH9K7bT/FlvMp2vBnvvi2kVox6k0w3RLayD/ZUGsOV9g52jyvUFv7xGjt7CWEspBUMHzke4rM8M29zZ2MsYYosb7SSowp9817ZHqE8bA/Z4s/7lVZrTS5BIJNLgHmNvfauMn1rSC0s0J1Gebywahc28hi3TgDgjaufbmm2el6l5HzQlfUNLGMV6P8AZbNVCRG4iUdFWU4/KhYbdTzNcsPQyGhwb2sNVbdDzQx3MM4iknCtjhdytn8RS3M14k9vC8quckjkEAkV6KLGFLt54DbMHxn7Shdlx/dOeB7U97RY5LOQxW8yCUArswuWyCcUKm76IHWXU8zvLhYpWjuJrRJEOGDNGuD+dT2Nz9pnWKLULQuxwo8yP+XWvQNStYyZBbW2nwzk/wCse2EhHr171PYeTbW0MUlvbzPGuDK0ShmPqcCo5JdUjRVlbS5x0MbvHO8fiG1MUeACEyCfY4rl9UJuGuPO1BXYIdpCgZ6j06168P7P3lhplpuPU+WOaQnT1Y7dKseef9Qv+FaKFjL2j7Hi3hrT7wi8uI7kJCWUs7vty20DGAp7CtFortyoN3u5I+VJG/klew2168KeXZ20UKk52xxgDP4VO1ze43SSpEvuAKHFt3Qe1tv+Z48mm3UmMTSk4zxbTH/2Wq91o94e9yQOeLaT/wCJr06/8WaVYgm81+1UjqqzAn8hXF638XvD1uHSG6ubw/7Jwp/M01GY1Lm6M4O8P2YsHmuFx13Iwx+YqgLuCZmH2mRvxNP8Q/E2HURIkGmR4foWO4/jXMNrN/PGVit4YUPUhAK6I6fEx+yk9ol3VBHsYhmP1NZujSxtJKoOcKP51BLa3N0vzu8jnoqCrGhabPbXFz5qlSUAA7jkV0wTJkklZnS6dLFBeWskyx+WrnO9to5UjrWh4gu7S5sVijntVc4xskyxORVSy0a91SaG10+1a6nZtyxAjJABJ61tW/gTXIde046jpaW0Ms6JliCOvXANcmInUVZKMbrua0o0nTblKz7Gn4T1Oa2t7eYsYIrl+NqDKDHHLA/Wu5/t0kfLqUp+iD/4it/TfDq2UYANkh/6Z2v+JrSNngECZR/27pWyTRwSkm7njereJ/N8YW9kL5ZJVx8n27y5BkZ/1Ij+bjn3rYudWvFlBElw2PunzCv6COtDVfhlHefEyx8YJq5imtQgNubRCH2qV65x0PcE1195a38k0XkalHDCpzIPscbO3sCeB+RrR9LE3PNdX1OW5XR45Lm5fOs6Z8jA7f8Aj+g77RXu9eZeOU22GnfvpHP9taVwUQD/AI/4PQV6bWTTW4gooopAFFFFABRRRQAUUUUAFFFFABRRRQBFdxC4tZoT0kQp+YxXxf8AtKXhuPGmmwsTiDTYkI9CWYn+dfatfEn7S9rdWvxOvUulAjKI9uwXAaJskfkxZf8AgNFhM8pzV/Q9Mu9Y1OCw0+EzXU7bUUfqSewA5JPQVTt4Zbm4jggRpJpWCIijJZicAAV7poml6f4A0SRGBu9auMRXDwHczueltF+P3m9s9gK5sTinQSUFeT2X9dDejR9o/edordkMqab8OtAaGB/tF3ONs86/K103B8te6xDv68E8kAbHw1+F+qfEK5XxL4vkaHTJD+4hGVMijoFH8Mf6n9a6zwF8K3vLr/hKPiJ5fmBQYbD/AJZQKOQCO+PT155JzXZat4nkkkOn+GLdUt4lPmyqMKi/3uP8/WuJV4YCN5Pmqy7bv07LzN/ZyxL5YK0F93q/M0bi+0nwdYx6doltCbthtSOGPAH4D/Pqaq2OiXF1dDUvELiS4J3JbluB/veuPSljXSfC2kPrWq3SeYV3G5nOC2eyA8j+deUat8aL6/1GWw8MW7YnbZG7qC5+g/hye+azpYCtjJe3xfTZfZXr3ZpLEQoLko7vd9X6dkd/8VviHa+Dbc2ti0c+syqCsPUQ+jPjrjsv0zxXmnh3QMf8Vd8RBNe3dxmWz02Y4e5x/wAtJc/ciHvwQPTANXTDY6HdTeJvEqW82ruMpHP88UEmfvso/wBZJj+EZweTiuG8beONQ8SXM6vJILaQ5becvNjoXI7eijgV6cMQ5r2OEXrJ7L07+S+85ZUlD38R8l1f+Re8eeMZ9b1CZkuPOkfiSdRtUL/zziH8KAcep71z+lLuSQ4+XNYqSbj6n2rorGPyoEUjDdT9a66NCOHhyx+/q/U5alWVWXM/+GOx+HsanxhoEjMN39o24C/9tF5qr8ErprPxr8JXBwk2l3UDe+67vh/MipPh8ceN9AGeP7Qt/wD0atV/hLA1x4k+DioMlbW4c/Rby7P9KT1kHQ+z6KKKgsK4C6/5KrrX/YF07/0ffV39ef3n/JVNa/7A2nf+j76nHcDcVqkDZHPNQfSnqcVqImu447+3a3vF86FsEqxODjmsubwloFwuJtMgbn3/AMa01OakDULyDU+ffFvh6K11G6t5kOUYgEenauXn8MtLKgtWwrEDac8fjXtnxQ00MIr9F+8Nj8d+1ef6W224hLdmGfwNatKcdS4VZQejOcu/hzqsZJjtxMP+mTj+tZE/ha9spUe4s7+LYc7hGSPzFfQlm4Kqa2LMhsA+tc08Mns2jphjpx3SZ80WkzWUpMOpXVtJnJznOa6bS/F+tWUqPHqlrcJnOJo8fyr6BOm2V3HtubO3nX0kjVv5is68+H3ha+OZ9EtFb+9EDGf/AB0ivOq5dOW1Q64ZnDacDitG+Jty0Kpe2NnM4zlopCufzrrNN8b6JdRA3aPbSd1yHH5iq5+E/hUZ8i2uoCe6XL/yJNUpfhHpRBEOqanGP95W/pWccHiobST+8mVfB1NeVo6U+IPDjfMNQjJxjGG/wpq634ffG29j+nT+lcZP8IT/AMu3iK6X/rpCD/Iiqr/CTVFJ8rxEjem+AjH5Gh0catrMS+pv7T/r5HeR6pokpf8A0yNdp25JHNW4rzTHMMVvf28js+FUN3wTn9K8zb4V+IQMDXrQgdMxsKjHwp8SZP8AxPrIemI2pwWOi78sRyhg5LSbPTLyXTIDJLc39uAoywR95H4Csu68TaDbQlonkuJB91Vwu73ya4kfCrxGcbvEVoPpExqRfhJq7D974nQf7tuT/wCzUSjjXtFL5hGODXxTb+RNffExo52S00CYoPus7Fi34AcfnWHd/E3xDh/I0W1Q9jIQMfma3ovg4G/4+/El43GD5cKr/Mmr8Hwc0EAfar7VbnnPzTKgP5LSWHxsvikkb/WcBBe7G/8AXmec3/jzxVdIfM1O1sAVxtg25Prz2rltY1C41BnN74jvJd+Ny7iRx049q+h7L4W+ELYg/wBkCcjvcSu/6E4ro7Dw3omn/wDHjpNhAcYykCg/nitfqVaXx1PuX+ZH9pUaf8OB8hW3hj+0Jg1jZ6ldOcnMMBIP9K6a0+F2uTxQrBoUsSgfM9xKqc+4619VbQiALwPQcCqlzwprpp4RL4pNnPPMpy+GKR8823wgvlAe9u7S3x/DEpc/mcVdX4e6fa4864mmI6jgA16vqL7QQTXL6g/3q7adGEdkck8VVnuzk3021sMi1iVEAx713Xwv8M2EmgXN5qNlBcG7mOzzEBwg449MnNcderJPIkUXMkrBEHqScCvatOtY9P062tIvuQRhB+ArSq7KyMbt7hBp1hayrJbWVtDIowrRxhSPxqZ3z15x60jOaiJJrACUyUhPNRU3J/GgY5zzUMj4FKxNVp244oQHM+N3zaaYP+o1pf8A6XwV6jXk3jNv9H0seutaX/6XQV6zU1NxIKKKKgYUUUUAFFFFABRRRQAUUUUAFFFFABXiv7Svw8vPF+labqGhWpuNWtJRAY1IBkicgdT/AHWwfYFjXrmsarZ6PZtdahMIoVGScE4Hc8dh3PQd65LSPEY1+We4sroOskzLp5iON8YHJ2noSQTuOQR0x3TlyajS5nY+XdL8D6r4O11E1WGOLUl5D79wgGPvD1OM4PTNezeCYdC0lRrGqQrLcQoEtIn5MXfOP7x79/6ZXxju7mS+Md0sYvoR8rxnIX2z3FUPBVjbW1iNS165jdV+cRE5HPPze/tXkV5yc3Klu9L9Ed9KMeXlqbLp3PQxPq3jG482dntNLzxjqw9FHc+54qn4x8aaB4Es30yyiF7rBAKWEPzNuP8AFM3b1x19AOtYevfEhbqyFh4V89riVdsl0q7fJHT5PT/ePTtXll7qGgeHEfZMb3UnJMpUg5YnJy39Tk+1Y0lTw0vdTqVJf1q+iNZ89aNm1CC/rbqxstn4l8eaoLvX7h47VM7Y14SJf7qL0UfmfXNWLnxRpPhjT5NP0aCOa4JO7aeM4xl3HJ6fdU/U9q4nX/GOo6tE1uJDb2f/ADxiYgN/vHqf5Vn6dbxS+HfFF04zPYafHcQEHAVzd28ROO/yyOOfWvR+q1cSlLFuyX2Vt8/6/wAjl+tQoe7h1r/M9yTU9Vu9UuPPvpjK3RQBhUHoq9AKo72LYIrX8bWEOl+M9e03T0Zbe0v7i3hTJYhFkZVGTyeAKq2dkT88/HH3M/zr1IKMIqMFZI8yUpTd5O7JdKti5WVx8inK+59a3lbj378VTi5IAwABV6GPPy45pOVy4qx0vw7Td430A+moW/8A6MWun/Zr0CW+vPBOrsh+zadodzhyOPMe+u1x9drE1V+GGmvL4p0h1QkR3UUhwOwcH+leo/stxKPgh4bl/iZbhT9BdTH+tZKWty0rnrFFFFIoK8+vTj4qa1/2BtO/9H31eg157f4/4WrrOf8AoC6d/wCj76nHcDYBp2eetRA807PNagTK1So1VlPPtTlNKwEetWa6jpk9qerLlT6HtXh8im01LypAR82CD6iveFNeZfEzRmhvEvoFwkpycdmHX861pvoJl7Tp8qvOcit+wm+YDNcbokm+1Qjtxj0rpbF+RTaEdjZNkA1pryAKxNNfKrW3DgisWOw7bjNNbipOlN/CpuFhmCRxSYp3bHalOeKdwI8UYNO4NHHNFwGUU4c9aXb1/Si4DBTh1pQopwGM0cwWGrkjOKQqzHIOKeuee3pTuaLhYiYkDmqF2+Aa0ZAcZrF1STajc04u4WOd1af5iK5e+lJB9TWvqMu5j3rm9WuFtreSaX7qjOB1J7Ae5PFdMUJmx4HsPt3iIXDDMNku/wD4GeF/qa9LY81geC9LfStBhW4UC8nPnT+zHov4DArcJrGpK7GhGNJmkNJmoGLkUE8dKaTTScUANY1UuOhqw7VUmbI9qcUBy/jEnydKH/Ua0v8A9LoK9crx/wAXtmPSv+w1pf8A6XQV7BU1NxIKKKKzGFFFFABRRRQAUUUUAFFFFABWF4t8T2PhqxE145aaQhIYEBZ5XPAVVHJJPQAZNZvjDximk3cej6NbNqniO4QtDZRMBsXp5krdEQH+I/hk8VR8N+GZIL46vrN0mo+IGUiS8IPk2gI+ZIFPQdi33j3wMAAr9jltVuGfU9JuviPFIlvqV2sFlpa4aCKTrGbxgcEkj5YxlFPJ3HLDpfE9utrNM+lqH8QSxlEki4Fup5OPTnnPWsX4jPJrFv8A2LY2YvNDvYpIdQnkVjh9yFCjAEBxhirNhQRVbwMdcfTJdCuYTLeWsrQNqgPOoQ/wSnOSvGAwJPPfNZVEpqxUHys851eO0gu4/wC3dZ+0arOzxxquSjbQCVTuSMjOcVz3j1k8MxQySSGVbgfJbeZ8pxzkj0NepeLfCOnWXxt+FyzwpM17/aZuVxhGaO3VlOPqfxxXcfFX4X6T480NLcpHZalbKfsl1Gg+TPOxgOqE9ux5HfPNSwUYpRex0VMS5O63PiPVNdvNQlZiwgiPSGH5FH4d/wAazQ5z1/Otrxn4T1jwdrUmma9aNbzryjdUlXsyN/EP5dDg5FYsCeZKq5Aye9dsYqGkTmk76s0rC1SSPfIu7PTmt63to4fBnjZkUgnSoh1/6f7SqFvCUQLtIxWqibfBPjY5P/ILh/8AS+0q3LoYx1ZreP0x8QvE+1QM6pdE4H/TVqxVQk1u/ECJ2+IXiYgt/wAhO56f9dWrOtrJ3cLgnPrS5wtZhawbmxnn866fRdJkupkSGJmkYgDjOfwq74O8H3+rX0cVpbNITyT0AHue1fRngnwRaeHo455gs19j738Kf7v+NS25FpEPw68Ijw9ZCWdR9vlA3n/nmP7v1PesH9lz/khPhn/t6/8ASqWvVQMV5V+y5/yQnwz/ANvX/pVLTLPVaKKKACvO9R/5KprP/YG07/0ffV6JXnepH/i6ms/9gbTv/R99VR3A1QelOBqMGlzzWoEgpwNR7hTgaAJgaravYx6lp81tN0ccH+6exqUNTwaAPKtPR9O1OWxuvkbO3npn/wCvXTWwKOM1a8a6ENStjcwL/pMa/MB1df8AGvPNB8ZppmoDRvEzlMHEF6ejDsH9Pr+dbJcyuiT1zS5OQM10tt8yiuQsiBsdGDowyrA5BHrmuo06XcoBrCaKLxpDzUuAaYVrNARN0pDT2FIQcc0wGYpcU4LntRjigBuKXFOxz0/OnbeaQEYH507HNPwPSl256igBgH0pQPapAgpxAAouBVuCFQ5rktauMZArotWl8tMVxWr3EcUUtxdSpDBGCzySNhVH1rWmhMx7tuHkdgqKMsTwAB3NZHga2/4S3xD/AGhtJ0PTXzESOLibsf8AdFcnc6pefEPXF0Lw6rxaSWzNcMCDKo6k+i+3evedD0u10PSbbT7FAsEC7R6se5Pua6J/u1Z7sSNAtzzTCaRjTSa5SgozTc0maAFJpjEUpPGaidhmhANkaqkh4OcYqV261VnPy9q0SEcx4rOV0rp/yGtM/wDS6CvZa8Y8Ufd0nj/mNaX/AOl0Fez1lV3BBRRRWYwooooAKKKKACiiq9/eW2n2kt1ezJBbxgs8jnAAoAsEgAknAHeuO1fXb3V5J9P8LypEqZS41SRd0Vv6hB/G/t09fehLqE/i6RUM0unaHIpeKNW2XV+oI5Veqx8jnqc9sg1tTyWej2kEUkKIEG22sYhwPr6n/PND0Fueba1dw/D5o7jQpftsMP8ApXiC3lIe/vYGKqLgv22E5CfKNpPQc12kuqRavpsF6JvI0GVA9uI/v3KkZBA7Aj/69ZuuRhNYs9V1EQtexCX/AEEJ8pEiqMyY6kbV68kDFRfDrwJ9gtZQ8s66W07z21q/SBWOTHH6Jkkj6/ic27lJWNC3tr3X2WC3UWmnRnG1R8q/X+81drpOmW2l23k2q4HVmPLMfUmrUMUcESxwoqIowFAwBT6pRsDdzyr4if8AJdvhH/3F/wD0lWvVa8q+In/JdvhH/wBxf/0lWvVaoRjeKvDOj+KtKfTtfsYby1bkBxhkP95WHKn3BFfNnj39mzUrN5LnwZeLf2/UWd0wjmX2D8K347fxr6sooA+AbjTPEXhibyPEehX8UY+UNLEyf98tja3610N9p8h+FHi3VY7G/hs57CFEmmgKxuft1twH6E8HjPY19uEBgQwBB6g15P8AtOQRW/wG8TpBEkSk2xIRQoz9qh54pWW5PLqc/qXwr1LVvFOs3hhSOC4vJZVeRsZDOTkd/wBK63w/8JdNsmWTUZTcMP4EG0fn1r0yiiyHYrafYWunWywWMEcEK9FQY/P1qzRRTGFeVfsuf8kJ8M/9vX/pVLXqteVfsuf8kJ8M/wDb1/6VS0Aeq0UUUAFec6ocfFTWP+wLp/8A6Pva9GrzfVj/AMXU1j/sC6f/AOj72qjuBqA5pc1GKcDWoiTNOHXrUWRxzTqBkoNPBqAGnhqAJga8x+LPghdU0+S+0+ImaMb2RBz7/hXpYb2pVNVCbg7oVj5c8J+M9Y8JXYgLvPYg828hyAP9n0r6F8D+PNC8RxRrY3qJdkfNbTHY4PoAev4VyfxD+G8GseZe6Oix3nVoeiufUehrwjUNGurC6dJI5IZ425BBBBFdfJTxCutGTdo+4YpcgA1LuyK+TfC3xB8X+H40BumvrMDiK7+cY9m6j869L8P/AB00afbFrdldadJ3kT97H+nI/KuWeFqR2VxqSZ7NSn2xXO6N4x0DWQp07WLGZj0TzQr/APfJwa31bIBHI9a53daMokNLiow1O3dDmkA7bxS7aQN70u9fWgBcClwKYXABOOKwtZ8YaBoysdS1iygKjJUygt/3yMmhJvRAdBUM8oUda8X8RfHzSLUyQ6BYXWpTZwskn7mL9csfyFeTeK/if4w8Qs0Mt39htn4+z2alMj0LfeP511U8HUnq1b1Jc0j3Tx/8QdF8Ph45rlJ73kLbQsGYH/a/u/jXgtxe+IviPrUdmGkaBnylunEa+5+nqaq+D/BWp+JL4R28RK5zJK+dqD1Jr6T8GeFdP8KaeILJA9ww/ezkcv7ewrofJh1prISvIPAfhOz8JaOttbhXuXAM82OWPoPYV0ZNIT60wtiuJycndlik02kJzSZpAKTSZpKGOKAGv1qN6c7VA75qkAxziqd01Tu+AeaoTtnPNWhGD4mPy6SP+o1pn/pdBXtNeIeI2ydHH/Ua0z/0ugr2+sau4IKKKKzGFFFFABRRXN+IPEws7xNL0iD+0dakGRArYSFf78rfwr+p7UAaOv63ZaHZie+c5dhHFEg3STOeioo5JPtXMf2Vd69exXniaBX2tvtdIB3RQ+jzHoz+33R7nFYw1C38PeL9MHiOSW51LVd0MetSKBaW0vP+jRjP7skDgnlvXqB0F3qj3XnW2jN5VuhP2i9kOAPxpN2FucF8StYnk8Trp2j2j/8ACVWgSSy1fYWW3ZyoCt8uwROWaLJJw2SQAAav+DvFKa9pMd7ZwzHXJHMF4kq/NaTrw0aj1zyD6Ed84ty6VBrF7DBpdjHI8Wf9MlX94c9SW/hXPOPx613fhvw7Z6HATFHG1zIS8soUDcx6n/6/U1HxDSsU9C8NJE4utS/e3BO4IxyAfU+prp6KKtKwBRRRTA8q+In/ACXb4R/9xf8A9JVr1WvKviJ/yXb4R/8AcX/9JVr1WgAooooAK8q/aj/5IT4m/wC3X/0qir1WuA+Pfh7VPFXwn13RtBtftepXPkeVD5ix7ts8bt8zEAfKpPJ7UAd/RRRQAUUUUAFeVfsuf8kJ8M/9vX/pVLXqteVfsuf8kJ8M/wDb1/6VS0Aeq0UUUAFeb6v/AMlU1j/sDaf/AOj72vSK831c4+Kesf8AYF0//wBH3tVHcC/Ts4FRg04HvWoDxThUeaUNQIkzQDTQfeloAeG+lSK3AqClDYoAs5rD8R+GdN1+M/a4gs4GFmQYYf41rB6XfQm1qhmT4G8L2tpY3Wj6tbW15b7/ADYZGQZIIwR6g8D9azvEXwV0S/Z5dNke0dv4G+ZPw7j9a6gN3FXoNUniwGIkX/a6/nT9pUi7xZLimfPmu/BbX7GbdaQpeRg5Bibr+HWsibTvGegyERPqdjtHSBnRPy6V9Uw6tA/EgaM+4yP0q4k0MwwkiPnsCK1+ty+3G4uS2zPlODx349s0wNWuWAHWaNX/AJinr8V/iBE3N3buP9q0T+gr6jl0ywmJM1lauT3aJT/SqMnhfQ5GLPpVmWPcRAU1iaPWArS7nzLc/F3x+W+W7tY/920T+oqq/j/4iaiQq6xdLu7QQon8lr6jTwroKPuXR7Hd6+SprQhsbO1X9xbW8Kj+5GqgVX1mgtqYcs+58pjw78QfE0Ia4l1m7jb+/KwU/gTiuj8NfAvWZ2V9Xnt7ND1BPmP+Q4/WvoqW9to/vTLn0Xn+VU5dYXnyYyfduP0pSxs3pCKQKn3Zyfh34TeF9FKzS2xvZ1533B+UEd9o4/PNcxfeAYNd8UXmpXsUVnYO/wC6t4UCsyjgE44GcZP1r0Se6muP9Y+R/dHAqEGsfa1G7tlKKWxFptja6bapa2ECQQJ0VB/P1NWs8dai3fSjeKzd2UPJppPNN3ZpMg0APzRmmZpCcDrQA5mxUZagnAqJj+VUAOfaoic0rHtmonPPBxTQEczDHvVGY8cVNMxyeaqTHrVoRheImBbRx/1GdM/9LoK9xrwnXj+90j/sNaZ/6XQV7tWNXcEFFFFZDCgkAEk4A71U1XUbPSbCa91K4jtrSFd0ksjYCivO7ibUPiDAJblrrR/BzHKxjMd1qa9s944j/wB9MPQEGnYTY/xn42v7rStXPguCS4ttOid7zUo1DBdoy0cAJAklx74H1wDb8BXehT+CrPV9HkePSr6MTyXEzbri4k6MHbuwbKnHAIIHFcf4o8XReDdcsZ7aa3l8K2qfZLrRIYdjWhVsC4jOAJArHa6gnaSM5J+Xm/Cjw+C/H1xoF5Esmha2ravoUUcoMMcjcyRZH8OMMoHbHdqlvsCOg8YaFd+JtSkk1W5lh8GXe+NrdWYTcRDy9iE7PlkXcGAzl2DEitv4c6d4h1bw9aWniHy41smMHnRNkXKrwsp/22HXPPfjOK6fTfD82qXC3usk+Xj5IenHYY/hX2rsYo0ijWOJVRFGAqjAAqbN7lWtsQWNlBYwCK2jCKOvqfqas0UVYgooooAKKKKAPKviJ/yXb4R/9xf/ANJVr1WvKviJ/wAl2+Ef/cX/APSVa9VoA4xviFp3/CezeEorO5l1GF41dvtFqi4eMSblR5llcBW5Koeh61f1fxroWjeKbPQNVv7ezvbu1e6iaeaONCFdUC5ZgdzFjtAHIR/SqmreFtT1fxBZ3GoazBLo9nfJqEFoLACZHRcKvnb8bNxLfc3HON2Kd4q8KXWr69a6pYalDZuthcabPHNamcSQzNGzFSJE2uDGME7hz0oAvT+M/C9vEks/iTRYonk8pXe+iUM+0NtBLddrKcejA9xTr3xf4ds726sp9c0tdQtommltPtcYmVVTeSULZHy/Nz256VxmvfCgahZ6JFZ6qLd9P0v+yZVZLhYriLC5ysFxCwyQcgsykHkcZptx8LL258R6ffXPiWWSwsbgTQWZjnPloIGi8pczmMD5iQ3ll+xY5NAHR6V8SvB+oaFp+qnxHpNpBexCREur6GN0JVSY2G/Add6hlycEitSLxb4blsLu+i8QaQ9laMEubhb2Mxwsegdt2FPsa4+w+GdzHplpZ6jrNtciz0C48P27R2BjxFIsSrI2ZWy6iIg4wG3fw45ZrPwpS/LyQau1rMsWnJAYopIwj2gmUEmOVHIYTHhWUrtHJoA7G48ZeGLa3tZ7jxHosUF0u+3ke+iVZlzjKEthhnjI71H4e8Y6Lr+taxpOn3sLajpVw1vPbmVC52qhMiqGJ2AuEyQPmVh2rk7P4VxwadeW76hD5t1pV7prukErAPcSb2m/fTSOTnqC5ycnI6V0Xg3wtdeGdQ1Rk1KG406+kS4MBtSsqTCGKInzN5BQrEDt2ZyfvcUAdXXlX7Ln/JCfDP8A29f+lUteq15V+y5/yQnwz/29f+lUtAHqtFFFABXlvi25fTPiTf3U+n6vNbXGk2UcctnplxdIXSa7LKWiRgCBIhwcfeFepUU07ageTf8ACS2//QM8Sf8AhPX/AP8AGacPEtt/0DPEv/hPX/8A8Zr1eiq52B5T/wAJNbf9A3xJ/wCE9f8A/wAZpR4mtv8AoG+JP/Cev/8A4zXqtFHOwPKv+Emtf+gb4l/8J6//APjNOHii1/6BviX/AMJ6/wD/AIzXqdFHOwPLR4otP+gb4k/8J6//APjNH/CUWn/QN8Sf+E9f/wDxmvUqKOdgeW/8JTa/9A3xL/4T1/8A/GaP+Eptc/8AIN8Sf+E9f/8AxmvUqKOdgeW/8JTa/wDQN8SH/uXr/wD+M0v/AAlVt/0DfEn/AIT1/wD/ABmvUaKOdgeXDxTa8503xJ/4T1//APGaX/hKrT/oG+JP/Cev/wD4zXqFFHOwPMl8XQJ92x8Tr9NA1Af+0akHjRB/y6eKf/BDqH/xmvSaKXMB5sfGcZ62nin/AMEGof8Axmom8V2jHLaf4lJ9/D1+f/aNenUUc4HmP/CVWn/QO8Sf+E9f/wDxmk/4Sq0/6B3iX/wnr/8A+M16fRT52B5h/wAJVaf9A7xL/wCE9f8A/wAZo/4Su1/6B3iX/wAJ6/8A/jNen0Uc7A8w/wCEqtP+gd4l/wDCev8A/wCM0f8ACVWn/QO8Sf8AhPX/AP8AGa9Poo52B5h/wlVp/wBA3xJ/4T1//wDGaX/hKrP/AKB3iT/wnr//AOM16dRRzsDzD/hKrT/oHeJP/Cev/wD4zQfFVp/0DvEn/hPX/wD8Zr0+ijnYHlp8UWv/AEDfEn/hPX//AMZpp8T2x/5hviT/AMJ6/wD/AIzXqlFHOwPJz4mtj/zDPEn/AIT1/wD/ABmo38RwEcaZ4l/8J+//APjNeuUUe0YHjb6/Gc40rxJ/4T99/wDGaqy65kHbpHiX/wAEF9/8Zr26in7VgeAXU9xqV9o8Fro/iDf/AGtp8haXRruJFRLuJ2ZneMKoCqSSSOle/wBFFTKTk7sArA8XeKtO8L2cct8zyXM7eXa2cC75rmQ9FRRyT+grL8WeMms9QGheGrYar4lkXcLcNiO1X/npO/8ACoz06noOorK0rQ10AXuvarNNrfiPyy11qCwl/ITvHBGPuqBngcnknsKW2rFfsVbDTZPE+tNfeL5ra7v7J1aDw7BMskdgzDcrTgH5pCOQW+Uc4zxjc8STm4jk0+Ce4bV5xtWW0fabY5yCp9eOc9RkHg15T4zvL+w8USeK/BcQuUW0Mlze24Kpf2gCl45CSR5qgbkcY3KCuCUAbu9Cuk13T4B4XDm0u4hI10/yvIp/vf3R7dc1nKTHFHMRaFP9qVr2WPUNVlkmae3WNZbbzJA0chjJ5xIrFinQMx9Kt678IZV+GUVnpNzOPEGkOL/SZZHDtDMjFwmccgjKgdB8p5xXq2g6FbaRENih7gjDSkfoPQVr0Ri92PTocr8MfF0HjfwXp+tQqI55FMd1B3gnXh0I6jnkZ7EHvXVV41z8NPjOf+WfhbxpJ9EttSH8vM/Un0WvZasQUUUUAFFFFABRRRQB5V8RP+S7fCP/ALi//pKteq15V8RP+S7fCP8A7i//AKSrXqtABXGfE7/j28N/9h+x/wDRldnRQB4dL8Y78+H/ADbb+yJdYttBvtQv7UK5+zXMEkaLGyh8qPmfKk7uByB12ZfGHi/TdfuLXUZdAuLWz1bTtOm8iymjeVbsxjcpMzBShfuG3Y/hr1iigDwS2+L/AImuU1IpY6NFNEhxazSRCa0f7THEFkjS5aVxhzkmOLBxwQa2Nf8AiLr+h2epx3934djuNN1U2U106CJZY/s0cwaOCW5Tc2ZACBKTgZAPSvY6KAKei3Zv9HsLwkk3EEcuTEYidyg/cJJXr90kkdMmrlFFABXlX7Ln/JCfDP8A29f+lUteq15V+y5/yQnwz/29f+lUtAHqtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFVNV1Kz0jT5r7U7mK1tIV3PLK21VFAFpiFUliABySe1ecar4p1PxXdXGl+BZUgsYW8u91+Rd0UXqkA/wCWknv0HryKqzyan8Qwk139p0fwSWykPMd3qo7Z7xxH0+8w9AQav+NL5fDegwrFbJDpyI0Zs7MYmt4tuBLGoGCUJ3EHsMjJGCNpE7mV4D1TRtHvta8NGym0S7tHNzJNdSeZPqsJJC3IfA3bjnIH3c4GOQNnUb5r63Vn3WWkIcJEv+snP+f/AK9eUeIdB1ea7e6hVbe/064juNDcz70wUj8xHBziJ8OTkjLHgYLZ9j0PQ59R8m+1lQrFQRCpO0cdB6L6d6zk3LRFxVjC0jw6+qxi2s4E0/R45WlWJeVVmOWIHckkn0GeAK9F0zT7bTLRLezjEcajsOv1qzHGkUapGoRFGAqjAFOqlGwNhRRRVCOW+JvhGDxv4Mv9FmYRTyKJLWfvBOvKOD1GDwcdiR3rM+DPi6fxX4RC6shh8Q6XK2n6pA33lnj4LfRhz6ZyO1d5XjXjj/i3HxU07xnEfL8Pa+U03WwPuxS/8sbg/wAiewz3agD2WigHIyOlFABRRRQAUUUUAeVfET/ku3wj/wC4v/6SrXqtcP4s8L3+q/E3wFr9q0AsdE+3/ag7kOfOhCJtGOeRzyK7igAooooAKKKKACiiigAooooAK8q/Zc/5IT4Z/wC3r/0qlr1WvKv2XP8AkhPhn/t6/wDSqWgD1WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5TxT4rNjepo2g2w1PxFMu9bYNhLdP+es7fwJ+p6AGgC94t8Uaf4XsUmvmkknmby7a0gUvNcyHokaDkk1xDabd6nfxax4+QXFwmZNO8OW485IMcl5AP9bIOP8AZXtk4Iuadptn4enm17xHqlvda7L+7n1W7YRw2wPHkwKeEXt6nqx6Acfr1/N47eOTw5MljDY3EiPqU6EiRNvJWVDh0YgI8YJBz0BUGk5WFa510nj23m1Gyg0y3u7u4voVkt7xrZzAAwXbjAO3qQd+05HPFNkeSO4b7KzXeqSna1wRu2n0Qev6Vn+HtGtY55rTwrpyWUM53TsmRv4GT1winA+VcZxzk16ToujQaXENoDzkfNIRz9B6Cs7ORa904C7v9L8G+IfD1t4mt5y+tTNDFeEBreGbgqkhznc3bjH5Ej1KsDx34V0/xp4Vv9C1VT5FymFkUfNC45V19wef06E1yPwZ8VahdJf+D/FrEeLNAxFM7H/j8g6R3Ck8nIxk+pBP3sVoklsS3c9NooopgFFFFABWR4u8P2Xinw1qOh6om60voTE+OqnqGHuCAR7gVr0UAeY/AvxBez6RfeE/ETD/AISPwxKLG4JP+vh/5YzDPJDKBz7ZPWvTq8e+MNvL4N8UaP8AEzS43aO0xYa5DGCTNZueHwOpRsH3+XsK9ctbiG7tYbm1kSW3mQSRyIcq6kZBB9CKAOa1rxjb6HrOpWeqweTbWulNqsdyJM+ciMVlTbgYZcx9znzB0qPTvHmmsbC21yO50fVLiDzXgubWdYVZYvMkRbho1jcqoYnB/hPpVnxj4N0zxbLpT6m9yjafcCdPIcL5q5BaKTIOY2KrkDBO0c1zt18H/D154on1y7nvZpppZ5XhcQbT50bxuhkEfmlNrthTJgHGMdKAOi0vxvoWp3Gnw2014r6g5jtPtGn3EC3BEbSko0kahhsVjuBx055GY08f+GXs7y6XU8wWlqt7O3kS/JCXeMNjbk/NG4wOeOmCKpP8Pw9rpscniXXnn0uUSWF0fsvm2w8poigPkYYFHIJcMeAcg1mXPwg0iXTRYxavrltA9kLC58qWHddRCV5VDlojyGkblduQcHIoA2b/AOJHhmx1OXT57q9a6iuDaFYdMupQZwu7ylZIyrPt52gk45xWp/wlmi/8IofEv23/AIkojMpuPKfIUHBym3cCDwRjIPaqg8FacL2K68678yPWG1oDeuPOaFoSv3fubWJx1z3xxVLXfBZf4aah4W0S4KvMkgimumHys8pkJJC9iTj5T260AT/8LD8N+SX+1XnnCf7N9k/s65+1eZs8zH2fy/Nxs+bO3GOc1W1r4l+HrDS57m0nm1CddO/tOK3tbWeQyQneFYlEbYpaNlLMPl/ixkZjHw4tBdHUBrmtDXjcfaDq26Dzz+68rZt8rytm3t5fXnOeat6b8P8AR7CG6iikvHjudKXSJRJKGLRBpWL5xnexnck5x0wBQAaV8QdG1D+zoQmqJfXsEc4thpd2zRK7bQz/ALr5ELBgHbCnaSDgV1F7d21haTXd9cQ21rCpeWaZwiIo6lmPAHua4mf4Z2l3Jo7ahreq3Z0ry/IaSGzWTCNuUealuJFHAU7GXI4OcnPbXtpbX9pNaX1vDc2sylJYZkDo6nqGU8EexoA5z/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qj/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaAD/hY/gf/AKHLw3/4NIP/AIqj/hY/gf8A6HLw3/4NIP8A4qj/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaAD/hY/gf/AKHLw3/4NIP/AIquU/Zc/wCSE+Gf+3r/ANKpa6v/AIVx4H/6E3w3/wCCuD/4mt/StNsdIsIrHSrK2sbKLPl29tEsUaZJJwqgAZJJ+pNAFuiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAornLjVLrWZpLTw84jgQlJ9TKhkQjqsQPDv7/dXvkgrXL/ABD1zQdP0m10bU9a1GC13qLl4J/3s8Y6o8n3gGOMlSDjIBANFxXL+r+Jr7Xru60nwVJGi27GK+1uRd8Fo3dIh0llA7fdXjcc/LWfqunjwn4SuH0CPajyCS8ubq78q7vRg7pDMyn5uhyRwMhdvFbqXem6dpVjHYQ27wmMGxsbPHlhOzccY756Vm3ckrXPn3zLdah/BF/yyg/+v+v0qHOw1G5xUCazrZa51+7t7bQSoS1tLOV5GkwFwwdgC2RwSeNwDAZJx2Gl6Tc65Ip8tLawRshUXCg+oHdvetPR/Dkt5P8AbNVZmVuiHgsOw9hXYxosaKkahUUYAAwBUqLlqyvh2INPsbfT7cQ2qBVHU92PqTVmiitSQry/4y+GNQZ9P8beEY8+KNBy4iH/AC+2vJkgb14JI9ycckEeoUUAYfgjxPp/jHwvYa5pEm61u4920n5o26Mje4OQf8K3K8Tvh/wp/wCJH29MReA/FFxtuV6Jp18eknoqP37D2CgH2wHIyOlABRRRQAUUUUAVtSsbbU9OurG/hSe0uYmhmicZDowwQfwNeWfBK+uvDmpav8NdbmaS70T9/pk0nW5sHb5D9UJCn0yAOleuV5V8ctGvrWPS/HnhuAy674bcyvEnW6s24liOOuBlh6fNjk0Aeq0VX067S/0+1vIkljjuIllVJkKOoYAgMp5B55B6GrFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSE+gzQAtZGsWTagjJfXJt9MA/eRRttaYejt2X2HXucZFP17W7PQ7Np72UAgcLnrXzj8Ufi1Peb7ezkKQ8gKp60XE2ludx8TfirY6DYnT9D8tFRfLBjAUKBwAoHQV8seJPEF7r987ySO249zmoL25udWuwGZmZzXe+B/Ak17PFuhZmYgAYyTWcpWJXvM7n9nXV9QgtZdDugSsh3W02CXT1jB9D1Hoc+tfROkaLFagPMoZ+oU84/wAa53wB4Dt/D8cNzcKPtSjKoOicd/eu7ojHqzS+lgooorQQUUUUAFFFFAGX4p0Gw8T+H77RtYhE1jeRmORT1How9CDgg9iBXnnwd16/0nUL34deLZzJrejqGsbpxj7fZfwOPVlGFI/mQxr1evOvjJ4Pvdc06z17wwwg8XaE5utPkH/LYfxwN6q44we/HAJoA9FormPhx4ws/HHhS11izUwyNmK5tm+/bzLw8be4P5gg966egAooooAKKKKAOE1fxvqUVz4gfRNAi1HTtBby72d78QSNII1ldIU2MHKo6k7mQEnAzVm8+ImhpBcfY7gzXFv5Hmq8E6xxecsbJvkSNwu5ZVI9TxxhsLrXgG01O91WaLV9Z0631YL/AGhaWc0axXJCBMncjMhKKqkxspIAzU0/gTSpbXWrZXuoodVntriVY2UCMwJEiKny8LiFM5z1PTjAATfEHwzDLfJLfyotlHPJLKbSbyiIATMEk2bJCgByqFjweOKytT+Kmh2wsjZRaheGa9itJoxp90ksSyI7rIIzFucEIduBhucHg1XHwd8NrdaxLC0sK6nFdRSKlrab4/tCsshSYwmYH52wC5AzjGOK1tU+H2n317Jex6hqVnes1o6TwNETE1usioVDoynIlcHcCDxjFAB4g+Iej6PFfJJHqJvoLWa5igm065hW48pN7KkjRbWOOu3OBk44NR2fxG0iS3S5vDJZW7WUV2Umt7hZ90knlqqxNEC4LYClSSx6LjBOWnwd0H/hIJ9YuL3Uri6nNyX8wW4LfaI3jkBkWISEYc7QXIXAwABir7/DSwmhi+16xrFzdQW8Fvb3btAssPky+bEy7Ygu5W45Ugjgg80AW7j4keGIIYHkvLwtN54WFNOuXmUw7PNDxLGXQr5iEhgODnpVjxT4maw0LRtT0hre5g1DULC3WRwSrQ3E8aFlwRztfIPrjg9Kq2Pw9022vBeSX2pXV6UvFmuJnj3TNciIOzBUCggQRhQoAAHQ1oSeErCTw3omiNLdfZNJks5IHDLvY2zI0e47cHJQZwB3xigDK/4Wb4dtrSKTU7wxSPFJcN9mtrm4jjhWV4jI7iIbFDIQSwAB7kYJ1v8AhM9C/t1dIF5IbwzfZgwtpTB52zf5XnbfL37edu7PtWQPhpo40zULD7TqHk3unTaZIfMTcIpJZJGI+T72ZWwTkYA4PUtt/hhoVt4xPiO3yl204uXRrS1kBk2gbhI8JmXOAcLIBnpjJoA7qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqtf31rp8BmvrmG3iGTulcKOBnv7CgCyCCTg9Otcn4y8aWHh62kzKrXAHCg9DXkWu+Pr/AFbxxcD4fWtzNbyRN9pPJS4ZR98D+EADGeO1eHeLvGN5q1zIJGkDZIYMcn6UrkuVjpviN8RbvVrqQecWyT34FeWT3EksheRixPrTHYucscmuq8E+C7/xNexRwQuVY44HWpbtqSk2bvwf8Mya3qwleNmjBAAAySfQV9geEfDFtodurmNTckdf7g9B7+9ZXww8C23g/SURlRrxh8zD+D2FdxRGPVmi0VgoooqwCiiigAooooAKKKKACiiigDxXxfFJ8KPiB/wmVijf8Ilrkiwa9Ao+W1nJwl0AOxJw31PUsMe0RSJLGkkTq8bgMrKchgehB7iq2sabZ6xpd1p2p26XFldRtFNE44ZSMEV5T8J9SvPBniWf4ZeIpmlECGfQLyTrdWnJ8sn+/GAePQHsBkA9hooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKiuriGztpbi6ljht4lLySSMFVFHUknoK+evjD8dreCKbR/CBFxO42yXX8IB/u0m7GtKjKprsl1/r8j3nVtb07SdOa+vruKK2BwHznef7qgcsfYZNcD4l0zUviPp1xp97EdM0p03RWzqPPkb+F5Tz5Y7hB8x74HFeafAfTtdsLmXX/ABk0cGmXI/0JrzLTiZiObePtkcE45wMdDXrmo6g187afErQwAF5IA+1ip/jnf+AH+6OTTT0M6iUZNI8E+IPjK58F6GnhLwxaRWzOgju9Tgk8xrlwMFVYAY6kYHTtXiVzbzRyBZ+bg8lepH196+i/HltF4mul0zw7EJZYjt+2BdqRtjAWMDp/M10fwn+B1rplqL3xZCJryVSDbsQcZ9SP6VmpJtpE8r6njPwv+GV/4nvI5GjYRZySRwB6k19deDPCOneFrBIbOJTPjDy45PsPQVpaBolhoGnpZ6XAIoVHrlm+pPJrSqlHqxrQKKKKoAooooAKKKKACiiigAooooAKKKKACopIIDOlzJFEZolZVlZRuRTjIB7A4GfoKlrL8U6ZPrXhzUdMtb1rCW8gaD7Sqb2jDDBIGRzgnBzweaAMXwx8QtA1/RL3VkuTp9jaTLDJJqBSAYcKY3yWxscOhUk87hxnirsvjfwpFYwXsvifQ0s5y4hna/iEcm0gNtbdg4LKDjpketcJ4q+Fz2WkXsfgyWXFyNOiayvJpLpc295E6ybpZchUjEgMYIyMAYI5ZefDrxBH4qs72y1Gwea8XUpdRvpLDMMbzpaxqscHnBhlYT8xZ+Qd2cgUAdtbeMbebxFd6WYF2xXUFrFOtzHiUy25nDAMVzgKRhN7HrjAJE58c+Ehbz3B8UaEIIJFhlk/tCHbG7btqsd2ATtbAPJ2n0NcpD8JraKO0t01Wb7Jby2zBTF+8KQ2Mlpt37uCRJv3Y4xjHeppPA3iR/DenaMviy2t4NP8tITaWE9r5sSoy7ZTFcq56q2UaMZXkEHAAN6Hx94al8TnQk1az+1myjvo3+0xeXNG+84Q7ssQsZc4GArKc81dh8XeG59PF9B4h0eSxMhi+0JexGPeFLldwbGQqs2PQE9q4Oy+EUtpo50pNeVrOfRf7Gu82Z8x0DzOjxt5mEIMxyGDghccZrUh+HdzPrtprGs6ta3V9DqFteutvp/kQssEE0SKEMjENmcsXJP3QAAMYAPQYJY54Y5oJEkikUOjowKspGQQR1Bp9FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFBIAJJwBVfULy206ymvL6eO3tYVLySyNtVQO5NeeSSX3xDVpJmn0nwUvJ3Exz6iPfukR9OrD60CuO8R+JpfE8d7pnhya3h0ZAYdQ1udQ8Kjo0cIPEjHpn7o968C8OS+BfCPxLlggiXWjJKE0+e5kU29q7EBTIRndyev8AD+o1vi/qnjJdbHhbR447fQnUizazj8qMwjHUn7m3OGORn8QKj8OeC9H8B2Mes+JP+Jhqjrut7XoWJ6HB5Vf9o8nsB1qHLqdKcaUbLVv8PT/PY9TQSTXk+ozXpeSLKTarKuEhA6x2ydB9fzNc/Nf3HiWVNI8PxTW+ktIQWU5mvH7knv7k8AVjQX+r+N72xsJIVjilP7iyh+QOo6u392Je5/AZJr3jwd4Xt/DlmAGWe9dQss4TaMD+BB/Co9PxJJqHeptojCNo+pB4N8IWnh+2jZo42ugOMD5Y89dvqfVup9uldTRRWqSSshbhRRRTAKKKKACiiigAoqD7XbfbRZm4h+2GPzhBvHmbM43beu3JAz0zRZXltf24uLG4huYCzKJIXDqSrFWGRxkEEH0IIoAnooooAKKKiuriO0tZri4bZDChkdsE4UDJOB7UAS0VX0+8g1Gwtr2zk8y2uYlmifBG5GAIODyOCOtWKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs3xBrVh4f0uXUNVnENvHx6s7HoqjqWPYCoPFPiKy8N6d9qvS7yOwjgt4hulnkPREXuT+lcXb2Fxc6gviLxi0LahCN1tYF82+mqe7H+KQ8ZPXsMDFArifYrvxXcQav4wja30qN99hoecliOkk/Zm/2ei/XNXtf1jNvcSTXEFtb2gDSyPkw2q44zj7746IOee2eeP1zxZe61qV1pPhpi1xEALu+eMstsp4AKjkuf4Yhyf4toBqTw/4F0jwjevq/iG8u76Xes0FlcPvSO4K4MjAfL5hwOcYXgDOAahyb2NYxiviNK0fUILO5v5d2n6ZNGfKtbmJXur1uMTzFh+6UAfLGuMZ59K8s122nubttQlhkv55JlhtoC3+vmc4VCfTPJPpXc+JdfF5Fc6nq032bTITlypyXJ6Ig7nsKsfCTSb7xPqQ8S6rbR2umQELp1ttyVweWB9ScZbHOMDAzShT59WvdRnUqa8q3Z2vww8Ff8Irpj3GoyJdeIL0Bry5A4UDpFGO0a9AB16/Tt6KK1buJKysFFFFIYUVz3ibxt4Z8Lqx1/XdPsXUZ8qWYeYfog+Y/gK4U/GddZyngDwj4g8Sk8LciD7Lak+8snT8RQB63UV1cwWlu893NFBAgy0krhVUe5PAryn7D8X/Eo/0zVNC8HWbfwWcJvboD0LN8n4qaltfgf4euZ0ufF+o614rvFO7dql65jU/7MakAD2OaALuufGvwRplz9ktNTfWtQPC2ukQtdO/sCvy/+PU/wt4y8YeItftB/wAILc6N4dJbzrvVLlUuMbTgLAOQd23rnjNdpomg6ToNt9n0TTLLT4e6WsCxg/XaBmtKgDhfidpWuudN1vwdbR3GvWXnWwjeRYw8MybTksR92RYpMd9hA5NcXqXhXxjpPiDQbHwvbXqaPpclhH9piv2EdxCrL9oMkbXSoGPzkjyHLddwNe3UUAeOWmk+L7WxtZZLDxJPrtrqEVxfTf2yrW1/CJiXSCJrgKgKEHayRjC7SfV0dr4/t5k1JtP1afzn1ZDp66lFuhE0iNasxMoTagVh8pJTPANew0UAeKxeDvGV1a28t/fa/HeLJo8TCLWnRRCI4lvThZNpb/WEk5YkZXk5PbaDo+r2vg/xBpd611PI096lh9qujPI0DFvKBkZix4OPmOQOtdpRQB4zaaR46021t9Mt7LUnhkk0Z1ni1CJYrOKFYVuosGQNz5b5CKVYMeSeDmWfhv4lrDrIub3Vvt8lrMivHOBBNIZVKPGzXj+WQoONsMQwSD2z7zRQBV02yj0+0W3ikuZVBZt9xO8zkkknLMSep4HQDgAAAVaoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsnxBrUekQoqQvd382Rb2kRAaUjqSTwqjux4A/AG7f3S2lu8rsqhe7dAf6/SvOr611HXL26jsk3o2BcEuAz/AN0SkHKoO0a/U9ckBK5nxatBDrP9p6lI2q65Nm3t3tlzHET/AMsLVT1/2pT+Y6V1Fjo1zPcrca4Y1dP3kVlE4ZYzzj/efj7x98Y5rmomtfB8f2p4f7Y8SyQv5lxaxborNQVURohI2gFh8o+Y4JNZq+JpNKtoLnTHOr30xLvFcT7/ACio2mR5AvY87TwM4ABAo5G9x7bF3xbr+k/DXRTpfhm0gi1KTfIIgOId3JYlup/2ieg5OMCuH8Hz3EOgXmveI70R6OSzSXNxvfzHPQIp6r6dCx56YqSz0YeKri417xRqZvjHJuu4Y/lCQrnCEAcsWAAiH1Oa4r4gajrHiG6jttduLXwx4bgP7q1v5xFIV7N5PMpJx2UgfWrjBNeRDbvc6jwXo978VfEUM1wWg8NWByiDA49SOR5jY/Afr9N2drDZWsVtaxLFBEoREUYCgdBXiXhT4hWNlo8Om/CzwNrmuRAA/ahALO1lbAG4yyd+O4FbH9n/ABf8TAfbtX0LwfaN/wAs7GE3tyB6Mz/Jn3U0TnzaJWSFCHLdvVs9Vu7mCzt3nu54oIEGWklcKq/UngV53rfxs8EaddfY7LUZdc1A/dtNHha6d/oy/If++qqWvwO8OXFwl34tvta8VXincH1W9dkU/wCyi4AHscivRNE0PSdCtvs+i6ZZafB3jtYFiB+oUDNQWea/8Jh8TPEZx4X8D2+iWzfdvPEVztOPeBPnU/nQPhl4q1/5vHPxD1WaFvvWOiotjFj+6WGWcfUA163RQBw3hj4TeB/DRV9N8O2TXAO77RdKbiXd6hpMkH6YruAAoAAAA4AFLRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUr/UYrQY+/L1CA8/U+grI1LxB5kz22lMrCNts10RlEP9xf7z/oO/pXO6nHc37f2fYRvM75Mnz8n/fb09fy9iAcv4w8W6jeQXN3pMPm2Fo6pLdFwgJY42W4P32/2vY49aNU8Z6F4a8OWms6JpLQXd0Cpu2B278fdcg/MxPZuODzkV119oOleFfDMV5qYN/NZM83zssayM/3gqn5RxwO+BjOK+cvjf8AEf8A4S3U0srGD7PpdsSYlxhpCRyTjp9PrVRlGLXPsZTlyrzNePxkja22oN4he412dxOlppVi11MSRgExgLGSFIGGbOOvQVsaZdeITcgeHvDFrpDysTLdeIr795PIeryW0PzhvTOQPxOfNfBOv6/ayQ2IkuX0q7fY6RgoNx6MSOv0OeOK9ktdDutPsn1K3XJZzFLiTY8D5A2gHsw4z15BFbTj1vp0Kg+ZXOf1LS7uLS7uTX/GGpXNvHlG0/QYk06J5f8Anl8oLSjuWOMDvmvVvhj8MPDWi6VbX8vhrS4dRmUS5bN08Wef9ZIWJPckYHpXJx2mmztNPrIht7MRP5su7CNt6xxn2/NjzyBW5pHxO8PeBdB0rS/Hd9Ho2oSW4uLe0S1nl22xZljLFEIDHYSRnj0HSsWuxbPXgMAAUV5V/wANB/DD/oZv/JC6/wDjdH/DQfww/wChm/8AJC6/+N1IHqtFeVf8NB/DD/oZv/JC6/8AjdH/AA0H8MP+hm/8kLr/AON0Aeq0V5V/w0H8MP8AoZv/ACQuv/jdH/DQfww/6Gb/AMkLr/43QB6rRXlX/DQfww/6Gb/yQuv/AI3R/wANB/DD/oZv/JC6/wDjdAHqtFeVf8NB/DD/AKGb/wAkLr/43XUeBviL4V8dS3cfhXVPt72iq0w+zyxbA2cffVc9D0oA62ivPdQ8a3uh674pOrpFdaVphsUt4bG1IuXe6k8tQWeXa2GI7L19sHN1Dx1qGteJdA0nRrLXNN33txBqKqlmZozCkbFCXd02YlVmKbm28LzkUAeqUV5H4T+LVrBoXg238StLNqusW9oGuUmtAGlmwATCJRKBkjJWPaM+lWND+KMz6Xa3/iPT5tLtjPqIklMMciSR2xmJ2lZ2ZWVYgGyp3NkLwQQAeqUVwcnxKtIUdLrQddt9QElqiWEkcHnSC4ZlidSJSm0sjA5YEEHIFXZ/Ff8AaXw/1/WNLjubG7sYbyMxXKJ5kE8IcEEAshwy9iQaAOvorhdJ+IVg2nJ9sjvGuYbuy02eTYgVp7iOJ1cfMPk/ejPAI5wDWRp3xv8ACuordvai8lWCFbhfKaCVpYzMkWQiSM6HdIh2yBGweAcEUAeo0VW025kvLKOeazuLKR85guChdcEgZ2My8jngng84ORVmgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivN/ij8VtI8FQyW4kW51TblYV/h+p9faplJRV2a0aM60uWC/4HqeiXE8VvA808iRxINzO5wAPUmuS1LVJdTtpZmMlnoi/Lu5Wa79Ao6qp/76PsK8q+DvjbVfHF7qsniwNLpNkv2qKQjbFG2QAjAff45A56fSvXbS2N3MurasBBBEpa1tZOkS95HH94/p0pRnzbCr0nSlyt3Ofga7vbgWumW6+enybPux2i5x/3164z6D1rS8Raxo3w60RZ7hm824dU3k/NK3uTwOM8fXvXkvxT8Ua74aN9cabqt5a2urTNJbNIMmQYAcoR/qyox+BHfmuF0DWrvxfdl/GGqTS6VaxiN24NxcAciID/AJaMcnJ7DknHXrVBuHPfQwc9bHoPjjWrzxfdappi3KWXhxZB9q1ObcQhX+AJna0mDwF9iema5fV/Aui3baVBHazaX8wiKyLumK5IDyH+N24JHAAIA9B2GlWVzeXP2SweCCztI/LgtRlo7MDrhukkg43PzgjAxxjrPEmqw+F7KSVfshvvJUG6HzLCefm57dMAZJPA7kZySasPlUk2zyeHxb4e0vxlZ2tk/wBl0nTSIjJMm5pCufmZR948lfWsr+17vxvqestdX81laNmRbc8uzhdqYAGAR3J6DvWd4e8O3eo+JoZmij1KS7nZvIl+/IScneB93IOcjp+Fe2aB8J9U/wCEqkvteudNWxUR7YrGNl8zAwQRxjgYPrntSoVdGpKzRjTlKWjVrDvh74N1i5udOh8XxWYtdKjE0UMCN+9diQpdvu9F3bAT1GcA4Ps1Q2ltDZ2sVtaxrFBEoREXgKB0FTVLdzoCiiikAUVHcTRW1vLPcSpFBEpeSSRgqooGSSTwAB3qhofiDRtfjlfQdX07U0hIEjWVykwQnoDtJx070AadFRXVxHaWs1xcNshhQyO2CcKBknA9qraTq9hq8CzabdxXCmOOUhW+ZVdQ6Fl6rlSCAQDg0AXqKpXmrabZNcreahZ25toRcziWZU8qIkgSNk/KuVYbjx8p9Ku0AFFFFAHN3PgnQrm/1G8uLa5lm1B4JLjfezlXaGRZIiEL7V2soI2gdx0JBtW3hfR7XVzqkFntvjNLcGXzXP7yVERzgnHKxoMYwMcYya2qKAOLt/hh4St3tTb6bPEtsbdkiS/uFjJgx5LOgk2uy7VwWBPGKuReAfDcc0sn2B3WR55DDLdTSQqZg4l2xM5RQ4kfIAAOc9a6iqWs6rZaNY/bNSm8m282KHftZvnkkWNBgAnlnUe2eeKAMTTvAXhzTwPIspmcTQXHmT3k88m6HPlfO7ltq5OFzt5PFacXh7S4tM1LTo7XFnqLzyXUfmN+8aYkyHOcjO49CMdsVq0UAcpN8PvDUuqwai9hKLmGWCZAt5OsZkhAWJ2jD7GZVUDcQTgYJxTrfwF4ft7Wa0it7z7DKFH2Q6jctboFdZFCRGTZHhlGNoHHHQkV1NFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIzBcbiBk4GaoaxrFjo8Ky6jcJCjZwWPXHWvF/ih8YLK2tmg0mZbi1uA0EzKfmibHyuv+e1TKSiFrnHfHn4q6zZ+MdR0KxMltBZssYwxUklQxbjrnPHtivMvD+mP4klvNb8QXrQ2FsVM8rHLux6IgPVjj8OtVtYvJ9fuJNT1qNpbiCLDyqeZQOFJPfqOfSuehvbu6VbRpHNtu3eWDgA+v1rltzJtb9We7Rr8ijGbuukUuv97+md5p3iW5Ot213YudN0nTnDRpGcgLnpj+J2756+wHH094RvR4+tY9RjldtH3AzFjh5pRz5e0H5Y1z079ec5r5s8BaPc+Khb6Zo+meHbm4BYqmo3l2DgdWZYMbR05J54x6V7Z4Z8FfFDRNMGn6Vqvg3QrQu0hSxtZ7j5jgE5mJJOAOpq6NNx16GWZ4qnXSjZ8y69Pl5dj03xp4T03xb4bn0fUYlELDMTqozA4+66+49O4yO9fJegeDL+2v4ZBfTWzTTOsMgGDIVbaySL1ibggg4yDjpmvfv+EG+I93/wAhD4qyxqf+WdnokEePo+c9Ko6r8JdZNldXI8e+MdQ1AISkMOprYLMePlLrG2Bj2xnHTrXfSrOCcd0zxXFN3LeoahLoVo9ta6a7s0Ctc+VavIYR6BRksx4wo5IwSQBmvLry38R69fte6tp11pNsjMLe0vFEJUH/AJaOXxuY9B6YwOnPF2Ulhd+K20XxVZaraSRuEnbWNZuJDG2QOQuwng8Y9e4r1fRPhp4IubtLHSvCunTXs8fmbpZZpFtEzt8yQNK2S3JVOP5mhNw1sD1F0XUvDuma5pNzf6roFlLZPGxvG1aBHMSqVKGJGJZiTyxyOvPau+vfjh8OLLPneKrRsf8APGKWXvj+BTWzp3w08FWCIIPCmhF1H+sewiZycYzkr39q6Cx0bS7DH2HTbK224x5MCpjHToKybu7lHnH/AAvjwdP/AMgqPXNU9PselzNu9MbgOvaj/hb9zc8aV8OfHVxno82miBG9CGLdPftXq1FIDyj/AIT/AOIN1/yDPhRekHOGvNXggx2yVIz+FL/bPxhu8/Z/CnhfT89PtmovNj/v2Pxr1aigDnNYs9X1H4d39lfR2j67c6ZLDIloxELTtEQQhfBCljxu7da81Twp4u0PT7pbe0utbvb3TbK2W6+2JbS2axMN8H7mSDdje7KVdd2CrOOC3ttFAHgsPh3x7Locdrrlrrt/akX6Ja22rC3mVnKfZ2mc3JZ4wpkBUyyEd9/Bq9PoPji10FLGCxvZogLCNVh1Fke3WOzCyeWsd1BkeaMEGVQc7sNgV7ZRQB89nwd45SylvJ7XXJvEdx4bFil3b6wI/Ju0e4x5o88BgVePaQHAYljg5auuk0fxgfGE0yLq3N/PIbz+0x9iayMTCOFbfzOJAxT5vLHIJ3nOK9WooA85+G2geIdEu9MbVrnVJo5dCgF/9t1FroDUARv2hnbbwSPk+U4HU1h61onjd9e8Svow1by7mKf7Nc3WoeUsZONqQIty6cjcFZoI2Xglia9iooA8gsdO8ZafqtlqVnp/iBtHttRL/wBj3erx3F08TWjoSzvMUZRKUYI0hxjIx0Enh3w540mEkurXepW1zHoqraiTUi8S3/n3JDSBHO/CPDnOVIwCCVG31uigDw/U9A8ZS6LpMek2Xie0eM/8TRLrWDcy3Mnl4V4mW+j2oG3EqHjzuU7DjA7HXND1vUPhbpemSme+1mOXTZJ2n8uORvKuoZJGfDsu4KjE4dskcE5Fd/RQB46mnePvsqaaYNU32i6vnUDqMe26MpkNrt/eb/l3IBvC7CBjgZpjeCvFNsb2Wz1DxC80NtpklmJdcldWuRKfte5Wlww2BflYbOTtFey0UAeCy+HPiWV8R5vNWN9La3qQSQ3AWCd3OYSjNeHyivGCsEWOQT3re8Q+GPE1tFq9ppNx4knsDeW09p5eomaRwIWEqs8l1DIse/adqyrzjA25FeuUUAZPhOO9i8M6WmqwfZr9bdBPD9pa4KPjkGRiWc+5JPueta1FFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVbUL62060e6vp0gt4xlnc4Arhfjl4xm8F+DFvLYyJNc3C2yyJjKZDMSM9yFI/GvlLV/Gviv4gXkOkRT3Vy08oWG33liSeAOazlNp2SOujh4Sip1JW8lu/0+87X9oD4oWPi6a10zQY5WW1kbbcKeZN3BAA6jgV514V8OSXNyZNT1DSLOIOY5Yb7VLe3kBB5BjkkDjn2r6X+C3wTtPCHkax4h8q91/7yIPmitT/ALP95/8Aa6Dt6n0jU/BPhXVb6W91Twzod7eS4Mk9xYRSSPgYGWZSTwAKFC61Mq0ouS5FZL+t+vr9x474T0T4Z22k3Nnr/izwzdQzKBHGusRK0QKncCVfk5PY44Brw7xT4Lj07xBfW3hnxH4c1DR937i6bXbGN2QjOGDSg5GcE4AOM96+yv8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+JqowUVZEKclqmeWfs/3XhHwV4VnOs+KPC0Gs3kxaXGrWzskYwFQsrkdi3B/ir1P/AIWP4H/6HLw3/wCDSD/4qj/hXHgf/oTfDf8A4K4P/iaP+FceB/8AoTfDf/grg/8AiaaVhTk5vmYf8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVH/AArjwP8A9Cb4b/8ABXB/8TR/wrjwP/0Jvhv/AMFcH/xNMk4n4hH4X+NVjmvPFvheHUIxsW6GoW7MyZyUb5wSPTBBB6HqD0eg+LPh1odoYNP8U+FIQxy/lajAoY9uN/QDoK0/+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiad21YVg/4WP4H/6HLw3/AODSD/4qtuw1jT9T0s6jpF3BqVnhistlIsyuVzkKVJBORjGetYn/AArjwP8A9Cb4b/8ABXB/8TW1Y6Np+m6U2m6TaQabZYYLFZRrAqbs5KhQADk5yO9IZ5rH8Xpf+Ea1bWn0nTZYbGwa9a2tNW865ibICxXEPlBoWOeSA6rg5OBk3fFXxMFpGkOjxOtzNdW1shuNLvZZIhLvJaS2EaPnEbbVDZbrwOuld/DSx1KK5TXda1rV/MsJdOje7eENBFLjftMcSlmO1eX3dPc5tweArQalHqF7qmqX18txb3LTTmFS7wrIqZCRquMSkHAHQe+QDn/CHxPgvLG6vtfmeOKS5nhsrW20S9ExSCR0eQ8MXHCk7VAjJ2sS1dIPiH4YOoQ2aai7ySm3CyJaTNCDOAYd0oTy13hhtywznHWsnV/hN4f1TTtPtbhpy1hPdzwzSQ29wR9plMsilJonjI3Hg7cgAc9c6Efw80lLSa3Wa6WOWewnYRiKMBrTy/LCqqBVB8pdwAA5O3bxgAj/AOFl+H7azWXU7oxuftMhFpbXNyqxQTNE8jERAqAV+YkAA5wSMMb/APwnfh061Hpcd7LLcyTrbB4rSaSDzWTeIzMqGMNt52ls1Rh+HGkQ2l5brc35S6sr2xcl0yI7qZppCPl+8GchewGMg9awV+HmqQeMrCSwu/I8NWuoJqTQveCRpZVg2EiL7OChJ6/vivU7cnAAO41XxRpel6tBply15JfzIJVhtbGe5KoW2hm8tGCLnjLYFYXg/wCJOkeIIIfPjutNupp7qKOO5tZ0jcQPICVleNUJ2R7ioOV5B5U1d8X+CLHxTqVhd393cxfYyrRxwxW+cht2RK0TSoTgA7HXj8awfEPwyS98Ptotlf3L2E+qfbWS5kVTZxvJI9wsDJGGJkEsiYdjgOcEYwQC5YfEfTpdR1GS4m/4lAjsn094rSZ57kzpI+BEAXY4TIAXOASasaT8RdL1bxXb6Pp8N5PDcWYuo7tLSfaG8x42Rx5eI9pQglyMNlSARTPFHwx0HxHLcyXwlVppLeVAI4XSFoUdE2xyRshG2RgQysOmAMCp9B8A2Wg3+nXWl395btaW7WrxwwWsUVzGZGkw6JCqrhmJzGEJ75oA7GiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAMLxp4W0vxj4fuNH1uEyWsuGDIdrxuOjoezD/EHIJFcP8Pvgh4d8Fa+ur21zfXtzFu8gXJXbHkYzhQMnBP59K9VopNXKUnHYKKKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: SenoRX, Inc. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4612=[""].join("\n");
var outline_f4_32_4612=null;
var title_f4_32_4613="Famciclovir: Pediatric drug information";
var content_f4_32_4613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Famciclovir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"    see \"Famciclovir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/9/16532?source=see_link\">",
"    see \"Famciclovir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Famvir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Famciclovir&reg;;",
"     </li>",
"     <li>",
"      Ava-Famciclovir;",
"     </li>",
"     <li>",
"      CO Famciclovir;",
"     </li>",
"     <li>",
"      Famvir&reg;;",
"     </li>",
"     <li>",
"      PMS-Famciclovir;",
"     </li>",
"     <li>",
"      Sandoz-Famciclovir",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiviral Agent, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"      see \"Famciclovir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents: Insufficient clinical data exists to identify an appropriate pediatric dose (AAP, 2006):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Herpes zoster: 500 mg every 8 hours for 7 days; initiate as soon as diagnosed; initiation of therapy within 48 hours of rash onset may be more beneficial; no efficacy data available for treatment initiated &gt;72 hours after onset of rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genital herpes: Treatment of initial clinical episode: 250 mg 3 times/day for 7-10 days;",
"     <b>",
"      Note:",
"     </b>",
"     Treatment may be continued if healing is not complete after 10 days of therapy (CDC, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recurrent genital herpes in immunocompetent patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: 1000 mg twice daily for 1 day or 125 mg twice daily for 5 days (CDC, 2006); initiate at first sign or symptom; efficacy is not established if treatment is started &gt;6 hours after onset of lesions or symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suppression: 250 mg twice daily for up to 1 year",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recurrent herpes labialis (cold sores): 1500 mg as a single dose; initiate at first sign or symptom such as tingling, burning, or itching; efficacy established for initiation of treatment within 1 hour of symptom onset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recurrent orolabial or genital herpes in HIV patients: Treatment: 500 mg twice daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Recurrent genital herpes in HIV patients: Suppression: 500 mg twice daily (CDC, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Herpes zoster:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: Administer 500 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: Administer 500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 250 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients on hemodialysis: Administer 250 mg after each dialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recurrent genital herpes: Treatment (single day regimen):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: Administer 1000 mg every 12 hours for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: Administer 500 mg every 12 hours for 1 day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 250 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients on hemodialysis: Administer 250 mg as a single dose after dialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recurrent genital herpes: Suppression:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;40 mL/minute: Administer 250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 125 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 125 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients on hemodialysis: Administer 125 mg after each dialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recurrent herpes labialis: Treatment (single dose regimen):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: Administer 1500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: Administer 750 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 500 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 250 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients on hemodialysis: Administer 250 mg as a single dose after dialysis session",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recurrent orolabial or genital herpes in HIV infected patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;40 mL/minute: Administer 500 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 500 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Administer 250 mg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Patients on hemodialysis: Administer 250 mg after each dialysis session",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 125 mg, 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Famvir&reg;: 125 mg [contains lactose 26.9 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Famvir&reg;: 250 mg [contains lactose 53.7 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Famvir&reg;: 500 mg [contains lactose 107.4 mg/tablet]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to meals; may be administered with food to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute herpes zoster (shingles); treatment or suppression of recurrent episodes of genital herpes in immunocompetent patients; treatment of recurrent episodes of herpes labialis (cold sores) in immunocompetent patients; treatment of recurrent episodes of mucocutaneous herpes simplex infections in HIV patients (FDA approved in ages &ge;18 years)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6743664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Famvir&reg; may be confused with Femara&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F169882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, migraine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rare but important or life-threatening: Anemia, angioedema (eyelid, face, periorbital, pharyngeal edema), cholestatic jaundice, confusion, delirium, disorientation, dizziness, erythema multiforme, hallucinations, somnolence, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to famciclovir, penciclovir, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and decrease dose in patients with renal dysfunction; acute renal failure has been reported in patients with renal dysfunction who received inappropriately high doses of famciclovir for their level of renal function. Dosage adjustment may be needed in patients with poorly compensated hepatic impairment. Tablets contain lactose; do not use in patients with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption syndromes. Efficacy has not been established in adults for treatment of initial episodes of genital herpes infection, ophthalmic zoster, disseminated zoster, or in immunocompromised patients with herpes zoster.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zoster Vaccine: Famciclovir may diminish the therapeutic effect of Zoster Vaccine.  Management: When possible, discontinue antiviral agents with anti-zoster activity (i.e., acyclovir, valacyclovir, famciclovir) for at least 24 hours prior to and 14 days after receiving a live attenuated zoster vaccine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rate of absorption and/or conversion to penciclovir and peak concentration are reduced with food, but bioavailability is not affected",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Data in pregnant women is limited. A registry has been established for women exposed to famciclovir during pregnancy (888-669-6682).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Resolution of rash, renal function, WBC, liver enzymes",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic guanine derivative, prodrug for penciclovir; penciclovir has inhibitory activity against varicella zoster virus (VZV) and herpes simplex virus type 1 and 2 (HSV 1 and HSV 2); penciclovir is converted to penciclovir monophosphate (by viral thymidine kinase in VZV-, HSV 1-, and HSV 2-infected cells), then to penciclovir triphosphate which competes with deoxyguanosine triphosphate for viral DNA polymerase and incorporation into viral DNA; therefore, inhibits DNA synthesis and viral replication",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Penciclovir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Healthy adults: 1.08 &plusmn; 0.17 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Famciclovir is a prodrug which is metabolized via deacetylation and oxidation in the intestinal wall and liver to penciclovir (active) during extensive first-pass metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 77% &plusmn; 8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum: Mean: 2-3 hours; increased with renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mean half-life, terminal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;80 mL/minute: 2.15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     60-80 mL/minute: 2.47 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-59 mL/minute: 3.87 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;29 mL/minute: 9.85 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intracellular penciclovir triphosphate: HSV 1: 10 hours; HSV 2: 20 hours; VZV: 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: &sim;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily excreted via the kidneys; after oral administration, 73% is excreted in the urine (predominantly as penciclovir) and 27% in feces; penciclovir undergoes tubular secretion; requires dosage adjustment with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Hemodialysis: May enhance elimination of penciclovir",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/9/16532?source=see_link\">",
"      see \"Famciclovir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Famciclovir is not a cure for genital herpes; may cause dizziness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boike SC, Pue MA, and Freed MI, &ldquo;Pharmacokinetics of Famciclovir in Subjects With Varying Degrees of Renal Impairment,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1994, 55(4):418-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/32/4613/abstract-text/8162668/pubmed\" id=\"8162668\" target=\"_blank\">",
"        8162668",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2006,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-11):1-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/32/4613/abstract-text/16888612/pubmed\" id=\"16888612\" target=\"_blank\">",
"        16888612",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2006 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 27th ed, Pickering LK, ed, Elk Grove Village IL: American Academy of Pediatrics, 2006, 787.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spruance SL, Bodsworth N, Resnick H, et al, \"Single-Dose, Patient-Initiated Famciclovir: A Randomized, Double-Blind, Placebo-Controlled Trial for Episodic Treatment of Herpes Labialis,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2006, 55(1):47-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/32/4613/abstract-text/16781291/pubmed\" id=\"16781291\" target=\"_blank\">",
"        16781291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13294 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.80.101-FFB583D007-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4613=[""].join("\n");
var outline_f4_32_4613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169842\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169843\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052683\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052677\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169817\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169803\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052686\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052685\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6743664\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169882\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052689\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052676\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299311\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220317\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052691\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169813\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169827\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052682\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052675\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052688\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052681\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13294\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13294|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=related_link\">",
"      Famciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/9/16532?source=related_link\">",
"      Famciclovir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_32_4614="LPL path";
var content_f4_32_4614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bone marrow histology of lymphoplasmacytic lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with Waldenstr&ouml;m macroglobulinemia demonstrating excess mature lymphocytes (thin arrow), lymphoplasmacytic cells, and plasma cells (thick arrow) consistent with lymphoplasmacytic lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4614=[""].join("\n");
var outline_f4_32_4614=null;
var title_f4_32_4615="B cell leukemias morphology";
var content_f4_32_4615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Peripheral blood morphology of four different B cell leukemias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) B-cell prolymphocytic leukemia, showing monomorphic prolymphocytes with condensed chromatin, prominent nucleolus, and scanty basophilic cytoplasm.",
"    <br>",
"     (B) Chronic lymphocytic leukemia with increased prolymphocytes, showing a single prolymphocyte, and several typical CLL cells, which are half the size of the prolymphocyte, have less cytoplasm and no nucleolus.",
"     <br>",
"      (C) Variant form of hairy cell leukemia,&nbsp;showing cells with condensed chromatin and a conspicuous single nucleolus, but with more abundant pale cytoplasm with cytoplasmic projections.",
"      <br>",
"       (D)&nbsp;Splenic marginal zone lymphoma&nbsp;showing lymphocytes with short polar villi and basophilic cytoplasm.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        This research was originally published in Blood. Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120:538. Copyright &copy; 2012 American Society of Hematology.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4615=[""].join("\n");
var outline_f4_32_4615=null;
var title_f4_32_4616="Indications for initiation of dialysis in chronic kidney disease";
var content_f4_32_4616=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for initiation of dialysis in chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/32/4616/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4616/contributors\">",
"     Anthony Bleyer, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/32/4616/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4616/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4616/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/32/4616/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4616/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/32/4616/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate dialysis in a patient with chronic kidney disease (CKD) involves the consideration of subjective and objective parameters by the physician and the patient. There are no absolute laboratory values that indicate a requirement to begin dialysis. The decision is partly based on the patient&rsquo;s perception of his or her quality of life and anxiety about starting a complex, potentially life-long therapy, In addition, the nephrologist&rsquo;s perception about the patient&rsquo;s state of health, decline of kidney function, and potential hazards of therapy influence the timing of initiation of renal replacement therapy. In short, the decision of when to start dialysis is clearly one of the most difficult decisions that both the patient and the nephrologist must make.",
"   </p>",
"   <p>",
"    This topic reviews the clinical indications for the initiation of chronic dialysis.",
"    <br/>",
"    <br/>",
"    The selection of dialysis modality is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34312?source=see_link\">",
"     \"Dialysis modality and patient outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=see_link\">",
"     \"Choosing a modality for chronic peritoneal dialysis\"",
"    </a>",
"    .) Considerations regarding transplantation are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=see_link\">",
"     \"Patient survival after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of clinical indications to initiate dialysis in patients with CKD. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pericarditis or pleuritis (urgent indication)",
"     </li>",
"     <li>",
"      Progressive uremic encephalopathy or neuropathy, with signs such as confusion, asterixis, myoclonus, wrist or foot drop, or, in severe cases, seizures (urgent indication)",
"     </li>",
"     <li>",
"      A clinically significant bleeding diathesis attributable to uremia (urgent indication)",
"     </li>",
"     <li>",
"      Persistent metabolic disturbances that are refractory to medical therapy; these include hyperkalemia, metabolic acidosis, hypercalcemia, hypocalcemia, and hyperphosphatemia",
"     </li>",
"     <li>",
"      Fluid overload refractory to diuretics",
"     </li>",
"     <li>",
"      Hypertension poorly responsive to antihypertensive medications",
"     </li>",
"     <li>",
"      Persistent nausea and vomiting",
"     </li>",
"     <li>",
"      Evidence of malnutrition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first five of the above indications are potentially acutely life-threatening and should not be allowed to develop prior to initiation of dialysis in patients with known CKD under medical care. The last two develop more insidiously and can also be due to other comorbidities or drug effects. They are no less dangerous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Relative indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since an important goal of dialysis is to enhance the quality of life as well as to prolong survival, it is therefore important to consider less acute indications for dialysis such as anorexia and nausea, impaired nutritional status, increased sleepiness, and decreased energy level, attentiveness, and cognitive tasking.",
"   </p>",
"   <p>",
"    Unfortunately, the expressions of these signs and symptoms are variable in patients with slowly progressive renal disease. The following are some of the factors that may contribute to this variability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients accommodate to these symptoms and downgrade their sense of well&ndash;being as renal failure progresses.",
"     </li>",
"     <li>",
"      Many of the medications given to patients with CKD have side effects that mimic uremic symptoms. As examples, oral iron therapy often leads to nausea and centrally-acting antihypertensive drugs can induce drowsiness independent of the degree of renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors illustrate the need to identify more objective markers of renal failure to lessen the subjective component of the decision to initiate dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     QUANTITATIVE MEASUREMENTS OF END-STAGE RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most widely evaluated quantitative measurements of end-stage renal disease have been estimation of the glomerular filtration rate (GFR) and assessment of nutritional status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Estimation of GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, 24 hour urine collections were performed to determine urea and creatinine clearance. However, inaccurate urine collections often caused incorrect determinations of clearance. These methods have been replaced by equations that estimate glomerular filtration rate based upon the serum creatinine. Estimation equations including the Cockcroft-Gault, the Modification of Diet in Renal Disease (MDRD) Study, and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) are reliable and reasonably accurate within the ranges of glomerular filtration rate that are generally present among patients who are being followed for the initiation of dialysis.",
"   </p>",
"   <p>",
"    A detailed discussion of GFR estimation formulas can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clearance of 125-I-iothalamate, Cr-51-EDTA, 99m-Tc-DTPA, or inulin, are considered to be highly accurate and can occasionally be used in the rare circumstances where it is felt the current estimation techniques may be unreliable. A retrospective study in the United States found that the GFR at initiation of dialysis varied with patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/4\">",
"     4",
"    </a>",
"    ]. Based upon the United States Renal Data Systems database from 1995 to 1999, the creatinine clearance at initiation was 14.76, 13.38, 11.63, and 11.60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    among those aged 20 to 44, 45 to 64, 65 to 74, and greater than 75 years, respectively.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have shown an increased mortality risk associated with malnutrition in patients on maintenance dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. As an example, an inverse relationship has been shown between the plasma albumin concentration and mortality risk in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The risk of death is increased when the plasma albumin concentration is below 3.5 to 4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (35 to 40",
"    <span class=\"nowrap\">",
"     g/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef70749 \" href=\"UTD.htm?19/37/20061\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Renal Data Systems analysis extended this observation by evaluating the relationship between the plasma albumin concentration at the time of initiation of dialysis and subsequent survival [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/8\">",
"     8",
"    </a>",
"    ]. The risk of death in patients starting hemodialysis with hypoalbuminemia was substantially higher than in patients with a normal plasma albumin concentration (",
"    <a class=\"graphic graphic_figure graphicRef65540 \" href=\"UTD.htm?19/7/19582\">",
"     figure 2",
"    </a>",
"    ). This relationship persisted even when diabetic patients, who may have significant proteinuria, were excluded from the analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/9\">",
"     9",
"    </a>",
"    ]. Worse outcomes in patients with lower plasma albumin concentrations at the initiation of dialysis have also been noted in patients with continuous peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The significance of hypoalbuminemia in patients with nephrotic syndrome (other than diabetes) and end-stage renal disease is undetermined at present. In this setting, the low plasma albumin concentration may not reflect malnutrition, but rather inflammation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ongoing urinary losses if not oliguric. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link&amp;anchor=H7#H7\">",
"     \"Assessment of nutritional status in end-stage renal disease\", section on 'Albumin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum creatinine is another marker of nutritional status at the time of dialysis initiation. The creatinine level reflects muscle mass as well as renal function. Thus, a patient who requires dialysis because of uremic symptoms or other indications but has a lower than usual plasma creatinine concentration may have a reduced muscle mass and be malnourished. Data from the USRDS are consistent with this hypothesis as the late mortality rate was increased in patients with a plasma creatinine concentration below 10",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (884",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    at the start of dialysis (",
"    <a class=\"graphic graphic_figure graphicRef65540 \" href=\"UTD.htm?19/7/19582\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/8\">",
"     8",
"    </a>",
"    ]. In comparison, the BUN level did not show a correlation with mortality risk.",
"   </p>",
"   <p>",
"    These data strongly suggest that malnutrition, as suggested by a low plasma albumin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a history of anorexia, nausea, or decreased protein and caloric intake, at the initiation of dialysis for symptomatic uremia, is an important prognostic variable. Other markers of malnutrition may also prove useful, including the plasma concentrations of transferrin, somatomedin C, prealbumin, and cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A simple determinant of nutritional status that can be easily monitored is protein intake, assuming that the patient is not on a low protein diet. Patients with CKD on an unrestricted diet tend to decrease their protein intake as the renal failure progresses. The magnitude of this effect was demonstrated in a report that evaluated 90 patients with CKD who received no dietary intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. A direct correlation was noted between the dietary protein intake and the creatinine clearance (Ccr):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1.1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day at a Ccr above 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"     <li>",
"      0.85",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day between 25 and 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"     <li>",
"      0.70",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day between 10 and 25",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"     <li>",
"      0.54",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day below 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These changes, which presumably reflect anorexia induced by renal failure, question the safety of restricting protein intake in patients with a creatinine clearance below 25",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    These decrements in dietary protein intake can be followed by assessing daily urinary urea nitrogen and non&ndash;urea nitrogen losses. If daily intake is relatively constant and the patient is in a steady state (as evidenced by a stable BUN and body weight), then urinary nitrogen excretion is roughly equal to nitrogen intake. The former can be estimated from the following [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Urinary nitrogen excretion &nbsp; = &nbsp; Urine urea nitrogen &nbsp; + &nbsp; Nonurea nitrogen",
"   </p>",
"   <p>",
"    Nonurea nitrogen excretion is relatively constant, averaging 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p>",
"    Each gram of nitrogen is derived from 6.25 grams of protein. Thus,",
"   </p>",
"   <p>",
"    &nbsp;Estimated protein intake &nbsp; = &nbsp; 6.25 (Urine urea nitrogen &nbsp;+ &nbsp;30",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"   </p>",
"   <p>",
"    If, for example, 24-hour urine urea nitrogen excretion is 8.2 grams in a 60 kg woman excreting 3.5 g of protein per day, then:",
"   </p>",
"   <p>",
"    &nbsp;Estimated protein intake &nbsp; = &nbsp; 6.25 (8.2 &nbsp;+ &nbsp;1.8) &nbsp; = &nbsp; 62.5 grams",
"   </p>",
"   <p>",
"    Thus, protein intake is approximately 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. Moderate urinary protein loss can be ignored, but each gram excreted above 5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    should be added to the above formula.",
"   </p>",
"   <p>",
"    A useful measurement of protein metabolism is the protein equivalent of nitrogen appearance (eg, excretion) normalized using the ideal body weight (nPNA) which is equivalent to the normalized protein catabolic rate. Values below 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day are considered indicative of a malnourished state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To best assess nutritional status, the serum albumin concentration and edema-free body weight should be serially measured, approximately every one to three months for those with estimated GFRs &lt;20",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73m2, and possibly even more frequently for those with estimated GFRs &le;15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Effect of dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the initiation of dialysis improves appetite in symptomatic uremia, there is a paucity of randomized control trial data showing that it is clearly associated with an improvement in nutritional status. Two observational studies reported that initiation of dialysis was associated with clear improvement in nutritional indices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over a one year period, different nutritional indices were evaluated every three months after dialysis initiation among 50 hemodialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/17\">",
"       17",
"      </a>",
"      ]. Marked improvements were observed in the serum albumin, serum prealbumin, nPNA, fat mass, and others. The degree of improvement was dependent upon nutrition at baseline, with the lower the baseline value the lower its value at one year.",
"     </li>",
"     <li>",
"      Among 97 patients initiating maintenance dialysis therapy, multiple nutritional indices, including predialysis serum albumin, iron, transferrin saturation, creatinine, and the nPNA, significantly increased over the first six months of therapy, with many indices continuing to increase at study end [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/18\">",
"       18",
"      </a>",
"      ]. In addition, dietary intake, as shown by the nPNA, directly correlated with serum albumin value.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given that dialysis was initiated based upon varying criteria, these two studies do not address the question of whether early or late initiation of dialysis is optimal. However, these results support the view that dialysis initiation improves nutritional parameters slowly in the first year after beginning renal replacement therapy. Preventing malnutrition (which may be difficult to discern in the obese) prior to dialysis initiation may be a key factor for improving outcomes once patients start dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DOES EARLY DIALYSIS OR REFERRAL IMPROVE SURVIVAL/OUTCOMES?",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351318599\">",
"    <span class=\"h2\">",
"     Survival and dialysis complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is conflicting evidence concerning the effect of the early initiation of dialysis on survival. Some retrospective and uncontrolled prospective studies have reported a benefit associated with early initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/19-22\">",
"     19-22",
"    </a>",
"    ] whereas others have reported increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only randomized controlled trial that examined mortality and time of dialysis initiation, the IDEAL study, found no difference in survival between early or late initiation of dialysis. In this study, 828 patients with progressive CKD and an estimated GFR between 10 and 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (as determined by the Cockcroft-Gault equation) were randomly assigned to dialysis initiation when the estimated GFR was either 10 to 14",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 or 5 to 7",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/27\">",
"     27",
"    </a>",
"    ]. The median time to the initiation of dialysis was 1.8 and 7.4 months in the early and late start groups, respectively. At a median followup period of 3.6 years, the two groups had no significant difference in survival (38 and 37 percent mortality, hazard ratio of 1.05 with early initiation, 95% CI 0.83-1.30) as well as no difference in cardiovascular events, infections, or dialysis complications.",
"   </p>",
"   <p>",
"    However, these results do not imply that the initiation of dialysis can be delayed until the GFR is between 5 to 7",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 in all patients. The design of the IDEAL study permitted clinicians to initiate dialysis based upon the presence of symptoms due to uremia (such as uremic symptoms, volume overload, and other features) as well as on the estimated GFR. As a result, 76 percent of patients assigned to the late start arm initiated dialysis when the GFR was much greater than 5 to 7",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. This resulted in a mean GFR of 9.8",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 at the start of dialysis for the late start group, which was only 2.2",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 less than the mean start GFR for the early group (12",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.72 m2). Thus, approximately 88 percent of all enrolled patients had initiated dialysis with an estimated GFR of approximately 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 or more, either because of symptoms or enrollment in the early dialysis arm.",
"   </p>",
"   <p>",
"    An accompanying editorial to the IDEAL study stated that the results of this trial largely supports current practice that dialysis initiation should be based upon clinical factors rather than the estimated GFR alone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients with progressive CKD require close followup, early nephrology referral, and adequate advance dialysis planning (including the presence of a functioning peritoneal or vascular access and referral for transplantation). In this study, for example, patients were followed by a nephrologist for approximately 2.5 years before dialysis was initiated.",
"   </p>",
"   <p>",
"    We suggest that, among patients with progressive CKD, clinicians must be vigilant for the presence of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of uremia and patients should also be fully informed of any symptoms of uremia to be able to contact their physicians appropriately. Dialysis should be considered based upon clinical factors plus the estimated GFR. Dialysis should be initiated in the patient with symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs due to uremia. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Indications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Relative indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among asymptomatic patients with progressive CKD, the timing of initiation of dialysis is unclear and there is no specific threshold GFR level that has been established for the initiation of dialysis. To help avoid the onset of possible life-threatening complications of uremia, the initiation of dialysis should be considered in the asymptomatic patient with an extremely low GFR, such as an estimated GFR of approximately 8 to 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2. However, some clinicians may choose to closely monitor (weekly) asymptomatic patients with progressive CKD even when GFR is below this level, with the initiation of dialysis upon the onset of uremic",
"    <span class=\"nowrap\">",
"     signs/symptoms.",
"    </span>",
"    Nevertheless, as noted in the IDEAL trial, the vast majority of patients are initiated on dialysis because of the onset of uremic symptoms at a GFR of approximately 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 or above. Even if dialysis is not begun immediately in an individual with a low GFR, it is important that at least placement of dialysis access has been carried out or carefully considered. Among all patients, vascular access should be constructed prior to the need for dialysis whenever possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37210?source=see_link&amp;anchor=H28054089#H28054089\">",
"     \"Creating an arteriovenous fistula for hemodialysis\", section on 'Timing of AVF creation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are some of the more recent National and International Guidelines for the initiation of dialysis, which were published before the results of the IDEAL trial were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2006 National Kidney Foundation Dialysis Outcomes Quality Initiative",
"      <span class=\"nowrap\">",
"       (K/DOQI)",
"      </span>",
"      for peritoneal dialysis and hemodialysis adequacy published guidelines concerning the initiation of dialysis among patients with renal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. The work group suggested that the benefits and risks of initiating renal replacement therapy should be considered in patients with GFR less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (stage 5 chronic kidney disease). As noted above however, the results of the IDEAL trial suggest that dialysis initiation should be based upon clinical factors rather than the estimated GFR alone [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/28\">",
"       28",
"      </a>",
"      ]. The 2006",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines also note that the initiation of dialysis prior to stage 5 chronic kidney disease may be required in patients with certain characteristics",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complications, such as declining health due to the loss of kidney function [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2005 European Best Practice Guidelines for peritoneal dialysis suggest that dialysis be initiated before the GFR is less than 6",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2, with consideration of initiation when the GFR is approximately 8 to 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/29-31\">",
"       29-31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may be two additional advantages to early dialysis: control of hypertension and increased dietary intake [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/22\">",
"     22",
"    </a>",
"    ]. Reversal of volume overload with dialysis often leads to a reduction in blood pressure, which is typically volume-dependent in CKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    .) Perhaps more importantly, patients on dialysis require at least 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of protein per day to replace dialysis losses and maintain nitrogen balance. Thus, early institution of dialysis can allow a more liberal diet in terms of both food and fluid. On the other hand, delaying the initiation of dialysis provides an opportunity to establish a functional vascular access if this was not possible previously, and to increase time for potential kidney transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829474\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal dialysis poses a unique challenge with regards to the timing of initiation of dialysis. Unlike a hemodialysis access, which is preferably created weeks to months before dialysis is started, a peritoneal dialysis catheter is generally placed only 10 to 14 days before it is used. After the catheter is placed however, the patient must be trained to perform dialysis, which is difficult to accomplish if he or she is uremic. As a result, among patients who require the acute initiation of chronic dialysis, hemodialysis is often initiated first, even if peritoneal dialysis is the preferred modality over the long term. For this reason, the timing of initiation of peritoneal dialysis is a more complex decision that requires coordination between the nephrologist, the patient, and the dialysis center that will perform the training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Possible value of early referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;A related issue to the criteria for the initiation of dialysis is the timing of referral of patients with CKD to a nephrologist. Referral occurs at variable levels of renal function, but often late in the course of progressive renal failure, just before or even after the onset of symptomatic uremia. Late referral reflects in part the absence of clear criteria for the initiation of dialysis.",
"   </p>",
"   <p>",
"    However, early referral affords the opportunity to assess the rate of progression of kidney disease, to exclude any reversible causes of a declining GFR, and to permit close followup and adequate advance dialysis planning. It may also improve patient outcomes. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25640?source=see_link\">",
"     \"Late referral to nephrologists of patients with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8478491\">",
"    <span class=\"h2\">",
"     Avoiding the emergent start of dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A problem with waiting too long for the initiation of dialysis is patients occasionally require an emergent dialysis start, often requiring hospitalization. A Canadian retrospective study of 377 incident dialysis patients at two tertiary care centers from January 2006 to April 2011 identified diabetic nephropathy, a history of pulmonary edema in the six months prior to dialysis initiation, and chronic obstructive pulmonary disease as independent risk factors for the emergent start of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4616/abstract/32\">",
"     32",
"    </a>",
"    ]. These findings would perhaps lead nephrologists to consider dialysis a little earlier in this patient population. In addition, this study suggests that careful review of a nephrologist&rsquo;s past results in this area may be helpful in improving future practices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INITIATION OF DIALYSIS AND DIALYSIS DISEQUILIBRIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important potential complication of the initiation of dialysis is the dialysis disequilibrium syndrome. This disorder, which appears to be related in part to a rapid reduction in the plasma osmolality due to urea removal, can produce a variety of symptoms including headache, nausea, vomiting, blurring of vision, muscle twitching, disorientation, tremor, and seizures. Patients with underlying neurologic disease or marked azotemia are at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link\">",
"     \"Dialysis disequilibrium syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       \"Patient information: Hemodialysis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       \"Patient information: Peritoneal dialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4828585\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no absolute levels of kidney function that indicate a requirement for dialysis. Clinical indications to initiate dialysis include pericarditis or pleuritis, progressive uremic encephalopathy or neuropathy, with signs such as confusion, asterixis, myoclonus, wrist or foot drop, or, in severe cases, seizures, a clinically significant bleeding diathesis attributable to uremia, fluid overload refractory to diuretics, hypertension poorly responsive to antihypertensive medications, persistent metabolic disturbances that are refractory to medical therapy (including hyperkalemia, metabolic acidosis, hypercalcemia, hypocalcemia, and hyperphosphatemia), persistent nausea and vomiting and evidence of malnutrition. However, many of these indications are potentially life-threatening and should not be allowed to develop prior to initiation of dialysis in patients with known CKD under medical care. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two most widely evaluated quantitative measurements of end-stage renal disease have been estimation of the glomerular filtration rate (GFR) and assessment of nutritional status. There is an increased mortality risk associated with hypoalbuminemia at the time of initiation of dialysis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Quantitative measurements of end-stage renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is conflicting evidence concerning the effect of the early initiation of dialysis on survival. We suggest that, among patients with progressive CKD, clinicians must be vigilant for the presence of symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs of uremia. Patients should also be fully informed of any symptoms of uremia to be able to contact their physicians appropriately. Dialysis should be considered based upon clinical factors plus the estimated GFR. Dialysis should be initiated in the patient with symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs due to uremia. The initiation of dialysis should be considered in the asymptomatic patient with an extremely low GFR, such as an estimated GFR of approximately 8 to 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2. However, some clinicians may choose to closely monitor asymptomatic patients with progressive CKD even when GFR is below this level, with the initiation of dialysis upon the onset of uremic",
"      <span class=\"nowrap\">",
"       signs/symptoms.",
"      </span>",
"     </li>",
"     <li>",
"      The timing of initiation of peritoneal dialysis poses a unique challenge because the catheter is usually placed within two weeks of being used and because the patient requires training that takes place only after the catheter is placed. Planning the initiation of peritoneal dialysis requires coordination between the nephrologist, the patient, and the dialysis center that will perform the training. (See",
"      <a class=\"local\" href=\"#H4829474\">",
"       'Peritoneal dialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23443186\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Nuhad Ismail, MD, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Pendse, S, Singh, A, Zawada, E. Initiation of dialysis in Handbook of Dialysis, 4th ed, Daugirdas, JT, Blake, PG, Ing, TS (Eds). Lippincott Williams &amp; Wilkins, Philadelphia 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/2\">",
"      K/DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy. Am J Kidney Dis 2006; 47(Suppl 4):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/3\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/4\">",
"      Balogun SA, Balogun RA, Evans J. Age-related differences in renal function at onset of renal replacement therapy in chronic kidney disease stage 5 patients. QJM 2006; 99:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/5\">",
"      Acchiardo SR, Moore LW, Latour PA. Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int Suppl 1983; 16:S199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/6\">",
"      Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/7\">",
"      Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/8\">",
"      Comorbid conditions and correlations with mortality risk among 3,399 incident hemodialysis patients. Am J Kidney Dis 1992; 20:32.",
"     </a>",
"    </li>",
"    <li>",
"     Hakim, RM. Initiation of dialysis. In: Advances in Nephrology, vol 23, Grunfeld, JP, Back, JF, Kreis, H, Maxwell, MH (Eds), Mosby Yearbook, Chicago 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/10\">",
"      Misra M, Nolph KD, Khanna R, et al. Retrospective evaluation of renal kt/V(urea) at the initiation of long-term peritoneal dialysis at the University of Missouri: relationships to longitudinal nutritional status on peritoneal dialysis. ASAIO J 2003; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/11\">",
"      Hakim RM, Levin N. Malnutrition in hemodialysis patients. Am J Kidney Dis 1993; 21:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/12\">",
"      Hakim RM, Lazarus JM. Initiation of dialysis. J Am Soc Nephrol 1995; 6:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/13\">",
"      Ikizler TA, Greene JH, Wingard RL, et al. Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol 1995; 6:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/14\">",
"      Hakim RM, Lazarus JM. Biochemical parameters in chronic renal failure. Am J Kidney Dis 1988; 11:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/15\">",
"      Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/16\">",
"      Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/17\">",
"      Pupim LB, Kent P, Caglar K, et al. Improvement in nutritional parameters after initiation of chronic hemodialysis. Am J Kidney Dis 2002; 40:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/18\">",
"      Mehrotra R, Berman N, Alistwani A, Kopple JD. Improvement of nutritional status after initiation of maintenance hemodialysis. Am J Kidney Dis 2002; 40:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/19\">",
"      Tang SC, Ho YW, Tang AW, et al. Delaying initiation of dialysis till symptomatic uraemia--is it too late? Nephrol Dial Transplant 2007; 22:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/20\">",
"      Bonomini V, Feletti C, Scolari MP, Stefoni S. Benefits of early initiation of dialysis. Kidney Int Suppl 1985; 17:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/21\">",
"      Korevaar JC, Jansen MA, Dekker FW, et al. When to initiate dialysis: effect of proposed US guidelines on survival. Lancet 2001; 358:1046.",
"     </a>",
"    </li>",
"    <li>",
"     Hakim, RM. Quand commencer la dialyze: Les bases de la decision. In: Actualites Nephrologiques, Funck &ndash; Brentano, JL, Back, JF, Kreis, H, Grunfeld, JP (Eds), Jean Hamburger, Hospital Necker, Medecines &ndash; Sciences/Flammarion, Paris 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/23\">",
"      Traynor JP, Simpson K, Geddes CC, et al. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 2002; 13:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/24\">",
"      Kazmi WH, Gilbertson DT, Obrador GT, et al. Effect of comorbidity on the increased mortality associated with early initiation of dialysis. Am J Kidney Dis 2005; 46:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/25\">",
"      Rosansky SJ, Eggers P, Jackson K, et al. Early start of hemodialysis may be harmful. Arch Intern Med 2011; 171:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/26\">",
"      Susantitaphong P, Altamimi S, Ashkar M, et al. GFR at initiation of dialysis and mortality in CKD: a meta-analysis. Am J Kidney Dis 2012; 59:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/27\">",
"      Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010; 363:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/28\">",
"      Lameire N, Van Biesen W. The initiation of renal-replacement therapy--just-in-time delivery. N Engl J Med 2010; 363:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/29\">",
"      European Best Practice Guidelines for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/30\">",
"      Tattersall J, Dekker F, Heimb&uuml;rger O, et al. When to start dialysis: updated guidance following publication of the Initiating Dialysis Early and Late (IDEAL) study. Nephrol Dial Transplant 2011; 26:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/31\">",
"      Rosansky SJ. The European Renal Best Practice Advisory Board's dialysis initiation guidelines: one size won't fit all. Kidney Int 2011; 80:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4616/abstract/32\">",
"      Chiu K, Alam A, Iqbal S. Predictors of suboptimal and crash initiation of dialysis at two tertiary care centers. Hemodial Int 2012; 16 Suppl 1:S39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1866 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4616=[""].join("\n");
var outline_f4_32_4616=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4828585\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Relative indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      QUANTITATIVE MEASUREMENTS OF END-STAGE RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Estimation of GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Effect of dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DOES EARLY DIALYSIS OR REFERRAL IMPROVE SURVIVAL/OUTCOMES?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351318599\">",
"      Survival and dialysis complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4829474\">",
"      Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Possible value of early referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8478491\">",
"      Avoiding the emergent start of dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INITIATION OF DIALYSIS AND DIALYSIS DISEQUILIBRIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4828585\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23443186\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1866\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1866|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/37/20061\" title=\"figure 1\">",
"      Risk of mortality among hemodial pts according to serum albumin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/7/19582\" title=\"figure 2\">",
"      HD survival initial nutrition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31286?source=related_link\">",
"      Choosing a modality for chronic peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37210?source=related_link\">",
"      Creating an arteriovenous fistula for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34312?source=related_link\">",
"      Dialysis modality and patient outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25640?source=related_link\">",
"      Late referral to nephrologists of patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=related_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17992?source=related_link\">",
"      Patient survival after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=related_link\">",
"      Protein catabolic rate in maintenance dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_32_4617="Intrahepatic cholestasis of pregnancy";
var content_f4_32_4617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intrahepatic cholestasis of pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/32/4617/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4617/contributors\">",
"     Yannick Bacq, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4617/contributors\">",
"     Richard H Lee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/32/4617/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4617/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4617/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/32/4617/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4617/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4617/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/32/4617/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrahepatic cholestasis of pregnancy (ICP) occurs in the second and third trimester, and is characterized by pruritus and an elevation in serum bile acid concentrations. The major clinical features, diagnosis and treatment of intrahepatic cholestasis of pregnancy will be reviewed here. A general approach to the pregnant woman who develops liver disease is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26198?source=see_link\">",
"     \"Approach to liver disease occurring during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ICP has varied widely in various reports (ranging from 0.1 to 15.6 percent), for reasons that are incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/1\">",
"     1",
"    </a>",
"    ]. Geographic variations in the rates of the disease may reflect differences in susceptibility between ethnic groups. The incidence of ICP is increased in Bolivia, and is highest among the Araucanos Indians in Chile [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/2\">",
"     2",
"    </a>",
"    ]. A study from Sweden that included 45,485 pregnancies occurring between 1999 and 2002 estimated the incidence to be 1.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/3\">",
"     3",
"    </a>",
"    ]. In reports from the United States, the incidence rates have varied from 0.32 percent in Bridgeport Hospital, Connecticut [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/4\">",
"     4",
"    </a>",
"    ], to 5.6 percent in a primarily Latin population in Los Angeles [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/5\">",
"     5",
"    </a>",
"    ]. For unknown reasons the disease is seen more commonly in the colder months in Chile and Scandinavia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of ICP is unknown but genetic, hormonal, and environmental factors are likely involved [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/6\">",
"     6",
"    </a>",
"    ]. Environmental factors may also influence the expression of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors could explain familial cases and the higher incidence in some ethnic groups. The ABCB4 (adenosine triphosphate-binding cassette, subfamily B, member 4) gene encoding the multidrug resistance 3 (MDR3) protein (a canalicular phospholipid translocator) is primarily involved in a subtype of progressive familial intrahepatic cholestasis called PFIC3 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/7\">",
"     7",
"    </a>",
"    ]. Heterozygous mutations in this gene have been found in a large consanguineous family in whom some women had episodes of cholestasis during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Several heterozygous mutations in the MDR 3 (ABCB4) gene were subsequently reported in patients with ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. The prevalence of such ABCB4 gene mutations in Caucasian patients suffering from ICP is 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the genetic basis of ICP is complex, and some genes encoding for other canalicular transporters or their regulator may potentially be involved in its pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Estrogens and progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogens are known to cause cholestasis in both experimental and clinical conditions, and a role in ICP is likely [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/21\">",
"     21",
"    </a>",
"    ]. ICP occurs mainly during the third trimester, when serum concentrations of estrogen reach their peak. ICP is also more common in twin pregnancies, which are associated with higher levels of circulating estrogens than singleton pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ICP also may be associated with alterations in progesterone metabolism and the administration of progesterone may be a risk factor for ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/23\">",
"     23",
"    </a>",
"    ]. The formation of large amounts of sulfated progesterone metabolites, possibly related to greater 5-alpha and 3-alpha reduction, may result in saturation of the hepatic transport system(s) utilized for biliary excretion of these compounds in some genetically predisposed women. In one study of 50 women with ICP from France, 32 (64 percent) had been treated with oral natural progesterone to prevent premature delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/24\">",
"     24",
"    </a>",
"    ]. During the same period, the percent of pregnant women without ICP who had been treated with natural progesterone during pregnancy was significantly lower (36 versus 64 percent, p&lt;0.01, odds ratio 3.16, 95% CI 1.29-7.80) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/24\">",
"     24",
"    </a>",
"    ]. It is recommended that progesterone treatment be avoided in pregnant women with a previous history of ICP and immediately withdrawn when cholestasis occurs during pregnancy.",
"   </p>",
"   <p>",
"    Whether in-vitro fertilization (IVF) affects the incidence or severity of ICP is unclear. A case report described a woman with a history of jaundice following exposure to oral contraceptives who developed severe pruritus and jaundice following IVF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/25\">",
"     25",
"    </a>",
"    ]. Symptoms and bilirubin levels gradually normalized after decreasing of estradiol values; however, at 34 weeks of pregnancy the patient developed recurrent pruritus and elevated liver enzymes compatible with ICP. This case shows that, in patients with a history of cholestasis under oral contraceptives, or ICP, symptoms of cholestasis may be observed after ovarian stimulation for IVF. While data are limited, this case suggests that patients with a history of cholestasis related to estrogen exposure should be monitored carefully when undergoing ovarian stimulation, and if possible, mildly stimulated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The seasonal variability that has been observed in some countries such as Finland and Sweden and the higher prevalence of ICP in Chile suggest that environmental factors could modulate the expression of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/1\">",
"     1",
"    </a>",
"    ]. However, no environmental factors except the treatment with natural progesterone during pregnancy (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Estrogens and progesterone'",
"    </a>",
"    above) have been identified clearly [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of ICP is typically heralded by the development of pruritus, which may be intolerable. It is often generalized but predominates on the palms and the soles of the feet, and is worse at night. Pruritus may precede laboratory abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/26\">",
"     26",
"    </a>",
"    ]. Abdominal pain is uncommon. Encephalopathy or other stigmata of liver failure are unusual and their presence should initiate a search for other causes of liver disease.",
"   </p>",
"   <p>",
"    Physical examination is nonspecific, but may show excoriations due to scratching. Jaundice occurs in less than 10 percent, typically after the onset of itching. The presence of jaundice without pruritus is rare and should prompt investigation of other causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum total bile acid concentrations increase in ICP, and may be the first or only laboratory abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/24,27,28\">",
"     24,27,28",
"    </a>",
"    ]. Serum cholic acid increases more than chenodeoxycholic acid, resulting in a marked elevation of the",
"    <span class=\"nowrap\">",
"     cholic/chenodeoxycholic",
"    </span>",
"    acid ratio compared to pregnant women without ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/29\">",
"     29",
"    </a>",
"    ]. However, most women with an elevated bile acid ratio also have elevated total bile acid levels; as a result, obtaining a ratio does not enhance diagnostic performance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/30\">",
"     30",
"    </a>",
"    ]. The ratio of",
"    <span class=\"nowrap\">",
"     glycine/taurine",
"    </span>",
"    conjugates is decreased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/22/22889?source=see_link\">",
"     \"Tests of the liver's capacity to transport organic anions and metabolize drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other laboratory findings reflecting cholestasis also may be present. These include elevations in the serum concentrations of alkaline phosphatase (which is not specific for cholestasis during pregnancy due to expression of the placental isoenzyme), 5' nucleotidase, and total and direct bilirubin concentrations. Total bilirubin levels rarely exceed 6",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Surprisingly, the serum concentrations of gamma glutamyl transpeptidase (GGT) are normal or modestly elevated, which is unusual in most other forms of cholestatic liver disease in which GGT levels parallel other cholestatic markers.",
"   </p>",
"   <p>",
"    Serum aminotransferases are also elevated, and may reach values greater than 1000",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    making distinction from viral hepatitis important [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/24\">",
"     24",
"    </a>",
"    ]. The prothrombin time is usually normal. When present, prolonged prothrombin times reflect vitamin K deficiency due to cholestasis or to the use of bile acid sequestrants (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    ) rather than liver dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ULTRASONOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;On ultrasonography, the biliary ducts are not dilated and hepatic parenchyma appears normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26198?source=see_link\">",
"     \"Approach to liver disease occurring during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women are diagnosed during the second or third trimester. The diagnosis of ICP is based upon the presence of pruritus associated with elevated total serum bile acids levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aminotransferases, and the absence of diseases that may produce similar laboratory findings and symptoms. The cardinal feature of ICP (ie, pruritus) helps distinguish it from other types of liver disease that can share similar laboratory features (such as early HELLP syndrome or preeclampsia). However, case reports have described an association of ICP with preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/31\">",
"     31",
"    </a>",
"    ] or acute fatty liver of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"     \"Acute fatty liver of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver biopsy is rarely necessary for the diagnosis. When performed, histopathology is characterized by cholestasis without inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/33\">",
"     33",
"    </a>",
"    ]. Bile plugs in hepatocytes and canaliculi predominate in zone 3. The portal tracts are unaffected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for ICP focuses on reducing symptoms and preventing maternal and fetal complications. Several drugs have been studied, and most focus on relieving symptoms.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    (UDCA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodiol",
"    </a>",
"    ) has emerged as the most promising treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ursodeoxycholic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    increases bile flow and has been used to relieve pruritus and improve liver biochemical tests in cholestatic liver diseases such as primary biliary cirrhosis. Initial pilot studies in ICP followed by controlled trials demonstrated that UDCA improved pruritus and liver tests, and had no adverse effects in the mothers or babies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. A meta-analysis of nine randomized trials with 454 patients found that patients who received UDCA had better outcomes than those who received an alternative agent (Sadenosyl-methionine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ), placebo, or no specific treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/36\">",
"     36",
"    </a>",
"    ]. In a pooled analysis that compared UDCA with all controls, patients who received UDCA were more likely to report an improvement in pruritus (61 versus 27 percent; odds ratio [OR] 0.27) and were more likely to have total resolution of pruritus (42 versus 6 percent; OR 0.23). Patients who received UDCA were also more likely to have improvements in their transaminase and serum bile acid concentrations and had a lower premature delivery rate (16 versus 34 percent; OR 0.44).",
"   </p>",
"   <p>",
"    Individual studies showed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial included 84 symptomatic patients who were randomly assigned to UDCA (8 to 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      body weight daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      (8 g daily) for 14 days [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/37\">",
"       37",
"      </a>",
"      ]. The onset of pruritus was approximately 31 to 32 weeks of gestation, while treatment was started at approximately 34 weeks of gestation. Pruritus was reduced more effectively in the UDCA group than in the cholestyramine group. Furthermore, babies were delivered closer to term in the UDCA group, while serum aminotransferases and endogenous bile acid levels improved more in the UDCA group. There were no adverse effects attributed to UDCA, while 12 patients randomized to cholestyramine reported treatment-related adverse effects (mainly nausea).",
"     </li>",
"     <li>",
"      A second trial included 130 women with ICP who were randomly assigned to UDCA (1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      for three weeks),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (12",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one week and placebo during weeks 2 and 3), or placebo for three weeks. UDCA was associated with improvement in some biochemical markers of cholestasis (ALT, bilirubin) irrespective of disease severity, while significant relief from pruritus and marked reduction of serum bile acids were observed only in patients with severe ICP (ie, 34 women with serum bile acids &ge;40",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      at inclusion) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third report provided further detail on the perinatal and long-term outcomes associated with treatment with UDCA [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/39\">",
"       39",
"      </a>",
"      ]. During a 12-year observation period, 32 patients had received UDCA (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) for at least three weeks before delivery. Patients were compared with 16 historic controls who did not receive UDCA. UDCA treatment was associated with improvement in pruritus, serum bilirubin, aminotransferase and bile salt levels, higher birth weight, and a greater proportion of deliveries at term. Twenty-six children whose mothers received UDCA were reexamined after 1 to 12 years of follow-up, all of whom were healthy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A concern with UDCA therapy is that bile acids can cross the placenta, which might lead to fetal toxicity. However, one study found that treatment restored the serum bile acid composition to more closely resemble that seen in healthy, pregnant controls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/29\">",
"     29",
"    </a>",
"    ] and in another report, meconium bile acid concentrations were not affected by maternal UDCA administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/40\">",
"     40",
"    </a>",
"    ]. Furthermore, UDCA appears to restore the transport capabilities of the placenta, which are altered in patients with ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/41\">",
"     41",
"    </a>",
"    ] and to normalize the serum bile acid pattern in babies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/42\">",
"     42",
"    </a>",
"    ]. Accumulation in the amniotic fluid and cord blood appears to be very low, even when high doses of UDCA (1.5 to 2.0",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    have been given [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the results of these studies, UDCA is considered as the first line treatment for ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/43\">",
"     43",
"    </a>",
"    ]. The optimal dose has yet to be determined; we usually prescribe 500 mg twice a day or 300 mg three times a day (or 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) until delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other treatments for ICP may be beneficial in individual patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"       Hydroxyzine",
"      </a>",
"      (25 to 50",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      may improve pruritus, although antihistamines can aggravate respiratory difficulties in preterm babies.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      (8 to 16",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      decreases ileal absorption of bile salts, thereby increasing their fecal excretion. Treatment should be initiated with a small dose and gradually increased. However, its effect on pruritus is limited in our experience, and it can increase steatorrhea, and exacerbate vitamin K deficiency. As noted above, it was less effective than UDCA in a controlled trial.",
"     </li>",
"     <li>",
"      The efficacy of the glutathione precursor S-adenosyl-methionine (SAMe) is controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. Early studies which found that SAMe reversed estrogen-induced models of cholestasis in rats prompted studies in humans. In an initial uncontrolled series, 18 women with ICP were given a 20-day course of SAMe (800 mg per day intravenously) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/45\">",
"       45",
"      </a>",
"      ]. Treatment was associated with clinical and biochemical improvement. However, subsequent studies, including a small controlled trial of 18 patients, have not reproduced these results [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/35\">",
"       35",
"      </a>",
"      ]. A controlled trial comparing SAMe with UDCA found that both equally reduced pruritus, but that UDCA was significantly more effective at improving the concentration of serum bile acids and other liver biochemical tests [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/47\">",
"       47",
"      </a>",
"      ]. We do not use SAMe for treating ICP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other modalities have produced disappointing results. A short course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    improved pruritus and decreased serum levels of bile acids in one report, but was associated with clinical deterioration in another [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In a more recent controlled study, dexamethasone did not improve pruritus or reduce the serum ALT, and was less effective than UDCA at reducing bilirubin and bile acids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/38\">",
"     38",
"    </a>",
"    ]. Other treatments, including charcoal, ultraviolet light, topical emollients, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    have been used, but few patients have been treated with uncertain efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications of cholestasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to alleviating symptoms, treatment should also focus on preventing complications of cholestasis. If cholestasis is severe, fat soluble vitamin deficiency can occur, and may be worsened by administration of anion exchange resins (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    ). However, steatorrhea is modest and nutritional requirements are generally easily met. An occasional exception is hypoprothrombinemia induced by vitamin K deficiency; this possibility should be treated before delivery to prevent hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MATERNAL FOLLOW-UP AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal prognosis in ICP is good [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/24\">",
"     24",
"    </a>",
"    ]. Pruritus usually disappears in the first few days following delivery, accompanied by normalization of serum bile acid concentrations and other liver tests. Affected women generally have no hepatic sequelae. We follow liver biochemical tests to confirm that previously noted abnormalities have resolved.",
"   </p>",
"   <p>",
"    Cholestasis recurs during subsequent pregnancies in 60 to 70 percent. Recurrent episodes are variable in severity. Affected women may be at increased risk for the development of gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Underlying liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of women with ICP appears to have underlying liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. This was best illustrated in a large population-based study that found an association between ICP and several chronic liver diseases such as hepatitis C and nonalcoholic liver cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/51\">",
"     51",
"    </a>",
"    ]. Progressive fibrosis was also reported in four sisters who had an atypical familial form of prolonged recurrent intrahepatic cholestasis during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/52\">",
"     52",
"    </a>",
"    ]. This suggests that some women who develop ICP have underlying liver disease revealed by pregnancy or contributing to the development of ICP. Thus, women in whom ICP is suspected",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who have elevated serum aminotransferase during pregnancy should be tested for chronic hepatitis (especially hepatitis C), and liver function tests should be checked several months after the delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hormonal contraception",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11113051\">",
"    <span class=\"h3\">",
"     Estrogen-progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of estrogen-progestin contraceptives to women with a history of ICP rarely results in recurrent cholestasis. Thus, contraceptives with a low dose of estrogen can be initiated after normalization of liver function tests. However, women should be informed of the possible risks of pruritus or cholestasis. We also routinely check liver function tests after three or six months of such contraception.",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention and the World Health Organization consider estrogen-progestin contraception an acceptable choice for women with a past history of ICP since the benefits generally outweigh the risks. However, in women with cholestasis related to use of estrogen-progestin oral contraceptives, non-estrogen methods of contraception are preferred due to the increased risk for recurrent cholestasis (",
"    <a class=\"graphic graphic_table graphicRef55954 \" href=\"UTD.htm?5/40/5774\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11113065\">",
"    <span class=\"h3\">",
"     Progestin-only",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of ICP or cholestasis related to use of estrogen-progestin oral contraceptives is not a restriction to use of progestin-only contraceptives (",
"    <a class=\"graphic graphic_table graphicRef55954 \" href=\"UTD.htm?5/40/5774\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 2",
"    </a>",
"    ). The risk of recurrent cholestasis is low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25607613\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICP is not a contraindication to breastfeeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FETAL FOLLOW-UP AND OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10703426\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the favorable prognosis for mothers, ICP carries significant risk for the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/24,56\">",
"     24,56",
"    </a>",
"    ]. The main complications are fetal prematurity, meconium stained amniotic fluid, intrauterine demise, and an increased risk for neonatal respiratory distress syndrome (which appears to be associated with bile acids entering the lungs) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/24,56-59\">",
"     24,56-59",
"    </a>",
"    ]. The incidence of prematurity varies greatly among studies (6 to 60 percent), and may in part reflect the high rate of multiple pregnancies in patients with ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/24\">",
"     24",
"    </a>",
"    ]. In one series of 61 babies born to women with ICP, the incidence of prematurity was 100 percent in multiple pregnancies and 41 percent in singleton pregnancies; three babies (5 percent) died. The incidence of fetal demise has been lower (1 to 3 percent) in other studies. The risk of prematurity also appears to correlate inversely with gestational age at onset of pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal demise rarely occurs before the last month of pregnancy. In a series including 20 intrauterine fetal deaths associated with ICP, the median gestational age at fetal death was 38 weeks, but only two fetal deaths occurred before 37 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/58\">",
"     58",
"    </a>",
"    ]. The pathophysiology of fetal death in ICP is poorly understood, but may be related to the sudden development of a fetal arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/60\">",
"     60",
"    </a>",
"    ] or vasospasm of the placental chorionic surface vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/61\">",
"     61",
"    </a>",
"    ] induced by high levels of bile acids.",
"   </p>",
"   <p>",
"    There is no ideal method for fetal surveillance in ICP. Some obstetricians recommend non stress tests or biophysical profile assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/26,62\">",
"     26,62",
"    </a>",
"    ]. However, no test reliably predicts the risk of fetal demise [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/56,63\">",
"     56,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10703433\">",
"    <span class=\"h2\">",
"     Predictive value of maternal bile acid level",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the serum total bile acid concentration has also been suggested to predict fetal risk in ICP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/3,64-66\">",
"     3,64-66",
"    </a>",
"    ]. In the largest study, which included 693 women with ICP, the probability of fetal complications (defined as preterm delivery, asphyxial events, meconium staining of amniotic fluid, placenta, and membranes) was directly related to concentration of bile acid levels even after controlling for other risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/3\">",
"     3",
"    </a>",
"    ]. In this study, fetal complications were not observed until bile acid levels were &ge;40",
"    <span class=\"nowrap\">",
"     micromol/L.",
"    </span>",
"    There were three fetal deaths, a rate similar to that in the general pregnant population. Maternal bile acid levels were 94, 130, and 27",
"    <span class=\"nowrap\">",
"     micromol/L.",
"    </span>",
"    A death in a patient with the lowest of these levels occurred in a twin with a tight knot in its umbilical cord.",
"   </p>",
"   <p>",
"    Further validation of these results is needed to determine the accuracy of this cutoff value. Indeed, an otherwise unexplained fetal death was reported at",
"    <span class=\"nowrap\">",
"     39",
"     <sup>",
"      3/7",
"     </sup>",
"    </span>",
"    weeks despite treatment with UDCA and low bile acid values [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/67\">",
"     67",
"    </a>",
"    ]. Furthermore, determination of bile acid concentrations may take several days even in major laboratories, making it an impractical tool for immediate risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25607628\">",
"    <span class=\"h2\">",
"     Antepartum testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of antepartum testing to identify fetuses at risk of demise in the setting of ICP is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/69\">",
"     69",
"    </a>",
"    ]. One study did not observe an increase in abnormal findings on nonstress tests (NSTs) in patients with ICP who went on to have a fetal demise [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/69\">",
"     69",
"    </a>",
"    ]. Several others reported intrauterine fetal demise occurring within a few days of a reactive NST [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/63,64,67,70-73\">",
"     63,64,67,70-73",
"    </a>",
"    ]. Nonstress tests and other tests for detection of the effects of chronic placental insufficiency on the fetus may not be useful in ICP because the mechanism of intrauterine fetal demise is thought to be a sudden event rather than the result of a chronic placental vascular process. However, in the absence of high quality evidence of the lack of value of nonstress testing or a proven mechanism for fetal death, we and most other obstetricians use antepartum testing in women with ICP to detect the rare fetal heart tracing suggesting fetal compromise and the need for immediate delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/70,72\">",
"     70,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Timing of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best approach is early delivery; the timing should be guided by the patient&rsquo;s symptoms and the potential risks associated with prematurity. No randomized trials have evaluated the optimum gestational age for delivery, and there is no consensus whether delivery should be at 37 or 38 weeks of gestation, or earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/56,69,74\">",
"     56,69,74",
"    </a>",
"    ]. Some obstetricians, including one of the authors (RL) and one of the section editors (CL), deliver patients with ICP at 37 weeks because the majority (90 percent) of in-utero demises occur after 37 weeks (median 38 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/58\">",
"     58",
"    </a>",
"    ], thus the risk of fetal death (1 to 3 percent) in ongoing pregnancies outweighs the morbidity associated with iatrogenic delivery at 37 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/72,75-77\">",
"     72,75-77",
"    </a>",
"    ]. A policy of early intervention, rather than waiting for spontaneous labor, is associated with rates of intrauterine fetal demise and asphyxial events that are similar to those in the general obstetrical population, even in patients with a total serum bile acid concentration &ge;40",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    and those not consistently treated with UDCA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/26\">",
"     26",
"    </a>",
"    ]. However, early delivery will result in increased rates of cesarean delivery and admission to the neonatal intensive care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4617/abstract/26,62\">",
"     26,62",
"    </a>",
"    ]. One author (RL) does not routinely perform amniocentesis to test for fetal lung maturity in these patients, unless they have poor gestational age dating criteria or request confirmation of fetal lung maturity prior to delivery. One section editor (CL) does perform amniocentesis at 37 weeks and delays delivery for one week if the results suggest pulmonary immaturity.",
"   </p>",
"   <p>",
"    Indications for delivery prior to 37 weeks of gestation because of ICP include excruciating and unremitting maternal pruritus not relieved with pharmacotherapy, jaundice, or a prior history of fetal demise due to ICP with recurring ICP in the current pregnancy. The timing of delivery in these situations is empirical and generally as long as possible after 35 weeks of gestation, depending on the individual&rsquo;s particular circumstances (severity of symptoms, gestational age of previous fetal demise). All patients electively delivered for ICP prior to 37 weeks are extensively counseled about the absence of definitive evidence that the maternal and fetal benefits of ending the pregnancy outweigh the potential morbidity of prematurity. We also discuss the limits of fetal lung maturity testing for prediction of neonatal status. If the patient chooses to be delivered after this discussion, we perform amniocentesis and deliver if the results are mature. If testing demonstrates pulmonary immaturity, we administer a course of corticosteroids and proceed with labor induction upon completion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrahepatic cholestasis of pregnancy (ICP) occurs in the second and third trimester, and is characterized by pruritus and an elevation in serum bile acid concentrations. The onset of ICP is typically heralded by the development of pruritus, which may be intolerable. It is often generalized but predominates on the palms and the soles of the feet, and is worse at night. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of ICP is based upon the presence of pruritus associated with elevated levels of serum bile acids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aminotransferases, and the absence of diseases that may produce similar symptoms. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for ICP focuses on reducing symptoms and preventing maternal and fetal complications. We suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodeoxycholic acid",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       ursodiol",
"      </a>",
"      or UDCA, a synthetic bile acid) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The optimal dose has yet to be determined; we usually prescribe 500 mg twice a day (or 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) until delivery. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest early delivery because of the risks to the fetus (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The timing of delivery is guided by the patients' symptoms, past obstetrical history, and potential risks associated with prematurity. Delivery should be accomplished by 37 or 38 weeks of gestation. However, when cholestasis is severe (such as when patients are jaundiced), delivery may be considered at an earlier gestation if lung maturity is achieved or as soon thereafter as fetal lung maturity is established. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Timing of delivery'",
"      </a>",
"      above.) There is no consensus for the obstetrical management in patients treated with UDCA.",
"     </li>",
"     <li>",
"      In addition to alleviating symptoms, treatment should also focus on preventing complications of cholestasis. Severe cholestasis leading to deficiencies of fat soluble vitamins is uncommon. An occasional exception is hypoprothrombinemia induced by vitamin K deficiency; this possibility should be treated before delivery to prevent hemorrhage.",
"     </li>",
"     <li>",
"      The maternal prognosis in ICP is good. Affected women generally have no hepatic sequelae. Cholestasis recurs during subsequent pregnancies in 60 to 70 percent of patients. Recurrent episodes are variable in severity. Affected women may be at increased risk for the development of gallstones. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Maternal follow-up and outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to the favorable prognosis for mothers, ICP carries significant risk for the fetus. The main complications are fetal prematurity, meconium stained amniotic fluid, intrauterine demise, and an increased risk for neonatal respiratory distress syndrome (which appears to be associated with bile acids entering the lungs). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Maternal follow-up and outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ICP is not a contraindication for breastfeeding. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Maternal follow-up and outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/1\">",
"      Bacq Y. Intrahepatic cholestasis of pregnancy. Clin Liver Dis 1999; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/2\">",
"      Reyes H, Gonzalez MC, Ribalta J, et al. Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann Intern Med 1978; 88:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/3\">",
"      Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology 2004; 40:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/4\">",
"      Laifer SA, Stiller RJ, Siddiqui DS, et al. Ursodeoxycholic acid for the treatment of intrahepatic cholestasis of pregnancy. J Matern Fetal Med 2001; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/5\">",
"      Lee RH, Goodwin TM, Greenspoon J, Incerpi M. The prevalence of intrahepatic cholestasis of pregnancy in a primarily Latina Los Angeles population. J Perinatol 2006; 26:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/6\">",
"      Arrese M, Macias RI, Briz O, et al. Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert Rev Mol Med 2008; 10:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/7\">",
"      Jacquemin E, De Vree JM, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 2001; 120:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/8\">",
"      de Vree JM, Jacquemin E, Sturm E, et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998; 95:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/9\">",
"      Jacquemin E, Cresteil D, Manouvrier S, et al. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 1999; 353:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/10\">",
"      Dixon PH, Weerasekera N, Linton KJ, et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 2000; 9:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/11\">",
"      Lucena JF, Herrero JI, Quiroga J, et al. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 2003; 124:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/12\">",
"      Gendrot C, Bacq Y, Brechot MC, et al. A second heterozygous MDR3 nonsense mutation associated with intrahepatic cholestasis of pregnancy. J Med Genet 2003; 40:e32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/13\">",
"      M&uuml;llenbach R, Linton KJ, Wiltshire S, et al. ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. J Med Genet 2003; 40:e70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/14\">",
"      Pauli-Magnus C, Lang T, Meier Y, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004; 14:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/15\">",
"      Floreani A, Carderi I, Paternoster D, et al. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment Pharmacol Ther 2006; 23:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/16\">",
"      Wasmuth HE, Glantz A, Keppeler H, et al. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut 2007; 56:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/17\">",
"      Bacq Y, Gendrot C, Perrotin F, et al. ABCB4 gene mutations and single-nucleotide polymorphisms in women with intrahepatic cholestasis of pregnancy. J Med Genet 2009; 46:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/18\">",
"      Keitel V, Vogt C, H&auml;ussinger D, Kubitz R. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy. Gastroenterology 2006; 131:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/19\">",
"      Van Mil SW, Milona A, Dixon PH, et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007; 133:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/20\">",
"      Sookoian S, Casta&ntilde;o G, Burgue&ntilde;o A, et al. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol 2008; 48:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/21\">",
"      Reyes H, Simon FR. Intrahepatic cholestasis of pregnancy: an estrogen-related disease. Semin Liver Dis 1993; 13:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/22\">",
"      Gonzalez MC, Reyes H, Arrese M, et al. Intrahepatic cholestasis of pregnancy in twin pregnancies. J Hepatol 1989; 9:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/23\">",
"      Meng LJ, Reyes H, Palma J, et al. Effects of ursodeoxycholic acid on conjugated bile acids and progesterone metabolites in serum and urine of patients with intrahepatic cholestasis of pregnancy. J Hepatol 1997; 27:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/24\">",
"      Bacq Y, Sapey T, Br&eacute;chot MC, et al. Intrahepatic cholestasis of pregnancy: a French prospective study. Hepatology 1997; 26:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/25\">",
"      W&aring;nggren K, Sparre LS, Wramsby H. Severe jaundice in early IVF pregnancy. Eur J Obstet Gynecol Reprod Biol 2004; 112:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/26\">",
"      Kenyon AP, Piercy CN, Girling J, et al. Obstetric cholestasis, outcome with active management: a series of 70 cases. BJOG 2002; 109:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/27\">",
"      Heikkinen J, M&auml;entausta O, Yl&ouml;stalo P, J&auml;nne O. Changes in serum bile acid concentrations during normal pregnancy, in patients with intrahepatic cholestasis of pregnancy and in pregnant women with itching. Br J Obstet Gynaecol 1981; 88:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/28\">",
"      Lunzer M, Barnes P, Byth K, O'Halloran M. Serum bile acid concentrations during pregnancy and their relationship to obstetric cholestasis. Gastroenterology 1986; 91:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/29\">",
"      Brites D, Rodrigues CM, Oliveira N, et al. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J Hepatol 1998; 28:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/30\">",
"      Huang WM, Gowda M, Donnelly JG. Bile acid ratio in diagnosis of intrahepatic cholestasis of pregnancy. Am J Perinatol 2009; 26:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/31\">",
"      Atabey S, Duvan CI, Eren U, Turhan NO. Intrahepatic cholestasis and eclampsia: a case report. Hypertens Pregnancy 2007; 26:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/32\">",
"      Vanjak D, Moreau R, Roche-Sicot J, et al. Intrahepatic cholestasis of pregnancy and acute fatty liver of pregnancy. An unusual but favorable association? Gastroenterology 1991; 100:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/33\">",
"      Rolfes DB, Ishak KG. Liver disease in pregnancy. Histopathology 1986; 10:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/34\">",
"      Meng LJ, Reyes H, Axelson M, et al. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy. Hepatology 1997; 26:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/35\">",
"      Palma J, Reyes H, Ribalta J, et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J Hepatol 1997; 27:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/36\">",
"      Bacq Y, Sentilhes L, Reyes HB, et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 2012; 143:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/37\">",
"      Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 2005; 129:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/38\">",
"      Glantz A, Marschall HU, Lammert F, Mattsson LA. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 2005; 42:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/39\">",
"      Zapata R, Sandoval L, Palma J, et al. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience. Liver Int 2005; 25:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/40\">",
"      Rodrigues CM, Mar&iacute;n JJ, Brites D. Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment. Gut 1999; 45:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/41\">",
"      Serrano MA, Brites D, Larena MG, et al. Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. J Hepatol 1998; 28:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/42\">",
"      Mazzella G, Rizzo N, Azzaroli F, et al. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers. Hepatology 2001; 33:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/43\">",
"      Pusl T, Beuers U. Intrahepatic cholestasis of pregnancy. Orphanet J Rare Dis 2007; 2:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/44\">",
"      Ribalta J, Reyes H, Gonzalez MC, et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blind, placebo-controlled study with negative results. Hepatology 1991; 13:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/45\">",
"      Frezza M, Pozzato G, Chiesa L, et al. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration. Hepatology 1984; 4:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/46\">",
"      Floreani A, Paternoster D, Melis A, Grella PV. S-adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. Eur J Obstet Gynecol Reprod Biol 1996; 67:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/47\">",
"      Roncaglia N, Locatelli A, Arreghini A, et al. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis. BJOG 2004; 111:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/48\">",
"      Hirvioja ML, Tuimala R, Vuori J. The treatment of intrahepatic cholestasis of pregnancy by dexamethasone. Br J Obstet Gynaecol 1992; 99:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/49\">",
"      Kretowicz E, McIntyre HD. Intrahepatic cholestasis of pregnancy, worsening after dexamethasone. Aust N Z J Obstet Gynaecol 1994; 34:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/50\">",
"      Hirvioja ML, Kivinen S. Inheritance of intrahepatic cholestasis of pregnancy in one kindred. Clin Genet 1993; 43:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/51\">",
"      Ropponen A, Sund R, Riikonen S, et al. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. Hepatology 2006; 43:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/52\">",
"      Leevy CB, Koneru B, Klein KM. Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease. Gastroenterology 1997; 113:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/53\">",
"      Turunen K, M&ouml;ls&auml; A, Helander K, et al. Health history after intrahepatic cholestasis of pregnancy. Acta Obstet Gynecol Scand 2012; 91:679.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th ed, 2010. Vol 59, p.17.",
"    </li>",
"    <li>",
"     WHO. Medical Eligiblity Criteria for Contraceptive Use, 4th ed. WHO, Geneva 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/56\">",
"      Rioseco AJ, Ivankovic MB, Manzur A, et al. Intrahepatic cholestasis of pregnancy: a retrospective case-control study of perinatal outcome. Am J Obstet Gynecol 1994; 170:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/57\">",
"      Zecca E, De Luca D, Marras M, et al. Intrahepatic cholestasis of pregnancy and neonatal respiratory distress syndrome. Pediatrics 2006; 117:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/58\">",
"      Williamson C, Hems LM, Goulis DG, et al. Clinical outcome in a series of cases of obstetric cholestasis identified via a patient support group. BJOG 2004; 111:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/59\">",
"      Zecca E, De Luca D, Baroni S, et al. Bile acid-induced lung injury in newborn infants: a bronchoalveolar lavage fluid study. Pediatrics 2008; 121:e146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/60\">",
"      Williamson C, Miragoli M, Sheikh Abdul Kadir S, et al. Bile acid signaling in fetal tissues: implications for intrahepatic cholestasis of pregnancy. Dig Dis 2011; 29:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/61\">",
"      Sep&uacute;lveda WH, Gonz&aacute;lez C, Cruz MA, Rudolph MI. Vasoconstrictive effect of bile acids on isolated human placental chorionic veins. Eur J Obstet Gynecol Reprod Biol 1991; 42:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/62\">",
"      Heinonen S, Kirkinen P. Pregnancy outcome with intrahepatic cholestasis. Obstet Gynecol 1999; 94:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/63\">",
"      Alsulyman OM, Ouzounian JG, Ames-Castro M, Goodwin TM. Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management. Am J Obstet Gynecol 1996; 175:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/64\">",
"      Laatikainen T, Tulenheimo A. Maternal serum bile acid levels and fetal distress in cholestasis of pregnancy. Int J Gynaecol Obstet 1984; 22:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/65\">",
"      Oztekin D, Aydal I, Oztekin O, et al. Predicting fetal asphyxia in intrahepatic cholestasis of pregnancy. Arch Gynecol Obstet 2009; 280:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/66\">",
"      Ambros-Rudolph CM, Glatz M, Trauner M, et al. The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe. Arch Dermatol 2007; 143:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/67\">",
"      Sentilhes L, Verspyck E, Pia P, Marpeau L. Fetal death in a patient with intrahepatic cholestasis of pregnancy. Obstet Gynecol 2006; 107:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/68\">",
"      Egerman RS, Riely CA. Predicting fetal outcome in intrahepatic cholestasis of pregnancy: is the bile acid level sufficient? Hepatology 2004; 40:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/69\">",
"      Fisk NM, Storey GN. Fetal outcome in obstetric cholestasis. Br J Obstet Gynaecol 1988; 95:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/70\">",
"      Lee RH, Incerpi MH, Miller DA, et al. Sudden fetal death in intrahepatic cholestasis of pregnancy. Obstet Gynecol 2009; 113:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/71\">",
"      Laatikainen T. Effect of cholestyramine and phenobarbital on pruritus and serum bile acid levels in cholestasis of pregnancy. Am J Obstet Gynecol 1978; 132:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/72\">",
"      Saleh MM, Abdo KR. Consensus on the management of obstetric cholestasis: National UK survey. BJOG 2007; 114:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/73\">",
"      Matos A, Bernardes J, Ayres-de-Campos D, Patr&iacute;cio B. Antepartum fetal cerebral hemorrhage not predicted by current surveillance methods in cholestasis of pregnancy. Obstet Gynecol 1997; 89:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/74\">",
"      Roncaglia N, Arreghini A, Locatelli A, et al. Obstetric cholestasis: outcome with active management. Eur J Obstet Gynecol Reprod Biol 2002; 100:167.",
"     </a>",
"    </li>",
"    <li>",
"     The Joint Commission. PC-01 Elective Delivery: Specifications Manual for Joint Commission National Quality Core Measures. Appendix A-Table 11.07A. 2010.  file://manual.jointcommission.org/releases/TJC2010A/MIF0166.html.",
"    </li>",
"    <li>",
"     Main, E, Oshiro, B, Chagolla, B, Bingham, D, Dang-Kilduf,f L, Kowalewski, L. Elimination of Non-medically Indicated (Elective) Deliveries Before 39 Weeks Gestational Age. (California Maternal Quality Care Collaborative Toolkit to Transform Maternity Care), Developed under contract #08-85012 with the California Department of Public Health. Maternal, Child and Adolescent Health Division, 1st ed, March of Dimes, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4617/abstract/77\">",
"      Lee RH, Kwok KM, Ingles S, et al. Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy. Am J Perinatol 2008; 25:341.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3560 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4617=[""].join("\n");
var outline_f4_32_4617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Estrogens and progesterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ULTRASONOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ursodeoxycholic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications of cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MATERNAL FOLLOW-UP AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Underlying liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hormonal contraception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11113051\">",
"      - Estrogen-progestin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11113065\">",
"      - Progestin-only",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25607613\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FETAL FOLLOW-UP AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10703426\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10703433\">",
"      Predictive value of maternal bile acid level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25607628\">",
"      Antepartum testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Timing of delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3560\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3560|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/40/5774\" title=\"table 1\">",
"      WHO MEC for gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 2\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26198?source=related_link\">",
"      Approach to liver disease occurring during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/22/22889?source=related_link\">",
"      Tests of the liver's capacity to transport organic anions and metabolize drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_32_4618="Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides";
var content_f4_32_4618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/32/4618/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4618/contributors\">",
"     Richard T Hoppe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4618/contributors\">",
"     Youn H Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/32/4618/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4618/contributors\">",
"     Timothy M Kuzel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4618/contributors\">",
"     John A Zic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/32/4618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/32/4618/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/32/4618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycosis fungoides (MF) and S&eacute;zary syndrome (SS) are the most common subtypes of cutaneous T cell lymphoma (CTCL) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MF is a mature T cell non-Hodgkin lymphoma with presentation in the skin but with potential involvement of the nodes, blood, and viscera [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/2\">",
"       2",
"      </a>",
"      ]. Skin lesions include patches or plaques that may be localized or widespread, tumors, and erythroderma.",
"     </li>",
"     <li>",
"      SS is defined as a distinctive erythrodermic CTCL with a leukemic involvement of malignant T cells clonally matching that in the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This group of disorders differs from other primary cutaneous T cell lymphomas by virtue of unique clinical features and histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This topic review will discuss the clinical features, diagnosis, and staging of MF. The diagnosis of SS and the management of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of MF is unclear. Current hypotheses include genetic and epigenetic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Although environmental and occupational exposure to solvents and chemicals has been implicated in the etiology of the disease, a large case-controlled study failed to support this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/10\">",
"     10",
"    </a>",
"    ]. An infectious etiology for MF has been suggested, but no relation has been confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/11\">",
"     11",
"    </a>",
"    ]. Human T-lymphotropic virus type I (HTLV-I) has been reported in the peripheral blood or cutaneous lesions of some patients with MF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, an equal number of studies have evidence against a role of HTLV-I [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Clonal abnormalities",
"      </strong>",
"      &mdash; Clonal abnormalities have been identified in tumor cells, mostly deletions and translocations involving several different chromosomes or chromosomal segments [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Growing evidence from gene expression profiles and microRNA profiling suggests that MF and S&eacute;zary syndrome (SS) may be separate entities with differing pathogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/18-21\">",
"       18-21",
"      </a>",
"      ]. Comparative genomic hybridization has identified chromosomal abnormalities that occur in both MF and SS and abnormalities that are present in either MF or SS, but not both [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. The pathogenesis of SS is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link&amp;anchor=H449461398#H449461398\">",
"       \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Role of adhesion molecules",
"      </strong>",
"      &mdash; In light of the epidermotropism characteristic of MF, the role of adhesion molecules has been studied in this disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. The expression of ICAM-1 on keratinocytes has been demonstrated to be restricted to epidermotropic areas, and the down-regulation of ICAM-1 expression is associated with the loss of epidermotropism [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/25-28\">",
"       25-28",
"      </a>",
"      ]. The possible role of alpha3beta1 integrin (VLA-3) has also been implicated in the mechanism of epidermotropism [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]. An increased expression of cutaneous lymphocyte antigen (CLA) and its ligand E-selectin has been demonstrated in lesional skin tissue and peripheral blood of patients with MF or SS [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/25-27\">",
"       25-27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Role of cytokines",
"      </strong>",
"      &mdash; Cytokines have been implicated in the pathophysiology of MF [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/25,29-31\">",
"       25,29-31",
"      </a>",
"      ], but whether cytokine abnormalities are primarily involved or are secondary processes in the pathogenesis is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/32\">",
"       32",
"      </a>",
"      ]. Studies have reported that soluble interleukin-2 (IL-2) receptor (sIL-2R) values in SS were significantly higher than for other malignant or inflammatory T cell diseases and that the serum levels correlated with clinical course and S&eacute;zary cell count. The highest sIL-2R levels were found in patients with advanced disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/30\">",
"       30",
"      </a>",
"      ]. Other investigators have shown that peripheral blood mononuclear cells from patients with the SS expressed higher levels of IL-4 and lower levels of IL-2 and interferon gamma after phytohemagglutinin (PHA) stimulation, compared with normal controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of MF in Europe and the United States is approximately six cases per million per year, accounting for about 4 percent of all cases of non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. According to Surveillance, Epidemiology, and End Results (SEER) data, the age-adjusted incidence of MF has been increasing since 1973 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/33\">",
"     33",
"    </a>",
"    ]. The reasons for this are unclear, but might be due to improvements in detection, changes in the classification of this disease, or an increase in the underlying etiologic agent(s).",
"   </p>",
"   <p>",
"    The peak age at presentation is in excess of 55 to 60 years, with a 2:1 male:female ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The disease is more common in Blacks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Although MF is a disease mainly of older patients, it can be seen in patients under the age of 35 years with similar clinical findings and course [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MF commonly present with persistent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    slowly progressive skin lesions of varying size and shape. Skin lesions may be localized or widespread patches or plaques, tumors,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    generalized erythroderma. The skin is often pruritic and the patient's quality of life can be profoundly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/43\">",
"     43",
"    </a>",
"    ]. Other clinical manifestations include opportunistic infections, alopecia, and, less commonly, involvement of other organs. Some of these clinical features are used in the point-based diagnostic algorithm. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Premycotic period",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of MF is often preceded by a \"premycotic\" period ranging from months to decades, during which the patient may have nonspecific, slightly scaling skin lesions and nondiagnostic biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/44\">",
"     44",
"    </a>",
"    ]. These lesions may wax and wane over years, and a diagnosis of parapsoriasis en plaque or nonspecific dermatitis is often made (",
"    <a class=\"graphic graphic_picture graphicRef68028 \" href=\"UTD.htm?32/12/32963\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with these nonspecific dermatoses, even those with demonstrated T cell clones [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/46\">",
"     46",
"    </a>",
"    ], may never progress to have a definitive diagnosis of MF; their skin eruptions may resolve without any specific treatment or occasionally after simple treatment with topical corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/47\">",
"     47",
"    </a>",
"    ]. Repeated biopsies must be obtained in patients suspected of having MF, even when an initial biopsy is negative.",
"   </p>",
"   <p>",
"    In the past, occasional patients presented with what was thought to be de novo tumors, so-called tumor d'emblee. However, with advances in immunophenotyping, most of these cases would now be classified as other cutaneous T cell lymphomas or B cell lymphomas of the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13602004\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;MF is characterized by heterogeneous cutaneous manifestations including patches, plaques, tumors, generalized erythroderma, alopecia, or rarely, papules. Lesions are often confined to the bathing trunk distribution, although any body surface may be affected, even the palms and soles [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/48\">",
"     48",
"    </a>",
"    ]. Patches or plaques will be limited to &lt;10 percent of the skin surface in approximately 30 percent of patients, while more generalized",
"    <span class=\"nowrap\">",
"     patch/plaque",
"    </span>",
"    involvement is seen in approximately 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/49\">",
"     49",
"    </a>",
"    ]. Tumors and erythroderma will be present in approximately 20 and 15 percent, respectively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patches, plaques, and tumors &mdash; The most common initial skin lesions are scaly patches or plaques, which can be pruritic. While most patch lesions are large (greater than 5 cm in diameter), they often vary in size, shape, and color (",
"      <a class=\"graphic graphic_picture graphicRef80073 graphicRef60650 graphicRef71926 \" href=\"UTD.htm?11/19/11578\">",
"       picture 2A-C",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/48\">",
"       48",
"      </a>",
"      ]. As the disease progresses, patches may evolve into infiltrated plaques with a more generalized distribution (",
"      <a class=\"graphic graphic_picture graphicRef52131 graphicRef73078 \" href=\"UTD.htm?1/16/1288\">",
"       picture 3A-B",
"      </a>",
"      ), and patients with a history of plaque disease may develop ulcerated or exophytic tumors (",
"      <a class=\"graphic graphic_picture graphicRef54786 graphicRef62423 \" href=\"UTD.htm?13/11/13498\">",
"       picture 4A-B",
"      </a>",
"      ). A tumor is defined as a dome-shaped solid skin lesion greater than 1 cm in diameter. However, the majority of patients with initial patch or plaque disease never progress to have more advanced cutaneous disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Papules &mdash; Keratosis pilaris-like lesions represent inflamed follicular-based papules or scale that may signal follicular involvement with or without mucinosis (",
"      <a class=\"graphic graphic_picture graphicRef83372 \" href=\"UTD.htm?11/54/12128\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypopigmented or hyperpigmented lesions (",
"      <a class=\"graphic graphic_picture graphicRef65345 \" href=\"UTD.htm?2/63/3059\">",
"       picture 6",
"      </a>",
"      ) &mdash; Poikiloderma is the presence of mottled pigmentation, epidermal atrophy, and telangiectasia associated with slight infiltration (",
"      <a class=\"graphic graphic_picture graphicRef63888 \" href=\"UTD.htm?39/16/40196\">",
"       picture 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/53\">",
"       53",
"      </a>",
"      ]. Hypopigmented lesions are relatively uncommon and mostly seen in patients with darker skin. These lesions may occur with or without more typical MF lesions. Rarely, the hypopigmented lesions may have an annular appearance [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Generalized erythroderma &mdash; Generalized erythroderma (",
"      <a class=\"graphic graphic_picture graphicRef72342 \" href=\"UTD.htm?11/30/11745\">",
"       picture 8",
"      </a>",
"      ) typically represents more advanced disease and may be accompanied by either atrophic or lichenified skin, and plaques or tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/44\">",
"       44",
"      </a>",
"      ]. These patients are almost always intensely symptomatic from pruritus and scaling, and often have lymphadenopathy due to diffuse and severe skin involvement. Generalized erythroderma is more commonly observed in those with S&eacute;zary syndrome where it is required to make the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link&amp;anchor=H449462700#H449462700\">",
"       \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Skin lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alopecia &mdash; Alopecia is common and can present as reduced hair density diffusely over the scalp and body or as patches of alopecia. Patients with MF can present with varying degrees of alopecia (",
"      <a class=\"graphic graphic_picture graphicRef83373 \" href=\"UTD.htm?8/38/8806\">",
"       picture 9",
"      </a>",
"      ). A retrospective analysis of 1550 patients with MF",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      S&eacute;zary syndrome found that 38 patients had patchy, total-scalp, or universal alopecia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/55\">",
"       55",
"      </a>",
"      ]. Patchy alopecia was clinically indistinguishable from alopecia areata in 34 percent. The majority of remaining cases presented with alopecia in discreet",
"      <span class=\"nowrap\">",
"       patch/plaque",
"      </span>",
"      or follicular lesions. Total-body hair loss was seen in five patients with generalized erythroderma and S&eacute;zary syndrome.",
"     </li>",
"     <li>",
"      Erosions and superinfection &mdash; Patients are often colonized with Staphylococcus aureus, and erosions and superinfection from constant scratching are common. (See",
"      <a class=\"local\" href=\"#H13602281\">",
"       'Infections'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17265505\">",
"    <span class=\"h3\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is one of the most common and the most debilitating symptoms of patients with MF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/43,56\">",
"     43,56",
"    </a>",
"    ]. In a retrospective analysis of bedside surveys from 486 patients with MF (85 percent) or S&eacute;zary syndrome (15 percent), pruritus was reported by 66 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/57\">",
"     57",
"    </a>",
"    ]. Using a visual analog scale of 1 to 10 to measure severity, the mean pruritus rating was 4.2 for all patients. The severity rating increased with increasing disease stage, being 3.4, 6.6, and 7.7 in patients with early stage (Ia to IIa) disease, late stage (IIb to IVb) disease, and S&eacute;zary syndrome, respectively. It is not necessarily related to the degree of blood involvement or the extent and depth of erythema, and it can be associated with sleep dysfunction, anxiety, and depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=see_link&amp;anchor=H33#H33\">",
"     \"Treatment of early stage (IA to IIA) mycosis fungoides\", section on 'Pruritus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Extracutaneous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of developing extracutaneous disease, exclusive of peripheral blood involvement, correlates with the extent of skin involvement. It is exceedingly rare among patients with limited patch or plaque disease, relatively uncommon among those with generalized plaque (8 percent), and most likely among patients with tumors or generalized erythroderma (30 to 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/44\">",
"     44",
"    </a>",
"    ]. Thus, extracutaneous disease is more commonly observed among those with S&eacute;zary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4713?source=see_link&amp;anchor=H1118942#H1118942\">",
"     \"Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome\", section on 'Stages IVA and IVB'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extracutaneous manifestations include involvement of regional lymph nodes (approximately 30 percent in MF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/58\">",
"     58",
"    </a>",
"    ]), lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/59\">",
"     59",
"    </a>",
"    ], spleen, liver, and gastrointestinal tract. Bone marrow involvement is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/4\">",
"     4",
"    </a>",
"    ]. Autopsy studies and a large case series have shown that involvement of any organ, including the central nervous system, can occur in the advanced stages of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=see_link&amp;anchor=H171056704#H171056704\">",
"     \"Secondary involvement of the central nervous system by non-Hodgkin lymphoma\", section on 'Incidence and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13602012\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13602281\">",
"    <span class=\"h3\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MF are at increased risk for infection due to a combination of immune dysfunction and physical factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/62\">",
"     62",
"    </a>",
"    ]. Patients with MF demonstrate impaired cellular and humoral immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/62\">",
"     62",
"    </a>",
"    ]. They have an increase in the severity of viral (eg, herpes) and bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/63\">",
"     63",
"    </a>",
"    ]. In one study, the majority of patients with MF demonstrated colonization with Staphylococcus aureus in the skin or nares [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/64\">",
"     64",
"    </a>",
"    ]. Colonized patients treated with antibiotics to eradicate the bacteria often demonstrate clinical improvement of signs of skin involvement with the lymphoma. There have also been reports of progressive multifocal leukoencephalopathy due to polyomavirus in patients with MF in the absence of immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Second malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the SEER (Surveillance, Epidemiology, and End Results Program) United States population-based and university referral center registries have demonstrated an increased incidence of second cancers, specifically lymphoma, in patients with mycosis fungoides or S&eacute;zary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MF was first described by the French dermatologist Alibert in 1806, with the mushroom-like appearance of the cutaneous tumor nodules giving the disease its name. Clinical-pathologic correlation is key to the diagnosis. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Diagnostic algorithm'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsies in MF demonstrate small to medium-sized atypical mononuclear cells with cerebriform nuclei infiltrating the upper dermis and epidermal keratinocytes (epidermotropism) or forming intraepidermal aggregates (Pautrier microabscesses) (",
"    <a class=\"graphic graphic_picture graphicRef83483 \" href=\"UTD.htm?43/35/44600\">",
"     picture 10",
"    </a>",
"    ). Pautrier microabscesses are pathognomonic, yet uncommon (",
"    <a class=\"graphic graphic_picture graphicRef61650 \" href=\"UTD.htm?39/13/40150\">",
"     picture 11",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/4\">",
"     4",
"    </a>",
"    ]. Spongiosis, or the collection of fluid in the epidermis, is not seen.",
"   </p>",
"   <p>",
"    Folliculotropic MF is a distinct entity with a worse prognosis than other forms of MF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. This variant often lacks evidence of epidermotropism and is characterized by atypical CD4+ T lymphocytes that surround and permeate the hair follicles (folliculotropism) with or without associated follicular mucinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective review of histology specimens from 64 patients with MF confirmed by clinical course and immunophenotyping results and 47 patients who were biopsied to exclude MF and did not have the disease, the following parameters were found to be significant discriminators between MF and non-MF on univariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pautrier's abscesses (present in 38 percent of cases of MF)",
"     </li>",
"     <li>",
"      Haloed lymphocytes",
"     </li>",
"     <li>",
"      Exocytosis",
"     </li>",
"     <li>",
"      Disproportionate epidermotropism",
"     </li>",
"     <li>",
"      Epidermal lymphocytes larger than dermal lymphocytes",
"     </li>",
"     <li>",
"      Hyperconvoluted intraepidermal lymphocytes",
"     </li>",
"     <li>",
"      Lymphocytes aligned within the basal layer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these findings, haloed lymphocytes (intraepidermal lymphocytes with vacuoles around them (",
"    <a class=\"graphic graphic_picture graphicRef83484 \" href=\"UTD.htm?2/45/2776\">",
"     picture 12",
"    </a>",
"    )) were the most robust discriminator of MF from non-MF on multivariate analysis. Based upon the severity of the epidermal and dermal involvement, the categories \"diagnostic of,\" \"consistent with,\" and \"suggestive of\" MF are often used. In practice, only those skin biopsies labeled as &ldquo;diagnostic of&rdquo; or &ldquo;consistent with&rdquo; MF have established the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Lymph node biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MF and extensive skin involvement may have enlarged lymph nodes demonstrating histologic findings of dermatopathic lymphadenitis, showing sinus histiocytosis, an abundance of pigment-laden macrophages, and a small number of atypical lymphocytes. The degree of lymph node replacement by these atypical cells can be described as a grade that has prognostic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4713?source=see_link\">",
"     \"Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The detection of abnormal cells in the lymph node is facilitated by the use of Southern blot or polymerase chain reaction (PCR) analysis. Potential neoplastic involvement with clonal TCR rearrangement may be demonstrated even in lymph nodes that show only dermatopathic changes in routine evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/73\">",
"     73",
"    </a>",
"    ]. However, the clinical implication of lymph node involvement that is detectable only at the molecular level is unclear, and usually is not associated with as severe an impact on prognosis as when involvement is detected by routine light microscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13602155\">",
"    <span class=\"h3\">",
"     Circulating S&eacute;zary cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;S&eacute;zary cells are mononuclear cells with a cerebriform nucleus (",
"    <a class=\"graphic graphic_picture graphicRef75793 \" href=\"UTD.htm?10/56/11137\">",
"     picture 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70592 \" href=\"UTD.htm?27/18/27936\">",
"     picture 14",
"    </a>",
"    ). These cells can be observed in small numbers among healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/2\">",
"     2",
"    </a>",
"    ]. In those with MF, an increased number of S&eacute;zary cells may be seen in the peripheral blood. An absolute count &ge;1000 S&eacute;zary",
"    <span class=\"nowrap\">",
"     cells/cubic",
"    </span>",
"    mm is a diagnostic criterion for S&eacute;zary syndrome. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Immunophenotyping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunophenotyping is used to support or confirm results of the routine histology [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Determining the immunophenotype can be technically difficult. Sensitivity and specificity vary depending upon the type of tissue used (frozen section versus paraffin block), antibody used, and cutoff value selected. In routine practice, expression of CD2, CD3, CD5, and CD7 are key factors in determining the immunophenotype while other markers are still under investigation. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Immunophenotyping can help distinguish MF and S&eacute;zary syndrome from reactive or inflammatory lymphoid infiltrates in the skin which display markers of mature lymphocytes. Mature T cell markers include CD2, CD3, CD5, and CD7. Lack of one or more of these markers indicates a more immature cell and is strongly suggestive of lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decrease in the expression of these markers can also be determined by evaluating the",
"    <span class=\"nowrap\">",
"     epidermal/dermal",
"    </span>",
"    discordance. Discordance is found when the antigen is deficient among the cells restricted to the epidermis but is present in the cells in the dermis. An",
"    <span class=\"nowrap\">",
"     epidermal/dermal",
"    </span>",
"    discordance for CD2, CD3, CD5, and CD7 suggests the diagnosis of a T cell lymphoma but is limited in its ability to subclassify it as MF.",
"   </p>",
"   <p>",
"    Expression of CD30 is present in 40 to 50 percent of histologically transformed MF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/77\">",
"     77",
"    </a>",
"    ]. Some expression of CD30 is common in all patients with MF, not limited to those with histologic large cell transformation; in a study of 47 cases of MF, at least rare dermal CD30-positive cells were seen in all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/78\">",
"     78",
"    </a>",
"    ]. The percentage of dermal CD30 positive cells increased with increasing disease stage and was an independent predictor of adverse outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     T cell receptor gene rearrangement",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cell receptor (TCR) gene rearrangements can be detected using PCR amplification method [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. The gene rearrangement tests are utilized primarily when the histology and immunophenotyping results are equivocal in patients whose clinical presentation is strongly suggestive of MF, and may be less valuable when used to determine prognosis. This is of particular importance in patients with erythroderma since morphology is often non-diagnostic in this patient group. Examination of multiple biopsies from the same patient taken simultaneously or consecutively from two anatomically distinct skin sites usually, but not always, demonstrates the same TCR gene rearrangement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of TCR gene rearrangement among T cell clones is not diagnostic of MF. Instead, the presence of such abnormalities is only one component of a possible diagnosis. As an example, there are non-malignant disorders in which T cell clonality is observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some non-malignant or pre-malignant cutaneous conditions may be accompanied by evidence of an expanded T cell clone [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/46,84\">",
"       46,84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Innocent cytotoxic T cell clones are occasionally detected in the peripheral blood of elderly patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18327877\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MF is suspected in patients who present with chronic nonspecific dermatitis, poikilodermatous skin findings, or generalized erythroderma. Skin biopsy with routine histology is the single most important laboratory tool that will assist the clinician in establishing the diagnosis of MF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/86\">",
"     86",
"    </a>",
"    ]. Often multiple skin biopsies are required. If only one biopsy is performed, it should include the lesional skin with the most induration. With the exception of emollients, all topical treatments should be avoided for two to four weeks prior to biopsy since they may interfere with the interpretation of the biopsy specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/48\">",
"     48",
"    </a>",
"    ]. A minimum of a 4 mm punch biopsy is recommended. In most cases, biopsies can be placed in formalin prior to hematoxylin and eosin staining and any additional pathology tests. Patients from endemic regions (eg, Japan and the Caribbean) should have serologic testing for HTLV-I.",
"   </p>",
"   <p>",
"    An algorithm for diagnosing and staging early MF, based upon clinical, histopathologic, molecular, and immunopathologic criteria, has been proposed by the International Society for Cutaneous Lymphoma and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/2,48\">",
"     2,48",
"    </a>",
"    ]. It is recommended that all patients enrolled in trials or databases for MF should have their diagnosis confirmed by the",
"    <span class=\"nowrap\">",
"     ISCL/EORTC",
"    </span>",
"    algorithm as described below. Diagnostic, staging, and treatment guidelines for MF are also available from the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diagnostic algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MF can be made using the point-based algorithm created by the",
"    <span class=\"nowrap\">",
"     ISCL/EORTC,",
"    </span>",
"    which incorporates clinical, histopathologic, molecular, and immunopathologic criteria (",
"    <a class=\"graphic graphic_table graphicRef74457 \" href=\"UTD.htm?32/40/33420\">",
"     table 1",
"    </a>",
"    ). Points are scored for clinical, histopathologic, molecular biological, and immunopathologic categories [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/2,48\">",
"     2,48",
"    </a>",
"    ]. A diagnosis of MF is made when a total of four points or more is determined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical criteria: Patient has persistent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progressive patches and plaques plus (two points given if two of the following are present, one point is given if one of the following is present): lesions in a non-sun-exposed location,",
"      <span class=\"nowrap\">",
"       size/shape",
"      </span>",
"      variation of lesions, poikiloderma (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Skin lesions'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Histopathologic criteria: Superficial lymphoid infiltrate present plus (two points are given if both of the following are present, one point is given if only one of the following is present): epidermotropism without spongiosis, lymphoid atypia.",
"     </li>",
"     <li>",
"      Molecular biological criteria: If clonal TCR gene rearrangement is present, give one point.",
"     </li>",
"     <li>",
"      Immunopathologic criteria: Give one point if any of the following is present: less than 50 percent of the T cells express CD2, CD3, or CD5; less than 10 percent of the T cells express CD7; there is discordance of the epidermal and dermal cells with regards to expression of CD2, CD3, CD5, or CD7.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MF typically presents as an indolent cutaneous eruption with erythematous scaly patches or plaques, often resembling common skin disorders such as eczema, psoriasis, parapsoriasis, photodermatitis, or drug reactions. The cutaneous tumors seen in patients with MF can also resemble those tumors seen with other cutaneous lymphomas. The",
"    <span class=\"nowrap\">",
"     ISCL/EORTC",
"    </span>",
"    diagnostic algorithm described above aims to use clinical, histopathologic, molecular biological, and immunopathologic features to help make these diagnostic decisions easier. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9894819\">",
"    <span class=\"h2\">",
"     Other causes of erythroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythroderma is a less common cutaneous presentation of MF and is seen most commonly in patients with generalized atopic dermatitis, contact dermatitis, drug eruptions, or erythrodermic psoriasis. It can also be seen in patients with the idiopathic hypereosinophilic syndrome, some of whom have abnormal T cell clones [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/88\">",
"     88",
"    </a>",
"    ]. The approach to patients with generalized erythroderma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13385?source=see_link\">",
"     \"Erythroderma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9894812\">",
"    <span class=\"h2\">",
"     Other causes of pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus is a frequent manifestation of MF, although it is typically not present in the absence of cutaneous findings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/89\">",
"     89",
"    </a>",
"    ]. The erythrodermic form of MF and S&eacute;zary syndrome are extremely pruritic and there are case reports of pruritus preceding the onset of skin findings by several years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/32/4618/abstract/90\">",
"     90",
"    </a>",
"    ]. Pruritus is a common symptom that occurs in a diverse range of skin diseases and may appear as a prominent feature of extracutaneous disorders such as systemic, neurologic, and psychiatric diseases (",
"    <a class=\"graphic graphic_table graphicRef74678 \" href=\"UTD.htm?2/21/2397\">",
"     table 2",
"    </a>",
"    ). The evaluation of the patient with pruritus is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=see_link\">",
"     \"Pruritus: Etiology and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13602468\">",
"    <span class=\"h2\">",
"     S&eacute;zary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, patients with MF may have atypical lymphocytes with cerebriform nuclei (ie, S&eacute;zary cells) in their peripheral blood (",
"    <a class=\"graphic graphic_picture graphicRef75793 \" href=\"UTD.htm?10/56/11137\">",
"     picture 13",
"    </a>",
"    ). A diagnosis of S&eacute;zary syndrome is made when there is a particularly high number of these cells circulating in the peripheral blood in the presence of a cutaneous erythroderma occupying more than 80 percent of the body surface area. This is equivalent to the T",
"    <sub>",
"     4",
"    </sub>",
"    and B",
"    <sub>",
"     2",
"    </sub>",
"    designation in the TNMB classification syndrome (",
"    <a class=\"graphic graphic_table graphicRef75768 \" href=\"UTD.htm?11/34/11822\">",
"     table 3",
"    </a>",
"    ). The diagnosis of S&eacute;zary syndrome is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18328269\">",
"    <span class=\"h2\">",
"     Adult T cell leukemia lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult T cell leukemia lymphoma (ATL) is a peripheral T cell lymphoma associated with infection by the human T-lymphotropic virus, type I (HTLV-I). Approximately 50 percent of patients with ATL will have skin lesions at diagnosis, often simulating those seen in MF. ATL, however, is much more likely to have disseminated extracutaneous disease with frequent lymphoma in the nodes, liver, bone, and central nervous system. A key differentiating feature is the presence of HTLV-I in the malignant cells of ATL, which can be determined by testing for the antibody in the blood. ATL is common in Japan and the Caribbean and is unusual in mainland US. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18328365\">",
"    <span class=\"h2\">",
"     Subcutaneous panniculitis-like T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is an uncommon peripheral T cell lymphoma that typically presents with one or more usually painless subcutaneous nodules or poorly circumscribed indurated plaques that may clinically resemble panniculitis. Similar to MF, SPTCL expresses CD3, does not express CD56 or demonstrate Epstein-Barr virus infection, and has clonally rearranged T cell receptor genes. SPTCL differs from MF in that it is centered on the subcutaneous tissue rather than the dermis and epidermis, does not express CD4, and expresses CD8 and cytotoxic granule proteins (TIA-1, granzyme B,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18328395\">",
"    <span class=\"h2\">",
"     Primary cutaneous anaplastic large cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cutaneous anaplastic large cell lymphoma (ALCL) is a peripheral T cell lymphoma characterized by the diffuse infiltration of the upper and deep dermis and the subcutaneous tissue by large lymphoid cells. Unlike MF, primary cutaneous ALCL expresses cytotoxic molecules (TIA-1, granzyme B,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforin) and CD30. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link&amp;anchor=H5619109#H5619109\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\", section on 'Primary cutaneous ALCL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18328323\">",
"    <span class=\"h2\">",
"     Cutaneous B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin lesions of MF cannot be distinguished clinically from those of B cell lymphomas. MF can be distinguished from cutaneous B cell lymphomas through their expression of T cell markers such as CD2, CD3, and CD5. In addition, MF can be identified by T cell receptor (TCR) gene rearrangement studies. The diagnosis of primary cutaneous B cell lymphomas is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=see_link\">",
"     \"Primary cutaneous follicle center lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=see_link\">",
"     \"Primary cutaneous marginal zone lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=see_link\">",
"     \"Primary cutaneous large B cell lymphoma, leg type\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13601561\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycosis fungoides (MF) is an extranodal indolent non-Hodgkin lymphoma of T cell origin that is characterized by skin involvement. The cause of MF is unclear. Current hypotheses include infectious agents and genetic abnormalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MF is an uncommon disease, accounting for approximately 4 percent of all cases of non-Hodgkin lymphoma. The peak age at presentation is in excess of 55 to 60 years. It is more common in males and Blacks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients present with skin changes that are often pruritic and may have been preceded by a \"premycotic\" period ranging from months to decades. The cutaneous manifestations are heterogeneous and include patches, plaques, tumors, generalized erythroderma, poikiloderma, or rarely, papules. Extracutaneous manifestations, while uncommon, include involvement of regional lymph nodes, lungs, spleen, liver, gastrointestinal tract, and bone marrow. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin biopsies demonstrate mononuclear cells with cerebriform nuclei infiltrating the upper dermis (epidermotropism) or forming intraepidermal aggregates (Pautrier microabscesses). Folliculotropic MF is a distinct entity that is characterized by atypical lymphocytes that surround and permeate the hair follicles (folliculotropism). Immunophenotype and T cell receptor (TCR) gene rearrangement studies can be used to support or confirm results of the routine histology in patients whose clinical presentation is strongly suggestive of MF. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A point-based algorithm that incorporates clinical, histopathologic, molecular, and immunopathologic criteria is used to confirm the diagnosis of MF (",
"      <a class=\"graphic graphic_table graphicRef74457 \" href=\"UTD.htm?32/40/33420\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of MF includes common skin disorders, such as eczema or psoriasis and other cutaneous lymphomas. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/1\">",
"      Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/2\">",
"      Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/3\">",
"      Siegel RS, Pandolfino T, Guitart J, et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18:2908.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/5\">",
"      van Doorn R, Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005; 23:3886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/6\">",
"      Shin J, Monti S, Aires DJ, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007; 110:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/7\">",
"      Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011; 155:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/8\">",
"      Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011; 86:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/9\">",
"      Whittaker S. Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). Semin Oncol 2006; 33:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/10\">",
"      Whittemore AS, Holly EA, Lee IM, et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J Natl Cancer Inst 1989; 81:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/11\">",
"      Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T-cell lymphoma. J Am Acad Dermatol 2011; 64:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/12\">",
"      Hall WW, Liu CR, Schneewind O, et al. Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science 1991; 253:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/13\">",
"      Ghosh SK, Abrams JT, Terunuma H, et al. Human T-cell leukemia virus type I tax/rex DNA and RNA in cutaneous T-cell lymphoma. Blood 1994; 84:2663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/14\">",
"      Wood GS, Salvekar A, Schaffer J, et al. Evidence against a role for human T-cell lymphotrophic virus type I (HTLV-I) in the pathogenesis of American cutaneous T-cell lymphoma. J Invest Dermatol 1996; 107:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/15\">",
"      Li G, Vowels BR, Benoit BM, et al. Failure to detect human T-lymphotropic virus type-I proviral DNA in cell lines and tissues from patients with cutaneous T-cell lymphoma. J Invest Dermatol 1996; 107:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/16\">",
"      Karenko L, Hahtola S, P&auml;ivinen S, et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res 2005; 65:8101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/17\">",
"      Zhang Y, Wang Y, Yu R, et al. Molecular markers of early-stage mycosis fungoides. J Invest Dermatol 2012; 132:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/18\">",
"      Ballabio E, Mitchell T, van Kester MS, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010; 116:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/19\">",
"      Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010; 116:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/20\">",
"      Laharanne E, Oumouhou N, Bonnet F, et al. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol 2010; 130:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/21\">",
"      Ralfkiaer U, Hagedorn PH, Bangsgaard N, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011; 118:5891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/22\">",
"      Karenko L, K&auml;hk&ouml;nen M, Hyytinen ER, et al. Notable losses at specific regions of chromosomes 10q and 13q in the S&eacute;zary syndrome detected by comparative genomic hybridization. J Invest Dermatol 1999; 112:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/23\">",
"      van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/24\">",
"      Vermeer MH, van Doorn R, Dijkman R, et al. Novel and highly recurrent chromosomal alterations in S&eacute;zary syndrome. Cancer Res 2008; 68:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/25\">",
"      Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/26\">",
"      Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and S&eacute;zary syndrome. Lancet 2008; 371:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/27\">",
"      Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/28\">",
"      L&oacute;pez-Lerma I, Estrach MT. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and S&eacute;zary syndrome. J Am Acad Dermatol 2009; 61:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/29\">",
"      Bernengo MG, Fierro MT, Novelli M, et al. Soluble interleukin-2 receptor in S&eacute;zary syndrome: its origin and clinical application. Br J Dermatol 1993; 128:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/30\">",
"      Wasik MA, Vonderheid EC, Bigler RD, et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996; 132:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/31\">",
"      Yamanaka K, Clark R, Rich B, et al. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006; 107:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/32\">",
"      Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003; 48:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/33\">",
"      Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/34\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/35\">",
"      Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113:5064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/36\">",
"      Fujita A, Hamada T, Iwatsuki K. Retrospective analysis of 133 patients with cutaneous lymphomas from a single Japanese medical center between 1995 and 2008. J Dermatol 2011; 38:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/37\">",
"      Sun G, Berthelot C, Li Y, et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol 2009; 60:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/38\">",
"      Hinds GA, Heald P. Cutaneous T-cell lymphoma in skin of color. J Am Acad Dermatol 2009; 60:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/39\">",
"      Wu XC, Andrews P, Chen VW, Groves FD. Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol 2009; 33:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/40\">",
"      Crowley JJ, Nikko A, Varghese A, et al. Mycosis fungoides in young patients: clinical characteristics and outcome. J Am Acad Dermatol 1998; 38:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/41\">",
"      Quaglino P, Zaccagna A, Verrone A, et al. Mycosis fungoides in patients under 20 years of age: report of 7 cases, review of the literature and study of the clinical course. Dermatology 1999; 199:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/42\">",
"      Pope E, Weitzman S, Ngan B, et al. Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma. J Cutan Med Surg 2010; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/43\">",
"      Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 2006; 107:2504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/44\">",
"      Morales MM, Olsen J, Johansen P, et al. Viral infection, atopy and mycosis fungoides: a European multicentre case-control study. Eur J Cancer 2003; 39:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/45\">",
"      Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol 2002; 47:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/46\">",
"      Guitart J, Magro C. Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones. Arch Dermatol 2007; 143:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/47\">",
"      Smoller BR, Bishop K, Glusac E, et al. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol 1995; 19:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/48\">",
"      Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/49\">",
"      Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/50\">",
"      Kim YH, Jensen RA, Watanabe GL, et al. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996; 132:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/51\">",
"      Kodama K, Fink-Puches R, Massone C, et al. Papular mycosis fungoides: a new clinical variant of early mycosis fungoides. J Am Acad Dermatol 2005; 52:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/52\">",
"      Monopoli A, Annessi G, Lombardo GA, et al. Purely follicular mycosis fungoides without mucinosis: report of two cases with review of the literature. J Am Acad Dermatol 2003; 48:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/53\">",
"      Abbott RA, Sahni D, Robson A, et al. Poikilodermatous mycosis fungoides: a study of its clinicopathological, immunophenotypic, and prognostic features. J Am Acad Dermatol 2011; 65:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/54\">",
"      Uhlenhake EE, Mehregan DM. Annular hypopigmented mycosis fungoides: a novel ringed variant. J Cutan Pathol 2012; 39:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/55\">",
"      Bi MY, Curry JL, Christiano AM, et al. The spectrum of hair loss in patients with mycosis fungoides and S&eacute;zary syndrome. J Am Acad Dermatol 2011; 64:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/56\">",
"      Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol 2012; 67:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/57\">",
"      Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol 2012; 51:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/58\">",
"      Vonderheid EC, Diamond LW, van Vloten WA, et al. Lymph node classification systems in cutaneous T-cell lymphoma. Evidence for the utility of the Working Formulation of Non-Hodgkin's Lymphomas for Clinical Usage. Cancer 1994; 73:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/59\">",
"      Baser S, Onn A, Lin E, et al. Pulmonary manifestations in patients with cutaneous T-cell lymphomas. Cancer 2007; 109:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/60\">",
"      Epstein EH Jr, Levin DL, Croft JD Jr, Lutzner MA. Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings. Medicine (Baltimore) 1972; 51:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/61\">",
"      Stein M, Farrar N, Jones GW, et al. Central neurologic involvement in mycosis fungoides: ten cases, actuarial risk assessment, and predictive factors. Cancer J 2006; 12:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/62\">",
"      Krejsgaard T, Odum N, Geisler C, et al. Regulatory T cells and immunodeficiency in mycosis fungoides and S&eacute;zary syndrome. Leukemia 2012; 26:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/63\">",
"      Mallo-Garc&iacute;a S, Coto-Segura P, Su&aacute;rez-Casado H, et al. Fatal outcome due to bacterial superinfection of eczema herpeticum in a patient with mycosis fungoides. Dermatol Online J 2008; 14:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/64\">",
"      Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and S&eacute;zary syndrome. Br J Dermatol 2008; 159:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/65\">",
"      Lee J, Richardson SK, Melhem ER, et al. Progressive multifocal leukoencephalopathy from JC virus in a patient with advanced mycosis fungoides. J Am Acad Dermatol 2007; 57:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/66\">",
"      Huang KP, Weinstock MA, Clarke CA, et al. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 2007; 143:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/67\">",
"      Herro E, Dicaudo DJ, Davis MD, et al. Review of contemporaneous mycosis fungoides and B-cell malignancy at Mayo Clinic. J Am Acad Dermatol 2009; 61:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/68\">",
"      Klemke CD, Dippel E, Assaf C, et al. Follicular mycosis fungoides. Br J Dermatol 1999; 141:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/69\">",
"      van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 2002; 138:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/70\">",
"      Lehman JS, Cook-Norris RH, Weed BR, et al. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol 2010; 146:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/71\">",
"      Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/S&eacute;zary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010; 28:4730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/72\">",
"      Sausville EA, Worsham GF, Matthews MJ, et al. Histologic assessment of lymph nodes in mycosis fungoides/S&eacute;zary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985; 16:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/73\">",
"      Kern DE, Kidd PG, Moe R, et al. Analysis of T-cell receptor gene rearrangement in lymph nodes of patients with mycosis fungoides. Prognostic implications. Arch Dermatol 1998; 134:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/74\">",
"      Oshtory S, Apisarnthanarax N, Gilliam AC, et al. Usefulness of flow cytometry in the diagnosis of mycosis fungoides. J Am Acad Dermatol 2007; 57:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/75\">",
"      Wood G, Weiss L, Warnke R, et al. The immunopathology of cutaneous lymphomas: Immunophenotypic and immunogenotypic characteristics. Semin Dermatol 1986; 5:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/76\">",
"      Smoller BR, Santucci M, Wood GS, Whittaker SJ. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/77\">",
"      Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 2012; 119:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/78\">",
"      Edinger JT, Clark BZ, Pucevich BE, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol 2009; 33:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/79\">",
"      Ashton-Key M, Diss TC, Du MQ, et al. The value of the polymerase chain reaction in the diagnosis of cutaneous T-cell infiltrates. Am J Surg Pathol 1997; 21:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/80\">",
"      Muche JM, Lukowsky A, Asadullah K, et al. Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood 1997; 90:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/81\">",
"      Delfau-Larue MH, Laroche L, Wechsler J, et al. Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood 2000; 96:2987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/82\">",
"      Vega F, Luthra R, Medeiros LJ, et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood 2002; 100:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/83\">",
"      Thurber SE, Zhang B, Kim YH, et al. T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol 2007; 57:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/84\">",
"      Guitart J. Beyond clonal detection: defining the T-cell clone. Arch Dermatol 2005; 141:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/85\">",
"      Khan N, Shariff N, Cobbold M, et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/86\">",
"      Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002; 46:325.",
"     </a>",
"    </li>",
"    <li>",
"     www.nccn.org (Accessed on April 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/88\">",
"      Simon HU, Pl&ouml;tz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/89\">",
"      Lober CW. Should the patient with generalized pruritus be evaluated for malignancy? J Am Acad Dermatol 1988; 19:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/32/4618/abstract/90\">",
"      Pujol RM, Gallardo F, Llistosella E, et al. Invisible mycosis fungoides: a diagnostic challenge. J Am Acad Dermatol 2002; 47:S168.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1674 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4618=[""].join("\n");
var outline_f4_32_4618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13601561\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Premycotic period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13602004\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17265505\">",
"      - Pruritus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Extracutaneous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13602012\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13602281\">",
"      - Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Second malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Lymph node biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13602155\">",
"      - Circulating S&eacute;zary cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Immunophenotyping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      T cell receptor gene rearrangement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18327877\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diagnostic algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9894819\">",
"      Other causes of erythroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9894812\">",
"      Other causes of pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13602468\">",
"      S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18328269\">",
"      Adult T cell leukemia lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18328365\">",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18328395\">",
"      Primary cutaneous anaplastic large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18328323\">",
"      Cutaneous B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13601561\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1674\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1674|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/12/32963\" title=\"picture 1\">",
"      Parapsoriasis large plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/16/34052\" title=\"picture 2A\">",
"      Mycosis fungoides patch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/36/35393\" title=\"picture 2B\">",
"      Mycosis fungoides patches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/38/34402\" title=\"picture 2C\">",
"      Hypopigmented mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/17/38163\" title=\"picture 3A\">",
"      Mycosis fungoides plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/2/35873\" title=\"picture 3B\">",
"      Mycosis fungoides plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/63/37875\" title=\"picture 4A\">",
"      Mycosis fungoides tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/14/3304\" title=\"picture 4B\">",
"      Mycosis fungoides tumor leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/54/12128\" title=\"picture 5\">",
"      Follicular involvement in MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/63/3059\" title=\"picture 6\">",
"      Mycosis fungoides hyperpig",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/16/40196\" title=\"picture 7\">",
"      Mycosis fungoides poikiloderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/30/11745\" title=\"picture 8\">",
"      Erythroderma in Sezary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/38/8806\" title=\"picture 9\">",
"      Localized alopecia in follicular MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/35/44600\" title=\"picture 10\">",
"      Skin biopsy MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/13/40150\" title=\"picture 11\">",
"      Pautrier microabscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/45/2776\" title=\"picture 12\">",
"      Haloed lymphocytes of MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/56/11137\" title=\"picture 13\">",
"      Sezary cells mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/18/27936\" title=\"picture 14\">",
"      Mycosis fungoides blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1674|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/40/33420\" title=\"table 1\">",
"      Diagnosis early MF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/21/2397\" title=\"table 2\">",
"      Causes of pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/34/11822\" title=\"table 3\">",
"      Mycosis fungoides TNMB classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35126?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13385?source=related_link\">",
"      Erythroderma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/6/15464?source=related_link\">",
"      Primary cutaneous follicle center lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=related_link\">",
"      Primary cutaneous large B cell lymphoma, leg type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/9/26776?source=related_link\">",
"      Primary cutaneous marginal zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10090?source=related_link\">",
"      Pruritus: Etiology and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/17/39194?source=related_link\">",
"      Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4713?source=related_link\">",
"      Staging and prognosis of mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17017?source=related_link\">",
"      Treatment of early stage (IA to IIA) mycosis fungoides",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_32_4619="PREMODA criteria";
var content_f4_32_4619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PREsentation et MODe d&rsquo;Accouchement (PREMODA) study criteria for planned vaginal breech birth",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Normal pelvimetry by x-ray or computed tomography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No hyperextension of the fetal head on ultrasound examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Estimated fetal weight 2500 to 3800 grams",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frank breech presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuous use of electronic fetal heart rate monitoring during labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient's written informed consent for vaginal breech birth",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Guideline (2000) of the Coll&egrave;ge National des Gyn&eacute;cologues et Obst&eacute;triciens Fran&ccedil;ais. Available at: file://www.cngof.asso.fr.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4619=[""].join("\n");
var outline_f4_32_4619=null;
var title_f4_32_4620="Management of asbestosis";
var content_f4_32_4620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for management after diagnosis of asbestosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1. Patient notification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.1. Inform patient of work-related illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.2. Report to appropriate authority as occupational",
"disease, as required by law",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.3. Inform patient that there are options for",
"compensation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        2. Impairment",
"assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.1. Conduct an assessment of functional impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.2. Rate impairment in accordance with ATS criteria,",
"which are incorporated into the AMA Guides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3. Tertiary",
"prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.1. Smoking cessation (primary prevention for",
"smoking-related disorders)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.2. Withdrawal from further excessive exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.3. Immunization (pneumococcal pneumonia, influenza)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3.4. Management of concurrent respiratory and other",
"diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        4. Monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.1. Chest film and pulmonary function testing should",
"be conducted every 3 to 5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.2. Active monitoring (periodic screening) for colon",
"cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4.3. Observation and elevated index of suspicion but",
"not screening for lung cancer, mesothelioma, gastrointestinal cancers",
"(other than colon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        5. Development of a",
"patient-specific management plan for symptomatic disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AMA: American Medical Association; ATS: American Thoracic Society.",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4620=[""].join("\n");
var outline_f4_32_4620=null;
var title_f4_32_4621="Clopidogrel desensitization protocol";
var content_f4_32_4621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F83638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F83638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clopidogrel desensitization protocol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Time",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration (mg/mL)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amount given (mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8:00 AM",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8:30 AM",
"       </td>",
"       <td>",
"        0.005",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9:00 AM",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9:30 AM",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.04",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10:00 AM",
"       </td>",
"       <td>",
"        0.04",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10:30 AM",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11:00 AM",
"       </td>",
"       <td>",
"        0.16",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11:30 AM",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12:00 PM",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12:30 PM",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1:00 PM",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1:30 PM",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2:00 PM",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2:30 PM",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3:00 PM",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3:30 PM",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        75 mg tablet",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     See text for specific information about the types of reactions for which clopidogrel desensitization has been performed, preparation of the patient, and risks and benefits of the procedure.",
"     <br/>",
"    </p>",
"    <div class=\"footnotes\">",
"     *Clopidogrel&nbsp;can be solubilized by different methods.&nbsp;1) Finely crushed clopidogrel&nbsp;may be&nbsp;combined with a small amount of Ora-Plus compounding agent (Paddock Laboratories Inc., Minneapolis, Minnesota) then diluted with Ora-Sweet (Paddock Laboratories Inc.) to final concentrations of 0.5 and 5 mg/mL. 2) Ethanol&nbsp;may be&nbsp;used as a solvent to dissolve finely crushed clopidogrel, which&nbsp;is then titrated to 0.5 and 5 mg/mL using purified drinking water. All solutions&nbsp;should be&nbsp;prepared just before use.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: von Tiehl KF, Price MJ, Valencia R, et al. Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007; 50:2039. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4621=[""].join("\n");
var outline_f4_32_4621=null;
var title_f4_32_4622="Contents: Malabsorption syndromes";
var content_f4_32_4622=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Malabsorption syndromes",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Malabsorption syndromes",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Celiac disease and tropical sprue",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/2/14377\">",
"           Diagnosis of celiac disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4714\">",
"           Management of celiac disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/44/40650\">",
"           Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/2/20518\">",
"           Tropical sprue",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cystic fibrosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29095\">",
"           Cystic fibrosis: Assessment and management of pancreatic insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/24/15754\">",
"           Cystic fibrosis: Nutritional issues",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrient absorption",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/21/38232\">",
"           Clinical features and diagnosis of malabsorption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41765\">",
"           Mechanisms of nutrient absorption and malabsorption",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Overview of treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/48/22279\">",
"           Overview of the treatment of malabsorption",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreatic exocrine function tests",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/25/34201\">",
"           Pancreatic exocrine function tests",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Protein losing gastroenteropathy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/50/3881\">",
"           Protein-losing gastroenteropathy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Short bowel syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/37/18007\">",
"           Chronic complications of the short bowel syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/6/44136\">",
"           Management of the short bowel syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/56/30601\">",
"           Pathophysiology of the short bowel syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Small intestinal bacterial overgrowth",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/45/11990\">",
"           Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/5/2136\">",
"           Etiology and pathogenesis of small intestinal bacterial overgrowth",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/50/28454\">",
"           Treatment of small intestinal bacterial overgrowth",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3C5B3FF1A9-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_32_4622=[""].join("\n");
var outline_f4_32_4622=null;
var title_f4_32_4623="Diagnostic evaluation of DPLD";
var content_f4_32_4623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Diagnostic evaluation of diffuse parenchymal lung disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 411px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagnostic process in diffuse&nbsp;parenchymal lung diseases begins with a clinical evaluation that includes a history, physical examination, chest radiograph, and lung function tests. On the basis of this information, the patients may be divided into two groups: cases that do not represent idiopathic interstitial pneumonia, owing to recognition of associated conditions or underlying exposures, and cases that could represent idiopathic interstitial pneumonia. Patients in the latter category typically undergo a high-resolution computerized tomography scan. This generally results in four categories of patients: (1) those with distinctive features that allow for a confident diagnosis of idiopathic pulmonary fibrosis/usual interstitial pneumonia in the appropriate clinical setting, (2) those with atypical clinical or high-resolution computerized tomography features for idiopathic pulmonary fibrosis, (3) those with features diagnostic of another diffuse&nbsp;parenchymal lung disease such as pulmonary Langerhans cell histiocytosis, and (4) those with suspected other forms of diffuse&nbsp;parenchymal lung disease. Although many patients will go directly to surgical lung biopsy, some patients may undergo transbronchial biopsy or bronchoalveolar lavage. If these findings are nondiagnostic, a surgical lung biopsy may be necessary to separate the various idiopathic interstitial pneumonias from non-idiopathic interstitial pneumonia.",
"    <div class=\"footnotes\">",
"     DPLD: diffuse&nbsp;parenchymal lung disease; IIP: idiopathic interstitial pneumonia; HRCT: high-resolution computerized tomography; IPF: idiopathic pulmonary fibrosis; TBBx: transbronchial biopsy; BAL: bronchoalveolar lavage; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; RB: respiratory bronchiolitis-associated interstitial pneumonia; DIP: desquamative interstitial pneumonia; DAD: diffuse alveolar damage; OP: organizing pneumonia; LIP: lymphoid interstitial pneumonia; PLCH: pulmonary Langerhans cell histiocytosis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_32_4623=[""].join("\n");
var outline_f4_32_4623=null;
